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Abstract  
 
 Plasminogen activator inhibitor type-1 (PAI-1) specifically inhibits the proteases tissue-
type plasminogen activator (tPA) and urokinase plasminogen activator (uPA) to control the 
activation of fibrinolysis. Vitronectin (VN) interacts with PAI-1 primarily through the 
somatomedin B (SMB) domain to stabilize and localize PAI-1 to sites of injury. Our laboratory 
observed that transition metals ions such as copper2+ have VN dependent, reciprocal effects on 
how long PAI-1 remains active. We aim to determine the molecular basis for effects of copper2+ on 
PAI-1 activity. We employed a computational algorithm (MUG) to predict metal binding clusters, 
and introduced amino acid substitutions hypothesized to create metal binding deficiency. We 
compared variants to wild-type by: measurement of stability kinetics, thermodynamic parameters 
using isothermal titration calorimetry, and protein dynamics using hydrogen deuterium exchange. 
Active PAI-1 binds copper2+ in the low nanomolar range. In a variant lacking the N-terminal 
histidines of PAI-1, we observed reduced copper2+ binding, but this does not abolish accelerated 
transition to the latent form. PAI-1 variants lacking the carboxylate containing resides in the gate 
region require more copper2+ than wild-type to promote accelerated latency formation, making 
these residues candidates for further metal binding characterization. SMB-PAI-1 complex binds 
copper2+ with comparable affinity and stoichiometry as PAI-1 alone.  Finally, the SMB domain 
stabilizes PAI-1 by localized effects on dynamics in the same regions that are affected by 
copper2+.   Thus, binding of SMB does not sterically interfere with copper binding to PAI-1, but 
rather negates copper2+ effects directly through changes in dynamics. 
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Chapter 1 PAI-1, Metals, and Disease 
 
1.1 Introduction 
1.1.a. PAI-1 Biological Function 
The serine protease inhibitor (serpin) superfamily of proteins functions in biological 
systems ranging from prokaryotic bacteria to eukaryotic human life forms. Serpins perform 
essential regulatory functions in a breadth of physiological processes, including control of 
inflammation, the circadian clock, and hemostasis [2]. Serine proteases cleave and activate each 
other in an incremental fashion to form intricate functional cascades. However, when protease 
activity lacks the appropriate regulation by a cognate serpin, disease states may arise. Plasminogen 
activator inhibitor type-1 (PAI-1) is a serpin that has known functions in a variety of tissues from 
zebrafish to humans [3]. The anti-proteolytic properties of PAI-1 are required to maintain a strict 
balance between coagulation, blood clot formation and breakdown, or fibrinolysis (Figure 1.1). 
The process of coagulation occurs through the proteolysis and activation of the serine protease pro-
thrombin into thrombin [4]. Active thrombin converts fibrinogen into insoluble fibrin clots. 
Similarly, fibrinolysis is activated by serine proteases, namely the plasminogen activators 
including tissue type plasminogen activator (tPA) and urokinase plasminogen activator (uPA) [5]. 
The plasminogen activators are responsible for cleavage and subsequent conversion of dormant 
plasminogen into active plasmin for breakdown of insoluble fibrin clots [6]. PAI-1 inhibits the 
plasminogen activators to control the levels of active plasmin, and subsequent clot breakdown. In 
the absence of PAI-1, hyperfibrinolytic bleeding states can occur [7-9], while higher than normal 
levels of PAI-1 result in thrombotic states that could occlude blood vessels [10-12]. 
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Figure 1.1 PAI-1 Regulation of Fibrinolysis. Blood clot formation and breakdown are 
catalyzed by cleavage mediated activation of serine proteases. In coagulation, pro-
thrombin is cleaved and activated into thrombin, which is responsible for forming 
insoluble fibrin clots from fibrinogen. In fibrinolysis, the plasminogen activators (tPA, 
uPA) are responsible for cleaving and activating plasminogen to active plasmin, 
resulting in the breakdown of fibrin clots. PAI-1 regulates this process by inhibiting the 
plasminogen activators, and thus plasmin activity. PAI-1 circulates in 1:1 complex with 
another glycoprotein cofactor vitronectin. Vitronectin aids in stabilization and directing 
PAI-1 to sites of injury. 	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PAI-1 interacts with another circulatory glycoprotein vitronectin (VN) in the circulation, 
at sites of injury, and within the extracellular matrix.  Circulating PAI-1 associates with VN to 
form a tight 1:1 complex, whereby VN associates with the fibrin matrix of the blood clot [13-15]. 
However, within the extracellular matrix PAI-1 and VN interact to form higher order oligomers. 
VN is important in localizing PAI-1 to fibrin blood clots as well as stabilizing PAI-1 in the active 
form, as it turns over quickly in vivo [16, 17]. VN is responsible for binding to the GPI-linked cell 
surface receptor urokinase receptor (uPAR), which cleaves uPA on the surface of migrating cells 
[18, 19]. VN also interacts with α-β heterodimeric cell surface integrins, namely αvβ3, αvβ5 [20, 
21]. These receptors are located at focal adhesions connected to the cell cytoskeletal machinery, 
and through these interactions, VN binding confers coordination of cell adhesion and migration 
tendencies [22-24]. Interestingly, VN and PAI-1 dysregulation have been implicated in a number 
of overlapping disease states, such as atherosclerosis [25] and angiogenesis [26].      
 
  The imbalance of PAI-1 levels can lead to numerous complications as it is involved in 
several biological processes (Figure 1.2, 1.3). Elevated PAI-1 levels shift the balance towards 
coagulation and are thus pro-thrombotic; increased levels of PAI-1 are associated with greater 
risks to cardiovascular disease [27-30]. Atherosclerotic plaques are known to form, which hardens 
blood vessels to cause tissue scarring and inflammation [31]. The system is also implicated in 
different types of stroke, in which blood vessels are significantly obstructed (ischemic) or ruptured 
(hemorrhagic) and there is lack of sufficient blood flow to the brain [32]. In addition to 
thrombosis, PAI-1 is intimately involved in angiogenesis and vascular remodeling [33-35]. 
Disease to the vessel wall often involves hyperplasia or increased production of smooth muscle 
cells, macrophages, and endothelial cells, all of which are involved in the atherosclerotic process  


























Figure 1.2 Regulatory Agents of PAI-1 Expression and the Pleotropic Physiological 
Effects. Several hormones, including insulin, TGF-β, TNF-α, IL-1,6,8 upregulate PAI-1 
expression through binding to the regulatory sequence before the PAI-1 gene. Through 
the inhibition of plasminogen activators fibrinolysis and extracellular matrix turnover 
are regulated. PAI-1 binding to uPA can affect localization to cell surface receptors, 
causing changes in mobility, proliferation, and apoptosis. The downstream effects of 
which in endothelium cause thrombosis and angiogeneis. In fibroblasts and smooth 
muscle, the effects cause wound healing, tissue remodeling, and atherosclerosis. 
Changes in proliferation, mobility, and apoptosis in different cell types are involved in 
cancer.    Adapted from Gramling, Church et al. Thrombosis Research. 2010	  	  























Figure 1.3 Diseases Associated with PAI-1 Imbalances. Knock-out, or inhibition 
of PAI-1 in vivo results in fibrosis of the heart, liver, and lungs.  Also, there is 
increased build up of atherosclerotic plaques, leading to myocardial infarction or 
heart attacks.  Loss of PAI-1 also leads to carcinogenic states due to the ability of 
PAI-1 to alter cell adhesion and migration properties, as well as PAI-1 having a role 
in angiogenesis. Overexpression of PAI-1 in vivo results in thrombotic states, 
inflammation, and metabolic syndrome. Interestingly, there is significant overlap in 
the disease states that also are linked to imbalances in metal ion homeostasis.	  	  	  	  
	   6 
and all express PAI-1 [33]. Furthermore, PAI-1 is associated with reduced as well as enhanced 
cellular migration, due to pro- and anti- adhesive properties [36, 37] mediated by the extracellular 
matrix. The manifestation of pathophysiology in angiogenesis is the cause of metastasis of several 
cancers [38], including breast [39-41], lung [42], and ovarian [43], among others. 
 
  PAI-1 contributes to metabolic syndrome through expression in adipose tissue, which is 
typically more abundant in patients with this ailment (Figure 1.2). In turn, more PAI-1 is 
produced, causing a decreased fibrinolytic response, providing a link with its role in cardiovascular 
disease [44]. PAI-1 secreted from adipose tissue significantly increases blood levels that can 
enhance further aspects of metabolic syndrome, including hypertension, type 2 diabetes, 
hyperlipidemia, and obesity [45]. PAI-1 is also involved in inflammatory response, as a number of 
pro-inflammatory cytokines, such as tumor necrosis factor alpha (TNF-α) [46], interleukin-1 (IL-
1) [47] as well as growth factors such as transforming growth factor beta (TGF-β) [48]. 
Interestingly, defects in the plasminogen activation system can cause several of the 
aforementioned disease states, but addition of PAI-1 for inhibition to mitigate issues often 
exacerbates their severity, commonly known as the as the “PAI-1 Paradox” [49-51]. Altogether, it 
is apparent that cells have established robust regulation of PAI-1 levels, which is required to 
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1.1.b. Control of PAI-1 Expression 
 The human PAI-1 gene is located on the long arm of chromosome 7, spanning approximately 
12.2 kilobases (kb), containing 9 exons and 8 introns [52]. The PAI-1 gene can be transcribed into 
either a 2.3 kb or 3.2 kb, with the sole difference between the mRNA transcripts being the latter 
contains a larger 3’ untranslated region, which may account for greater mRNA stability [52]. The 
5’ flanking region contains a TATA box, transcription initiation site, and a regulatory region that 
confers transcriptional responsiveness to TGF-β [53], TNF-α [46], IL-1 [47], angiotensin II, 
glucocorticoids, very low density lipoprotein (VLDL), glucose, insulin, and glucagon [28, 54-57] 
(Figure 1.2). Glucagon or cAMP activate liver PAI-1 expression through the protein kinase A 
(PKA) pathway, while glucocorticoids bind directly to response elements in the flanking region 
[58].  Glucose activates liver PAI-1 expression through increases in nuclear factor kappa B (NF-
κB) and IL-1 [58]. Insulin and TGF-β binding to their respective liver cell surface receptors 
activate PAI-1 expression through the mitogen activated protein kinase/extracellular response 
kinase (MAPK/ERK) pathway [58]. These key elements link the expression of PAI-1 to metabolic 
and inflammatory disorders [58]. Additionally, several microRNAs can bind to the non-coding 
PAI-1 mRNA sequence to regulate transcription in a tissue specific manner [59]. The 4G/5G 
polymorphism in the regulatory region 675 base pairs from the start site is located in an important 
transcription factor binding site [60]. The allele containing 4 guanines results in increased PAI-1 
expression, while a PAI-1 allele with 5 guanines is down regulated. This results in higher PAI-1 
levels in the 4G allele and higher risk for thrombotic events in a variety of tissues and organs [60]. 
There are no observable developmental disorders as a result of PAI-1 gene deletion, apart from 
mild bleeding states individuals develop normally [7]. 
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 PAI-1 is expressed as a 45 kilodalton (kDa) protein sequence consisting of 402 total amino 
acids residues, including the signal peptide at the N-terminus.  
(MQMSPALTCLVLGLALVFGEGSA). Because the signal endopeptidase is able to cleave at two 
separate sites, the N-terminus of PAI-1 can start as VHHPPSY or SAVHHPPSY and contain either 
379 or 381 residues, respectively (The former version and all numbering will be henceforth used 
through out this document). Unlike many other serpins, PAI-1 is an acute response protein 
circulating at relatively low concentrations (5-20 ng/mL), with a fast turnover rate in blood [61]. 
PAI-1 is expressed by liver hepatocytes, endothelial cells, epithelial cells, adipocytes, 
megakaryocytes, fibroblasts, and smooth muscle cells [62]. Despite stringent regulation of PAI-1 
expression, there is further regulation subjected to PAI-1 at the protein level, particularly the 
amount of available active fraction in circulation. 
 
1.1.c. PAI-1 Inhibitory Function 
 Serine proteases perform necessary biological functions through highly specific cleavage of 
peptide bonds for digestion, protein turnover, or, as in the case of tPA or uPA, activation to 
perform a function. Peptide bonds can be broken in a thermodynamically favorable hydrolysis 
reaction, although they are kinetically trapped in bonded form with planar, double-bond like 
character. Serine proteases employ an active site triad consisting of a serine, histidine, and 
aspartate residues to perform the acid-base catalyzed reaction. The histidine acts as a base, 
accepting a hydrogen ion from the serine hydroxyl group, forming a potent alkoxide nucleophile. 
The negatively charged aspartate interacts with the histidine to aid in orientation and stabilization 
throughout the reaction. The alkoxide performs nucleophilic attack on the carbonyl α carbon, 
forming an unstable tetrahedral intermediate that is then stabilized by the oxyanion hole. The 
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histidine donates a hydrogen ion to the peptide bond nitrogen, resulting in collapse of the 
intermediate, peptide bond cleavage, release of the N-terminal portion of the peptide, and an acyl 
enzyme intermediate. In the second step, water acts as a nucleophile to repeat the process, forming 
a tetrahedral intermediate, which collapses into a carboxylic acid as the C-terminal half of the 
peptide is released, regenerating the active site serine for future reactions. 
 
 PAI-1 utilizes a canonical serpin suicide inhibitory mechanism that parallels the proteolytic 
reaction until the final inhibitory step: E + I <-> EI* <-> EI <-> E~I -> E-I [63] (Figure 1.4). PAI-
1 has a solvent exposed loop termed the reactive center loop (RCL) that contains the arginine-
methionine scissile bond, which is also located on the natural substrate of tPA, plasminogen. 
Initially, PAI-1 uses proximal RCL loop residues to engage in non-covalent interaction with the 
exosite residues of tPA, in a non-covalent Michaelis complex (EI*). This Michaelis complex 
structure has been determined by x-ray crystallography with PAI-1 bound to either uPA or tPA, 
with each active site serine mutated to alanine to prevent the mechanism from progressing further 
[64, 65]. Formation of Michaelis complex is followed by nucleophilic attack of the PAI-1 scissile 
bond carbonyl to form the loop-bound acyl-enzyme complex (EI) [66], followed by release of the 
C-terminal half of the loop forming the loop-displaced acyl-enzyme (E~I). In the final inhibitory 
step, the N-terminal acyl bound half of the loop inserts into the central beta sheet of the protein 
body, translocating the protease with a distorted active site approximately 70Å to the opposite pole 
of the inhibitor [67]. The PAI-1-protease complex remains quite stable, due to a negligible rate of 
deacylation of the bond that joins them (E-I) [67]. However, if loop insertion is delayed, 
deacylation will occur, and results in release of the intact serine protease, leaving a cleaved or 
“substrate-like” PAI-1 form [68].   










Figure 1.4 Serpin Mechanism. Serpins are folded around a core β-sheet from which protrudes 
a surface-exposed loop (the reactive- center loop or RCL).  Within this loop region are the 
residues recognized as substrates by the target protease (uPA or tPA), with the reactive center 
peptide bond denoted P1-P1'.  Initial binding of the protease to the target site in the RCL forms 
a noncovalent Michaelis complex.  Upon attack by the protease, this P1-P1' peptide bond is 
cleaved by nucleophilic attack of the active-site serine, and an acyl-intermediate is formed.  In 
contrast to the normal progression of proteolysis, this acyl-intermediate is extremely long-lived 
due to a negligible rate of deacylation.  Structural rearrangements occur so that the two ends of 
the cleaved loop separate, and the P1 end is inserted into the central β-sheet, with the 
covalently coupled protease transferred to the opposite “pole” of the serpin.	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PAI-1 is a fast acting inhibitor that has a reaction rate constant (3.5 x 107 M-1S-1) approaching the 
diffusion limit [69]. Approach to equilibrium kinetics has determined the interaction rates of PAI-
1 with tPA or uPA at each step of the inhibition mechanism [70]. The rate of Michaelis complex 
formation is fast, so the overall inhibition rate is limited by the rates of the subsequent steps [69-
71]. These rates can vary depending on the protease, presence of VN, as well as the presence of 
amino acid substitutions [71-73] [74] [75]. If the limiting rates are faster than the inhibitory rates, 
then PAI-1 will exhibit “substrate-like” behavior (Figure 1.5) [68]. Native PAI-1 inhibits two-
chain tPA with the highest rate constant, followed by uPA, and single chain tPA [71]. Binding of 
VN slows the overall rate of inhibition by stabilizing the loop displaced acyl enzyme [71], just 
before the peptide insertion and destruction of the protease active site occurs.     
 
1.1.d. PAI-1 Structure/Latency Conversion 
 Interestingly, PAI-1 is relatively unique in the serpin protein family in that it has a tendency to 
spontaneously insert into the protein body, due to its metastable fold in the active conformation 
[76]. Despite serpins having rather low sequence homology, they fold into highly similar tertiary 
structures [77]. This fold consists of nine α-helices, and sixteen total β-strands that are organized 
into three β-sheets (Figure 1.6). The secondary structural features of PAI-1 will be referred to as 
helices hA-hI, and numbered strands of each sheet A-C (ie. s1A). The properly folded active form 
of PAI-1 is a flexible, kinetically trapped intermediate, which readily relaxes into a rigid, compact 
fold of lowest thermodynamic energy [78]. This folding process involves RCL peptide insertion 
into the protein body, the loop is no longer solvent accessible, and thus unavailable for interaction 
with target proteases, and this conformation is called the latent conformational state (Figure 1.7) 
[1].  PAI-1 is by far the most labile of all serpins, with the conformational shift to the latent form  






Figure 1.5 Structures of PAI-1-S195A tPA Michaelis Complex, Protease-Serpin 
Complex, and Cleaved PAI-1. PAI-1 and tPA initially interact in a michaelis complex 
(pdb 5BRR) in which the loop makes non-covalent interactions with the protease 
(magenta) exosite residues. In the final inhibitory step, the N-terminal half of the RCL 
(orange) of PAI-1 inserts into the protein body at a rate of klim which can be influenced by 
the presence of cofactors, mutations, pH, temperature, as well as other factors. Full 
peptide insertion results in a stable protease-serpin complex (top right, protease in 
magenta). PAI-1-tPA complex has not been solved, so α-1-proteinase inhibitor in 
complex with elastase is shown (pdb 2D26). If the rate of peptide insertion is too slow, the 
intact protease can be released post RCL cleavage. This is termed the cleaved or substrate 
like PAI-1 (bottom right pdb 9PAI).	  	  	  	  	  	  







Figure 1.6 PAI-1 Primary Sequence and Secondary Structure. PAI-1 is composed to 379 or 
381 amino acids, depending on the cleavage of the signal peptide by the signal peptide peptidase. 
PAI-1 is composed of nine α-helices (shown in green), three β-sheets (shown in blue), and the 
inhibitory RCL loop (shown in orange). The nomenclature of PAI-1 secondary structure: helicies 
A to I are named hA to hI; the strands are classified into three sheets A-C, and named in order of 
the sequence by number (ie. s1A is strand 1 of sheet A). 
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Figure 1.7: The Active and Latent Conformations of PAI-1. The crystal structures of 
active PAI-1 (pdb code 3Q02, left) and latent PAI-1 (pdb code 1DVN, right) are shown. The 
RCL (orange) is the contains the same scissile bond proteases target, but it spontaneously 
inserts into the central β-sheet A strands 3 and 5, converting PAI-1 to an inactive, or latent 
conformation. Multiple steps during the latency transition process have been proposed, 
including local unfolding of the hydrophobic core. The shutter region strands 3 and 5 (green) 
open up, as well as the gate region loops (teal) for RCL insertion to occur during the latency 
conversion process. Helix F (blue) and the underlying shutter region may be transiently 
rearranged to allow for the RCL to fully insert in the shutter. The flexible joint region (red), 
contains the binding interface of the SMB domain of VN, as well as other important protein -
protein interactions. As a point of reference, the “top” of PAI-1 will be described as the pole 
that contains the RCL, and the “front” of PAI-1 will be described as the side that central β-
sheet A faces. PAI-1 helices A-I are abbreviated as hA-hI, and β strands are abbreviated as 
follows: strand 1 of sheet A is written as s1A.      	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occurring over a half-life of 1-2 hours [79].  Antithrombin and neuroserpin also undergo latency 
conversion, although over a much longer timespan [80, 81].   
 
 Although structural information is available for the active and latent forms of PAI-1, the 
mechanism of how this conformational change occurs is not completely understood. There appears 
to be concerted movement that involves communication between many important regions of PAI-
1, named after their involvement in PAI-1 inhibition and/or latency conversion. At an absolute 
minimum the gate region (s3C, s4C, s3B, hG) of strands of PAI-1 must open up to allow for the 
uncleaved RCL to pass through [82].  Directly C-terminal of the loop, strand s1C becomes 
unstructured and detached to facilitate this task [83].  Opening of the shutter region (s3A, s5A) 
strands occurs next to accommodate loop insertion, forming a sixth beta strand in in the central 
beta sheet A [1].  For complete insertion, hF, which sterically blocks the lower part of the shutter, 
must be transiently displaced [84].  The flexible joint region (hD, hE, s1A) is an important region 
for protein-protein interactions that have an effect on the stability and inhibitory function of PAI-1 
[71].  Additionally, the underlying shutter region and other areas of the hydrophobic core have 
been identified to undergo transient unfolding events that are consistent with the timescale of 
latency conversion [85].  Calorimetric studies monitoring the latency conversion show no 
detectable changes in enthalpy, indicating that the process is largely entropically driven [86]. Since 
the major difference between the fast acting inhibitory mechanism and relatively slower latency 
conversion is the lack of RCL cleavage, passage of the RCL through the gate region is regarded as 
the rate-limiting step in the process [87]. The latency conversion process is irreversible under 
physiological conditions; reversing the process requires the presence of denaturants or negatively 
charged phospholipids [88]. Latent PAI-1 in platelets is suggested to be in a “pro-form” that is 
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activated by the significant amount of negative phospholipids on the outside of platelets [89], but 
this method of activation has yet to be confirmed.  
 
1.1.e. Factors Influencing PAI-1 Latency Conversion 
 Why PAI-1 may have evolved a regulatory mechanism to inactivate itself has remained 
elusive to investigators of the field. Many intrinsic factors contribute to how long PAI-1 remains 
active before converting to the latent form.  Directed evolution studies comparing PAI-1 to other 
serpin protein sequences indicate that the metastability of PAI-1 is the result of positive 
evolutionary selection [87, 90]. Mutating a PAI-1 amino acid residue to the consensus identity at 
that position in most serpins typically results in significantly stabilizing the variant PAI-1 
compared with wtPAI-1 [87]. PAI-1 in the active form is highly dynamic as evidenced by 
hydrogen deuterium exchange (HDX) experiments, and this is thought to play a key role in the 
latency transition process [91]. Environmental pH has an effect on how long PAI-1 remains active, 
as PAI-1 is increasingly more stable in the active form as pH drops from the physiological range to 
pH 5 [92].  This effect has been pinpointed to the stabilizing interactions that PAI-1 histidines 
make in the protonated state [92]. Additionally, the basic residues in the s3C/s4C loop are 
proposed to stabilize the active form, because mutation to acidic residues in those positions 
accelerates latency transition [93].  Further, introducing double cysteine mutations to cross-link 
areas that must be mobile to allow for the latency transition, such as the hinges of the RCL, 
significantly delayed latency transition [94].  It should be noted that many of the mutations also 
alter the thermodynamics of protein folding, as determined from chemical denaturation 
experiments [95].  For example, the 14-1B PAI-1 quadruple variant (N150H, K154T, Q319L, 
M154I) creates a hydrogen bonding network at the hF-s3A loop-shutter and s1C-gate region 
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interactions extends the half-life of PAI-1 to approximately 145 hours [96]. This also results in 
altered protein folding thermodynamics, in which 14-1B has a significantly higher melting 
temperature compared with wild-type PAI-1 [95]. However, a recent crystal structure of active 
PAI-1 containing only one mutation in the N-terminal hinge prior to the RCL (W175F) retains 
wild-type like thermodynamics of protein folding [95].  This currently represents our most 
accurate structural model for active PAI-1.     
 The metastable structure and overall stability of PAI-1 is influenced by ligand binding. A 
cofactor glycoprotein, VN, binds PAI-1 with high affinity (Kd ~0.1nM); this interaction is required 
to direct circulating PAI-1 to blood clots for thrombolysis [16]. VN binding to PAI-1 results in a 
delay in latency transition, which increases the half-life by ~1.5 fold. [79]. VN has an N-terminal 
somatomedin B domain (SMB) responsible for the primary high-affinity interaction with PAI-1 
(Figure 1.8) [97]. Interaction of SMB with PAI-1 has been investigated through mutagenesis 
(Figure 1.9), x-ray crystallography, and NMR, determining that SMB binds through the flexible 
joint region residues R103, M112, and Q125 [97]. The primary interactions responsible for 
stabilization observed when VN is bound to PAI-1 have been pinpointed to the SMB-PAI-1 
interaction [97, 98]. The SMB is flanked in primary sequence by a region that is predicted to be 
intrinsically disordered (IDD), and central and C-terminal domains that are hemopexin-like and 
have predicted beta-propeller structure [99].  Interestingly, VN is still able to bind PAI-1 even 
when the SMB domain is removed, albeit at a lower affinity (Kd ~ 50nM), indicating that the 
interaction includes regions of VN other than the SMB domain [98, 100]. Mutagenesis studies 
mapped the lower affinity interaction the more distal regions of helices D and E of PAI-1 [98].  
 





Figure 1.8 Vitronectin Domains, Structural Model. VN is composed of four domains, the 
SMB domain, which is the primary binding interface with PAI-1, the intrinsically disordered 
domain, containing the integrin binding sequence, the central domain, and C-terminal domain.  
The IDD region has prevented crystallization of VN, but our lab has produced a model of VN 
structure.  The SMB has been crystallized, and the central/C-terminal domains homology 
modeled to similar proteins.  A combination of  small angle X-ray scattering and computational 
modeling of the domains determined the overall shape, which is peanut-like. Data from Zhou et 
al., Nat Struc Bio, 2003 ; Peterson lab, JBC, 2004;  Proteins, 2001;  Biochemistry, 2005.	  	  




Figure 1.9 PAI-1/VN Interaction Interface. The interaction of PAI-1 and VN was 
investigated by surface plasmon resonance (SPR) and site directed mutagenesis. The SMB 
domain, full length VN and a VN deletion variant lacking the SMB domain (ΔSMB VN) 
were tested against a battery of PAI-1 variant for binding. The effects of VN binding to 
these constructs were mapped on the PAI-1 structure (3q02). The residues in red were those 
that only influenced binding to ΔSMB VN, the residues in green are important for SMB 
binding, and the residues in yellow were important for all VN proteins tested. The residues 
in blue were tested by had no effect on the VN proteins tested.	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Using a combination of SAXS, NMR and crystallography on SMB [101], and molecular 
modeling [99], a structural model for VN has been proposed by our lab [102].  
 
  PAI-1 binding of RNA aptamers, glycans, and antibodies in different areas of PAI-1 have 
produced significant effects on latency transition. SELEX library generation of high-affinity RNA 
aptamers identified two aptamers that can significantly stabilize PAI-1 in the active form (Figure 
1.10) [103]. Human PAI-1 is a glycoprotein that can be post-translationally modified by N-linked 
glycosylation at three residues (N209, N265, N309) (Figure 1.11) [104]. Purified plasma PAI-1 is 
only modified at residues 209 and 265, the latter modification protects a hydrophobic cleft at s1C, 
resulting in stabilization in the active form [83, 104, 105]. Otherwise, PAI-1 expressed in bacteria 
that lacks these modifications has the same biochemical properties as plasma purified protein 
fraction [104]. There are examples of PAI-1 monocolonal antibodies in which binding either 
delays or facilitates latency conversion.  Antibodies have been particularly useful in identifying 
different conformational states of PAI-1. Several antibodies (Mab-2,6, 55F4C12, 33H1F7) have 
binding epitopes located on hF or the loop to S3A, and disrupt hF translocation to form a substrate-
like or cleaved form of PAI-1. Similarly, Mab-8H9D4 blocks the active site distortion of the target 
protease by binding to the shutter region, rendering PAI-1 in the substrate-like form.  Mab-1 binds 
to hC and is stabilizing, whereas a H4B3 epitope is in the gate region and destabilizes, likely due 
to favoring the formation of a pre-latent state [83, 106]. The predicted pre-latent state resembles a 
partial insertion of the N-terminal part of the RCL into beta-sheet A, and partial detachment of 
s1C, much like a pre-latent state in another serpin, alpha-1-antichymotrypsin [107]. Another 
antibody Mab-33B8 binds at the pre-inserted N-terminal hinge and hD to accelerate latency  






Figure 1.10 RNA Aptamer Binding to PAI-1. The nucleotide sequences of paionap-5 and 
paionap-40 are shown (top) with regions of variable sequence bolded. A gel shift assay was 
used to monitor PAI-1 RNA-aptamer binding in the nanomolar range. The migration of the 
nucleotides are reduced due to protein binding, separating free aptamer from complex in the 
experiment (bottom left). Site directed mutagenesis was used to identify important residues in 
aptamer binding on PAI-1 (bottom right).  The residues shown in red are implicated for their 
importance to binding both aptamers, while K122 in pink is only important in binding 
paionap-40. Adapted figure from Madsen et. Al. Biochemistry, 2010.	  	  







Figure 1.11 Functional Glycosylation Sites of PAI-1. PAI-1 has three potential glycosylation 
sites for N-linked glycosylation: N209, N261, and N309. However, only N209 and N261 are 
glycosylated in PAI-1 isolated from plasma samples. The glycosylation sites are shown in green 
space filling spheres on the active PAI-1 structure (pdb 3q02). PAI-1 is stabilized by 
glycosylation, particularly at N265 due to protection of a hydrophobic cleft at s1C.	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conversion. Finally, the initial Michaelis complex formation with tPA can be inhibited through a 
variety of antibodies that have varying binding epitopes in the gate region and some partial 
overlap with the RCL [83] [108].  
 
1.1.f. Copper2+ Effects on PAI-1 
 Our lab has recently uncovered an interesting and unusual effect of transition metal ions on 
PAI-1 stability, which is dependent on the presence or absence of VN [79].  Physiologically 
relevant metals such as calcium2+, magnesium2+, and manganese2+ confer a modest stabilizing 
effect on PAI-1 in the presence as well as the absence of VN.  VN stabilizes PAI-1 modestly (t1/2 ~ 
1.5 hours with VN; t1/2 ~ 1 hour alone) [79]. However, in the presence of different transition metals 
such as nickel2+, copper2+, and cobalt2+, PAI-1 is significantly destabilized (t1/2 ~10 minutes) [79].  
PAI-1 bound to any of these three transition metal ions along with VN is significantly stabilized 
(t1/2 ~ 3 hours with Cu2+), representing a longer half-life than observed upon binding of VN alone 
[79]. Competition experiments determined that transition metal ion binding occurs at the same 
site(s) in PAI-1 [109].  Furthermore, metal ions bind to the active form and the latent form, albeit 
with a weaker affinity for latent PAI-1 [109].  Monitoring intrinsic tryptophan fluorescence of 
PAI-1 in the presence of metal ions using approach-to-equilibrium kinetics yielded a triple 
exponential. The first exponential is concentration dependent and likely the binding event, a 
second exponential captures a currently uncharacterized conformational change, and the third 
exponential occurs with kinetics close to the timescale of latency transition [109].  The copper ion 
binding affinity to PAI-1 determined from the binding exponential (Kd ~ 90nM) is well within 
physiologically relevant range, considering the micromolar copper2+ concentrations of liver and 
brain [109-114].  
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1.1.g. Eukaryotic Copper Ion Metabolism/Physiology 
 
 Copper ions are an essential cofactor for enzymes and are required for proper physiological 
function, but levels must be intricately controlled to prevent toxic effects.  The use of copper2+ as a 
cofactor originated 2.7 billion years ago, as photosynthetic cyanobacteria mass-produced 
atmospheric oxygen, leading to the oxidation of iron to Fe2+ to Fe3+. This subsequently lead to less 
soluble iron, and organisms adapted by using copper2+, which was best suited for red-ox reactions 
in the new atmosphere [115] [116] [117]. Copper ions are found in 1+ and 2+ oxidation states, and in 
excess amounts this presents the opportunity for oxidative damage. Compounds such as ascorbic 
acid or glutathione are able to reduce copper1+ to copper2+ if the coordination has a negative 
reduction potential [117]. Subsequent re-oxdiation by O2 or H2O2 results in the generation of 
hydroxyl radicals, which are highly reactive and damaging to a variety of biomolecules, such as 
creating DNA strand breaks or peroxidation of lipids [117]. Copper toxicity has been strongly 
linked with many overlapping disease states as PAI-1, such as angiogenesis, cancer, cardiovascular 
disease, and diabetes (Figure 1.3). The chelation of copper ions has resulted in the suppression of 
several pro-angiogenic cytokines and growth factors that are required for early tumor growth 
[118]. The localization of physiological copper ions during angiogenesis has been monitored by X-
ray fluorescence [119]. Copper ions are subjected to large scale reorganization which is strictly 
controlled during angiogenesis [120]. Copper is found in atherosclerotic plaques, and is known to 
interfere with platelet endothelium interaction, and cause vascular leakages [121]. The levels of 
plasma copper transporting ceruloplasmin are significantly increased in individuals with type 1 and 
2 diabetes [122]. Cellular and extracellular copper trafficking is only partially understood at the 
molecular level.    
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 Copper is ingested through the diet and initially stored in the liver, entering hepatocytes via 
the high affinity transmembrane protein human copper transporter-1 hCtr1 (Figure 1.12) [123].  
Virtually all intracellular copper ions are bound to a copper ion chaperone or transporter until 
trafficked to a destination, like the CuA/CuB clusters of the mitochondrial electron transport chain, 
for example [124].  Intracellular copper ion homeostasis is not completely understood, but an 
emerging hypothesis is “one transporter for each destination” [125].  Copper ion transporters 
include superoxide dismutase (SOD), the cytosolic copper chaperones CCS and atox1, and copper 
transporter 2 (Ctr2) [125].  Copper ions can be shuttled to the golgi network, whereby they can be 
internalized via the Menke’s disease p-type ATPase ATP7A for distribution to several cupro-
proteins [126].  Likewise, another p-type Wilson’s disease ATPase ATP7B controls copper 
distribution in and out of tissues, also using the golgi network [127].  Copper ions are either 
distributed to ceruloplasmin destined for the serum, or excreted when levels are too high [128].  
Polymorphisms to these two p-type ATPases results in widespread imbalances in copper ion levels 
across all tissues, leading to the aforementioned disease states [126, 127]. Wilson’s disease is an 
autosomal recessive disorder that is characterized by an extreme excess of copper2+ within brain 
and liver tissue[127]. Approximately 1 in 100 people are carriers for the disease, and two carriers 
have a high chance of producing offspring with the disease [127]. Symptoms of the disease include 
various liver diseases, neuropsychiatric problems such as dementia, depression, loss of cognitive 
abilities, seizures, and migraines [127]. Patients with the x-linked Menkes’s disease have an even 
worse fate, including sparse, wooly hair, nervous system breakdown, defects in growth 
development, and often death by age 3 [128]. In this case, many proteins in many tissues lack the  
 







Figure 1.12 Copper Ion Metabolism in Eukaryotes. Copper ions enter the body through the 
diet, and initially enters a hepatocyte cell in the liver. Copper ions are bound to transfer or 
carrier proteins within a cell to prevent causing harmful side reactions that could cause 
formation of reactive oxygen species. Copper reaches its destination through a specific 
transporter, or is sent in a vesicle to ceruloplasmin for distribution throughout the body.	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delivery of required copper ions to function properly [128].  Taken as a whole, copper ion binding 
could be one of many regulating physiological factors on PAI-1.  
 
1.1.h. Metalloprotein Interactions 
  Copper ions are considered soft acids and thus require coordination through soft ligands; 
sulfur and nitrogen containing cysteine, histidine, and methionine residues tend to dominate 
coordination centers of cuproproteins [129]. Copper1+ prefers binding strongly to the anionic 
thiolate group of cysteine and somewhat weaker to the thioether group of methionine [129]. 
Copper2+ preferentially binds to the deprotonated nitrogen in the imidazole of neutral histidine at 
physiological pH [129]. Given their differences in d-orbital valence electrons, Copper1+ and 2+ also 
differ in their coordination geometries. Copper1+ is most often found in linear, trigonal planar, or 
octahedral coordination geometry, while copper2+ usually coordinates in tetrahedral, square planar, 
or square pyramidal forms [117]. The red-ox active proteins that interconvert copper1+ and 2+ most 
often bind copper ions in tetrahedral coordination geometry [117].  
Several coordination centers have been determined through a variety of techniques. The 
copper1+ binding ATPase family of proteins uses linear binding using two cysteine residues, while 
many chaperones coordinate through trigonal planar geometry with two cysteines and a histidine. 
Superoxide dismutase uses tetrahedral binding geometry with four histidines to coordinate and 
transport copper2+ to the mitochondria (Figure 1.13) [130]. Likewise, Plastocyanin and umecyanin 
are photosynthetic electron transport proteins that use tetrahedral copper2+ binding; both using two 
histidines, a cysteine, with the fourth ligand in each being methionine in the former [131], a 
carboxylate containing residue in the latter [132]. Within the circulation and extracellular matrix, 
the physiologically relevant oxidation state of copper is 2+ [129], which is complementary to the  
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Figure 1.13 Copper2+ Coordination by Superoxide Dismutase. Superoxide dismutase 
coordinates copper2+ by using four tetrahedral histidine ligands and water.  Illustration based 
on crystal structure of copper2+ bound superoxide dismutase (pdb 4BCY). 	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lack of cysteine residues within PAI-1. Several additional binding geometries have been proposed 
that are relevant for PAI-1, including a two histidine motif possibly including water or another 
anion, and a two histidine, two amide backbone coordination (Figure 1.14) [129]  
 
1.2 Rationale for Study and Organization of Dissertation 
  In this dissertation work, we further probe the observations in which transition metal ions 
incur an interesting and unusual regulatory effect on PAI-1, which is dependent on the presence of 
the cofactor VN. There are unquestioned parallels between the dysregulation of PAI-1 and copper 
ion levels and the disease states that arise. A physiological relevance of the interaction between 
copper2+ and PAI-1 is apparent from the strength of their interactions, their relative concentrations, 
and their particular localization in vivo. In order to understand the molecular basis for metal ion 
effects on PAI-1, we must identify the metal ion binding site or sites. To this end, we are unable to 
use several traditional structural methods such as X-ray crystallography due to the fast timescale 
by which copper promotes latency conversion. Alternatively, we have opted to use kinetic, 
thermodynamic, and isotopic exchange measurements to answer several key questions regarding 
copper2+-PAI-1-VN interactions. Where is copper2+ binding on PAI-1? How does copper2+ binding 
promote the latency transition? Are the copper2+ effects mediated directly through PAI-1 or 
through interactions that involve VN? How does PAI-1 ligand binding influence protein 
dynamics? Does PAI-1 protein dynamics play a role in the latency conversion process? This work 
aims to address these questions to explain the molecular basis of copper2+ binding on PAI-1 
function. This work sheds significant light on PAI-1 metal ion interaction, but also aims to 
investigate the role of protein dynamics in the latency conversion process, which is yet to be 
completely understood. 










Figure 1.14 Potential N-terminal copper coordination chemistries. The following 
coordination strategies are suspected to be used by the N-terminus of copper binding proteins, 
but none have been structurally characterized to date. 	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 In chapter 2, we investigate the effects of ligands on PAI-1 protein dynamics using hydrogen 
deuterium exchange coupled to mass spectrometry (HDX-MS). Copper2+ destabilizes PAI-1, 
significantly accelerating latency transition, but copper2+ and SMB domain are able to stabilize 
PAI-1, slowing down the latency transition process. If PAI-1 latency is tied to protein dynamics, 
then we would expect to see localized increases in dynamics in the presence of copper2+, but 
localized decreases in dynamics in the presence of both ligands. PAI-1 in the presence and 
absence of copper2+ and SMB are compared in active, as well as latent forms of PAI-1. In 
addition, a PAI-1 variant hypothesized to bind copper2+ is compared with wild-type.  
 Our approach has been to combine computational prediction and targeted mutagenesis. In 
Chapter 3, we describe prediction of metal binding clusters using a computational algorithm that 
accounts for clusters of metal ion ligands. With a goal of producing a PAI-1 variant that is 
insensitive to metal ion effects, we have used site directed mutagenesis to engineer mutations at 
several regions of PAI-1 hypothesized to contain metal ion binding clusters. A battery of PAI-1 
variants that are hypothesized to be metal ion binding deficient have been generated. The 
inhibitory activity of each PAI-1 variant has been tested as well as measurement of the rate of 
latency transition for comparison with wild-type PAI-1. This is to ensure that incorporation of the 
mutations does not significantly alter the biochemical properties independent of metal ion effects. 
Metal-binding properties were assessed by measurement of PAI-1 latency transition in the 
presence of copper2+. A complementary assay was also used to monitor formation of PAI-1-tc-tPA 
in a gel in which PAI-1 is incubated with titrating amounts of copper2+. This assay offers a more 
direct perspective on PAI-1 metal ion sensitivity as it relates to function. Finally, we use 
isothermal titration calorimetry (ITC) to measure the thermodynamic characteristics- enthalpy 
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change, stoichiometry, and affinity of copper2+ PAI-1 interaction in active and latent conformations 
for wild-type PAI-1 and the variants with targeted amino acid substitutions.  
 
 Chapter 4 focuses on the active W175F PAI-1 crystal structure, highlighting the differences 
from previous structures of the active form. The study of PAI-1 from a structural perspective is 
disadvantaged by its conversion to the latent form. The existing structures typically have several 
mutations that favor the active form, so that the protein is not latent at the end of the crystallization 
process. For example, the first crystal structure for active PAI-1 is the 14-1b quadruple variant 
with four amino acid substitutions. However, introduction of these amino acid switches incurs 
structural and functional effects that can change the thermodynamics and functionality of the 
protein. While W175F PAI-1 is highly stable and retains similar thermodynamic characteristics to 
that of wild-type PAI-1, the structure of W175F PAI-1 revealed several interesting differences, 
including the presence of a halogen-binding site in the gate region. In this work, we aim to 
characterize halogen binding in terms of structure and function to determine the physiological 
relevance of halogen binding on PAI-1.  We measured wild-type and W175F PAI-1 latency 
conversion kinetics in the presence of several halogens. Additionally, we investigate the existence 
of a preference for different halogens binding to PAI-1.  
 
 Throughout the studies described in Chapters 2 through 4, we have aimed to investigate the 
binding of ligands to PAI-1 and determine effects on protein dynamics and overall function. At the 
end of these chapters, we present overall conclusions and future directions for work on the 
molecular effects of copper2+ on PAI-1 protein function. A summary of the findings from chapters 
2-4 are described with relation to PAI-1 involvement in human disease. The aforementioned PAI 
	   33 
questions research questions are addressed, and a model for the effects of copper2+ on PAI-1 
function is illustrated. Of course, this work opens up further questioning of how ligands can affect 
1 stability, inhibitory function, and dynamics. The final portion of this chapter will outline new 
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Chapter 2 Ligand Effects on PAI-1 Protein Dynamics Measured by HDX-MS 
2.1. Introduction 
This chapter was adapted from the manuscript currently in the submission process to the American 
Chemical Society Journal Biochemistry. It has been reviewed favorably and revisions are pending: 
 Copper (II) Ions Increase PAI-1 Dynamics in Key Structural Regions that Govern Stability. Joel 
C. Bucci, Morten Beck Trelle, Carlee S. McClintock, Tihami Qureshi, Thomas J.D. Jørgensen, 
Cynthia B. Peterson 
  
2.1.a. Hydrogen Deuterium Exchange 
 The exchange of hydrogen atoms from different groups on the surfaces of proteins with their 
immediate solvent surroundings was observed some time ago. This phenomenon goes unnoticed 
unless the protein is placed under conditions of heavy isotopes of hydrogen, including deuterium 
or tritium. The hydrogen-deuterium exchange (HDX) can be monitored by several analytical 
techniques, such as radioactive scintillation, nuclear magnetic resonance (NMR), infrared 
spectroscopy (IR), or mass spectrometry (MS). Using mass spectrometry to measure HDX takes 
advantage of the mass difference between hydrogen and deuterium, which are 1.008 amu and 
2.014 amu, respectively. A mass spectrometer is capable of making highly sensitive measurements 
to differentiate the mass difference between the two isotopes. As the heavier deuterium 
incorporates into the protein, the degree of mass shift indicates how much exchange occurs over a 
specific experimental timeframe. The experiments monitor global exchange from a structured 
perspective, but can be investigated at peptide level resolution. 
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 The exchange reaction itself is acid-base catalyzed, so several factors need to be considered 
when designing experiments. Hydrogen atoms are bound to several chemical groups in proteins 
that exchange at differing rates (Figure 2.1). For example, hydrogen bound to electronegative 
atoms (either nitrogen, oxygen, or sulfur) on amino acid side chains exchange too quickly to 
monitor by current analytical techniques. Conversely, carbon bound side chain hydrogen exchange 
at negligible rates for HDX experiments. However, the amide hydrogens of the protein backbone 
exchange at an intermediate rate that is measureable by the analytical techniques. This is useful 
because each amino acid in the protein has one backbone amide hydrogen, with the exception of 
proline, in which it is incorporated into the main chain. The intrinsic exchange rate constant (kint) 
can be defined as kint = kH[H+] + kOH[OH-]; where kH is the acid catalyzed rate constant, kOH is the 
base catalyzed rate constant, and [H+] and [OH-] are the relative proton and hydroxide 
concentrations (Figure 2.2) [133]. The environmental pH, temperature, accessibility to solvent, 
and tendency to form intra- and inter-molecular hydrogen bonding are chief components governing 
HDX rates within proteins. Amide hydrogen bonding is integrally involved in formation and 
stability of protein secondary structure, making HDX a useful tool to assess protein dynamics.  
 Amide hydrogen exchange dependence on pH has implications on overall experimental  
conditions. Exchange rates are slowest at acidic conditions (~ pH 2.5) increase as the pH steadily 
becomes alkaline. Each reaction is completed at physiological (7.4) pH, where exchange readily 
occurs. At specific time points, samples are taken and quenched by addition of small amounts of 
concentrated formic acid, and flash frozen. The purpose of acid/temperature quenching is two-
fold. Acid and temperature reduction lowers the pH and stops further exchange, so that no back-
exchange occurs when the samples enter protiated solvent in the liquid chromatography 
separation and gas phase ionization process. Secondly, the acid quenching ensures that basic  





Figure 2.1 HDX of Functional Groups in Proteins. The peptide Gln-Asp-His-Pro-Lys-Leu 
is used as a representative peptide to illustrate the rates of hydrogen deuterium exchange of 
different functional groups on proteins. Hydrogens on non-electronegative atoms such as 
carbon will not exchange with the surrounding solvent at any appreciable rate. HDX can not 
be measured on the methyl hydrogens of the alanine due to negligible exchange. Likewise, 
HDX measurements are not possible on hydrogens of electronegative atoms such as nitrogen 
or oxygen within amino acid side chains. For example, the hydrogen on the carboxylic acid 
group of aspartate will exchange with the surrounding solvent at a rate so fast it can not be 
measured by instrumentation. However, Amide backbone hydrogens (shown in green) 
exchange with the solvent at an intermediate rate that is measureable by instrumentation such 
as NMR or mass spectrometer.    	  





Figure 2.2 Hydrogen Deuterium Exchange Rates of Protein Functional Groups in the 
pH Spectrum. The y-axis represents the logarithm of the intrinsic hydrogen deuterium 
exchange rate (kex) in inverse minutes. This value is plotted as a function of the pH scale on 
the x-axis. HDX is an acid-base catalyzed reaction, where as the pH becomes more alkaline, 
the isotopic exchange generally within all functional groups, although the signatures do vary 
somewhat. Amide backbone hydrogens offer an intermediate rate at physiological pH 7.4, but 
also importantly the exchange can be quenched at low pH (2-2.5). This is important to protect 
against back exchange during analysis, and to charge the analyte for viewing in the 
instrument. Pepsin is used to cleavage the protein into peptides prior to instrumentation 
because it is optimally active in acidic conditions.	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amino acid side chains (arginine, lysine, histidine) as well as peptide N-termini remain in the 
protonated and charged state required for monitoring in the mass spectrometer instrumentation.   
 To achieve peptide level resolution of HDX, the protein is cleaved by a protease into several 
peptides. The most used protease is typically trypsin, having predictable cleavage at basic 
residues along with the N-terminus guarantees two charges per peptide. However, Pepsin is used 
in HDX, taking advantage of its robust activity in acidic conditions. Pepsin cleavage is less 
predictable than trypsin, but nonetheless is experimentally reproducible. Pepsin cleaves C-
terminal peptide bonds of hydrophobic residues, with specific preference for cleavage of aromatic 
amino acids. Following cleavage, the peptides are separated prior to monitoring of mass shift 
change. 
  Isolation of each peptide is completed using reverse phase liquid chromatography (LC), 
followed by ionization and separation by mass to charge ratio (m/z) in the MS. Peptides are bound 
to a hydrophobic C18 column under non-polar conditions, followed by peptide separation and 
elution under a linear gradient of increasing aqueous phase. As peptides elute, they enter the ion 
source of the MS to undergo electrospray ionization in which the aqueous droplets are converted to 
an aerosol gas phase (Figure 2.3). The taylor cone from the LC sprays the solvent into an area 
under high voltage. Under high voltage, the droplets evaporate, making each more charged. At a 
point, called the Rayleigh limit, the concentration of charge on a droplet exceeds the amount it can 
harbor physically, causing explosive dissociation of ions into the gas phase as they enter the MS. 
Inside the instrument ions are subjected to separation by quadrupole mass analyzer, followed by a  




Figure 2.3 Electrospray Ionization. Peptides are separated by a reverse phase 
chromatography to be separated on basis of hydrophobicity. As they elute from the C18 
column, they enter the mass spectrometer. The fine needle sprays the analyte ions through 
the taylor cone to create a jet of liquid phase ions. The liquid phase ions are subjected to a 
high voltage and heat, which causes the droplets to gradually evaporate, as they are in a 
mixture of aqueous and volatile solution such as acetonitrile. Evaporation of each droplet 
concentrates the charge to the extent that is can not be contained reaching the Rayleigh 
limit. At this point, the liquid phase ions burst into the gas phase for separation by the mass 
spectrometer. Electrospray ionization is a soft ionization technique fit for biomolecules such 
as proteins, and allow for multiply charged ions that increases the range of masses that can 
be detected by the instrument.   	  




Figure 2.4 Quadrupole Mass Analyzer. Ions enter between four long metal rods, 
separated into two pairs. They are charged by radio frequency voltage (RF) and also an 
offset direct current voltage (DC) applied to the two pairs. The charge of the two pairs is 
controlled simultaneously to keep ions of a specific m/z range on a stable, periodic, 
hyperbolic, trajectory between the center of the rods, to the detector. Ions that have a m/z 
that is not within this range will enter unstable trajectories, collide with the rods, and never 
reach the detector. In this way, quadrupole mass analyzers separate on the basis of m/z to 
analyze ions of a desired m/z range.       	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time of flight mass analyzer. A quadrupole is a set of four metal rods that are parallel to one 
another in space (Figure 2.4). The two pairs are connected electrically through radio frequency 
current (RF), and direct current (DC) voltage is applied between one pair and the other in a 
concerted fashion. Since the electronics and voltage guide the ion flight based on their m/z ratio, 
the desired ions in the m/z range will proceed through to the detector, while ions not in this m/z 
range will enter trajectories that collide with the rods and will not appear in the ion 
chromatograms. The time of flight mass analyzer uses a known electric field strength, which 
gives each ion a velocity that depends directly on m/z ratio (Figure 2.5). This method separates 
by m/z ratio because lighter molecules will travel faster and hit the detector before heavier ones.  
 Each amide hydrogen in a protein can be found in a closed, open or exchanged state defined 
by: closed <-> open -> exchanged, where closed is an amide hydrogen participating in a hydrogen 
bond, and open is available for exchange. The rate of amide opening is kopen, while the rate of 
amide closing is kclose, and kch refers to the rate of hydrogen/deuterium exchange when the amide 
hydrogen is in the open state (ch for deuterium chemical exchange rate) [133]. The EX2 exchange 
limit (EX2 kinetics) is defined as the limit at which the rate of amide closing is markedly faster 
than the rate of chemical deuterium exchange, or kclose >> kch [133]. Most proteins exist in a stable 
fold and usually exhibit exchange in EX2 kinetics. Many openings are required for this type of 
exchange for each event, resulting in a mass shift of a single population peak in the mass spectra as 
a function of labeling time due to incorporation of the heavier deuterium isotope. The EX1 
exchange limit (EX1 kinetics) is defined as the limit at which the chemical exchange rate is 
significantly faster than the rate of amide closing, or kch >> kclose [133].  In this observed exchange, 
the rate of chemical exchange becomes equal to kopen. EX1 kinetics is less common, but when it 







Figure 2.5 Time of Flight Mass Analyzer. Ions of the analyte containing ions of ranging 
masses are accelerated toward the detector using an electric field. Each ion has the same kinetic 
energy in this state, but their velocity towards the detector is directly dependent on their mass to 
charge (m/z) ratio. Ions of lowest m/z reach the detector in the shortest time period, and ions 
with the largest m/z reach the detector in the longest time period. In this way, time of flight 
mass analyzers separate ions on basis of m/z.  	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 is observed, there is broadening of the peaks in the isotopic packet or even a bimodal isotope 
distribution detecting an unfolding event. If the two isotopic population peaks in a bimodal 
distribution are adequately separated by mass (deuterium content), then it is possible to determine 
the rate of unfolding as it is equal to the rate at which the lower mass population peak (folded 
form)  interconverts with the higher mass population peak (unfolded form).  
 
2.1.b. Serpin Protein Dynamics 
 Previous studies using hydrogen/deuterium exchange coupled to mass spectrometry (HDX-
MS) have shown that wild-type PAI-1 is highly dynamic in the active form [91]. Peptides covering 
hD-s2A, hE-s1A of the flexible joint region quickly reach full deuteration early in the 
experimental time course, which is consistent with weak structural protection against isotopic 
exchange and high dynamics [91]. Additionally, peptides spanning the N-terminal half of hF, s3A-
s4C, and s5A-N-terminal RCL loop of the shutter region also exchange rapidly, and are thus 
highly dynamic regions within active wtPAI-1 [91]. However, several peptides covering beta sheet 
B core undergo much slower exchange, and do not become fully deuterated during the time course 
[91]. These peptides spanning s6B-hB, s1B-s2B, s2B-s3B, s4B, and s4B-s5B are significantly 
protected from exchange, and comprise the least dynamic regions of PAI-1. In contrast, the latent 
form of PAI-1 is much more structurally resistant to isotopic exchange, featuring lower dynamics 
in almost all regions [91]. A peptide covering s4C to the N-terminal half of s3C is a lone example 
of a more dynamic area in the latent form compared with the active [91]. This observation is 
consistent with the opening of the gate region loops as a result of latency conversion, as well as the 
loss of secondary structure to s1C proximal to the gate [83].  
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 HDX experiments were utilized in several stabilized serpins to compare with active wtPAI-1 
in evaluating the role of protein dynamics in the latency transition process. The highly stabilized 
14-1b PAI-1 variant contains N150H, K154T, Q319L reinforcing interactions between the hF-
s3A loop and the shutter and M354I in the gate result in reduced dynamics [1, 91]. Peptides near 
the site of three of the four the amino acid substitutions (N-terminal half of hF, s2C-s6A) had 
lower exchange, as expected [91]. Interestingly, regions more remote from the stabilizing 
mutations also featured moderate protection, particularly peptides spanning s6B to N-terminal 
part of hB, hB-hC, C-terminal half of hE-s1A, s2B-s3B, and hI) [91]. Neuroserpin [134] (tm ~ 51-
56°C, latency t1/2 > 24h) and α-1-antitrypsin [135] (t ~ 59°C, do not undergo latency at 
physiological conditions) are also stabilized compared with PAI-1 and feature structural 
differences within HDX patterns. Some similarities shared with PAI-1 include a protected core 
consisting of β-sheet B and part of β-sheet C [136, 137]. These two serpins feature some of the 
same highly dynamic regions in peptides spanning the N-terminal part of hA, hD, and the RCL 
[136, 137]. Key regions of difference were observed in the shutter region (peptides spanning s3A 
and s5A) and the underlying shutter (hC) of α-1-antitrypsin, compared with neuroserpin or PAI-1 
[136, 137]. A summary of the current understanding of these serpin thermodynamics, dynamics 
and latency transition is found in Figure 2.6.   
 HDX has also been used to detect partial unfolding events within the hydrophobic core of 
PAI-1 [85] that offer new insight to how PAI-1 converts from the active to latent form. Peptides 
spanning hA-s6B-hB and s5A-RCL undergo local unfolding events on timescale that is consistent 
with being on the path to latency conversion (t1/2 ~ 24, 18 minutes, respectively) [85]. A peptide 
spanning hB-hC undergoes unfolding on a timescale very early in the latency conversion process 
(t1/2 ~ 1 minute) [85]. These findings identified new regions of PAI-1 that have functional  









Figure 2.6 Serpin Thermodynamics, Dynamics, Latency Transition Summary. The 
thermodynamic melting point in degrees (°C), hydrogen deuterium exchange dynamic regions, 
and latency conversion kinetics half-life (t1/2 in hours) are summarized for comparison. The 
serpins to be compared are wild-type PAI-1 in the active form, latent form, as well as two 
variants, W175F, and 14-1b, that stabilize PAI-1 through varying mechanisms. They are also 
compared against neuroserpin and α-1-anti-trypsin, serpins that do not convert to latency as 
readily (or at all) as PAI-1.	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relevance to the latency transition process. As a technique, HDX proves to be powerful in 
uncovering the structural changes that occur during the path to the latent state.  
 
2.1.c. Ligand Effects on PAI-1 Dynamics  
 
 PAI-1 ligands such as the SMB domain of VN, Mab-1 monoclonal antibody and RNA 
aptamers prolong the length of time PAI-1 remains active [79, 103, 138]. Ligand binding is 
expected to protect against isotopic exchange by sterically blocking the binding interface, but the 
protected regions often extend beyond the interface [91, 139]. The binding of the SMB domain 
significantly protects against exchange in peptides spanning s2A-hE, hE-s1A, and N-terminal half 
of hF constituting or proximal to the binding interface [91]. In addition, SMB protects against 
exchange in peptides of hA, hB-hC, hD, C-terminal hF-hF-s3A loop, hI, and hI-s5A [91].  Thus, 
SMB binding confers stabilization on peptides that are not at the PAI-1:SMB interface and are 
positioned at the bottom pole of the molecule [91]. The mab-1 antibody binds at E53 of hC, Q56 of 
hC, and D305 of hI and stabilizes PAI-1 similarly to SMB domain (1.4 fold increase) [138]. Mab-1 
binding results in HDX protection to several of the same peptides, although in this case the 
changes are more localized to the binding epitope [91]. Peptides spanning hB-hC, hI are 
significantly affected, while only peptides s6B-hB and hF-s3A away from the epitope exhibit 
protection from exchange [91]. Two RNA aptamers paionap-5, and paionap-40 bind to flexible 
joint residues R76, K80, F114, and R118. Paionap-40 additionally binds to K122. The two 
aptamers strongly stabilize the active form of PAI-1 (t1/2 ~ 2, 28 hours respectively) [103]. The 
protection signatures of the aptamers are similar to that of SMB, with some notable differences. In 
addition to where SMB protects, the aptamers also protected exchange in hA, s4B, s5B, s6B, and 
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hB. Paionap-40 strongly protects the peptide containing K122 spanning s1A-hF [139]. Despite the 
highly similar HDX patterns between ligands, the mechanism for the most potent stabilization of 
PAI-1 by paionap-40 is not completely understood [103]. Overall, PAI-1 conformational flexibility 
in the active form allows for binding of several different stabilizing ligands and influences in 
dynamics are uniformly observed.    
 
2.2. Rationale for Study 
 
 Copper2+ binding to PAI-1 accelerates the latency transition in the absence of VN and slows 
latency transition in the presence of VN [79]. This work aims to further understand the influence 
of copper2+ ions on PAI-1 dynamics, either in destabilizing or stabilizing the inhibitor in the active 
form. A zinc2+ ion was identified in the most recent PAI-1 structure (3Q02), coordinated to two N-
terminal histidines (H2 and H3) of one PAI-1 molecule and carboxylate-containing residues from 
the gate region of a second PAI-1 molecule, forming an asymmetric dimer interface [95].  To 
determine whether the PAI-1 N-terminal histidines coordinate copper2+ to influence structural 
effects, we have also engineered and analyzed a variant form of PAI-1 that has alanine 
substitutions at those positions (H2AH3A PAI-1).  We hypothesize that ligands govern the 
stability of PAI-1 conformations through protein dynamics. This work aims to address many 
unanswered questions using HDX. Copper2+ causes destabilization of PAI-1 and acceleration of 
latency, while binding of SMB domain stabilizes, causing a delay in latency. Does copper2+ 
binding increase the dynamics in regions of PAI-1 important to latency transition?  Are these same 
regions stabilized in the presence of copper2+ and the SMB domain?  Are the structural effects 
imparted by copper2+ specifically targeted to the active conformation?  
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2.3. Materials and Methods 
2.3.a. Expression, Purification, Activity Assessment of PAI-1 
 Wild-type and PAI-1 variants were cloned into the pET-24d expression vector plasmid for 
recombinant expression in Rosetta 2 (DE3) pLysS Escherichia coli cells (Novagen-EMD). PCR 
based mutagenesis was used to introduce mutations, in which primers developed to incorporate the 
intended triplet codons necessary for alanine substitution at residues H2, H3, E81, E212, D222, 
E242, E350, H364 in the sequence of PAI-1 (Several of these variants will be tested in Chapter 3). 
Figure 3.3 shows the relative locations of the investigated residues on the three dimensional PAI-1 
structure. Verification of mutations was completed by sequencing of each variant plasmid DNA at 
the UTK molecular biology and sequencing center (Walters Life Sciences Building).  Wild-type 
and variant plasmids were transformed into the expression cell line using a standard heat shock 
method of 42°C for 45 seconds.  Bacterial colonies were grown on LB agar plates, which 
contained 50 µg/mL kanamycin and 34 µg/mL chlorphenicol for antibiotic selection.  A single 
colony was isolated for growth in a 12 mL TB liquid culture with the same antibiotics at 37°C, and 
shaking at 250 rpm. The cell growth proceeded to an optical density (OD600) of 1.0 absorbance 
unit, at which time the temperature was lowered to 15°C in order to express PAI-1 that is 
predominantly in the active form.  After one hour of growth at 15°C, 1mM IPTG (Research 
Products International) was added to start protein expression for 16 hours.  The cell harvest was 
performed via centrifugation at 10,000xg for 30 minutes.  
 
 Cell lysis was performed using 50mM phosphate buffer 1mM EDTA, pH 6.5 at 25°C 
containing 20mg lysozyme and protease inhibitor cocktail (1mg/100mg of cell pellet), followed by 
cell sonication, and centrifugation at 10,000xg for 30 minutes at 4°C.  Wild-type PAI-1 and 
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variants are purified according to standard published procedures [79] using three column steps. 
Sulfopropyl sepharose (SP) cation exchange column (volume 120mL), in which PAI-1 is bound 
using a buffer of 50mM sodium phosphate, 80mM (NH4)2SO4 , and 1mM EDTA, pH 6.5 at 4°C. 
PAI-1 is eluted from the SP column using an (NH4)2SO4  gradient of 80-500mM, pooled, and 
extensively dialyzed to remove the EDTA. Next, PAI-1 is bound to a nickel charged immobilized 
metal affinity (IMAC) column (volume 20mL), in a buffer of 50mM sodium phosphate, 20mM 
imidazole, and 500mM NaCl, pH 7 at 4°C. PAI-1 is eluted from the IMAC column using a 
gradient of 20-200mM imidazole.  Final purification of PAI-1 is achieved using a Sephacryl (s-
100) gel filtration column (volume 600mL) in a buffer of 50mM sodium phosphate, 300mM NaCl, 
and 1mM EDTA pH 6.25 at 4°C to separate PAI-1 from any contaminants based on size.  
Purification of variants lacking the N-terminal histidines required modifications to the procedure, 
because there were difficulties in binding SP and IMAC columns. For variants lacking H2 or H3, 
the pH was lowered to 5.5 for more adequate binding to the SP column. Instead an of IMAC step, 
these variants were purified using a phenyl sepharose column with a reverse 600-10mM salt 
gradient; otherwise the steps were the same as for wild-type PAI-1. Protein purity was verified 
using a 10% polyacrylamide SDS-PAGE gel in reducing conditions and protein concentration was 
measured using at 280 nm using Beer’s law, where the PAI-1 extinction coefficient: e280  = 0.93 
mL mg_1 cm-1 and a molecular weight of 43,760 g/mol. 
 Two activity assays are performed to determine adequate inhibitory ability of the purified 
forms of PAI-1. First, PAI-1 is buffer exchanged into a buffer composed of 50mM MOPS, 100mM 
(NH4)2SO4  pH 7.4 at 37°C for all metal ion studies, since sodium phosphate and EDTA 
significantly interact with metal ions. Inhibition was tested by titration against two chain tPA in a 
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plate based assay.  Two chain tPA at 100nM is in a buffer of 50mM MOPS, 100mM (NH4)2SO4 , 
2mM EDTA, and 1% bovine serum albumin (w/v), pH 7.4 at 37°C. The proteins are mixed at PAI-
1:tPA ratios ranging from 0.25 up to 4, followed by 1mM tPA substrate Spectrozyme tPA addition 
(in the same buffer as tPA).  Activity of tPA is directly measured through cleavage of the para-
nitro-aniline group on the substrate by tPA that absorbs at 405 nm over 20 minutes.  Wild-type 
PAI-1 with proper and timely preparation results in a protein fraction that adequately inhibits tPA 
activity with 1.25 equivalents of PAI-1. Additionally, an activity assay in an SDS-PAGE gel using 
similar PAI-1/ single-chain tPA ratios can be used to monitor their complex formation, latent, and 
cleaved PAI-1 forms. This is completed using 4uM tPA and ratios of PAI-1 ranging from 0.25 to 3 
molar equivalents relative to that. This assay is completed in 50mM MOPS, 100mM (NH4)2SO4 , 
pH 7.4 at 37°C. Electrophoresis is completed in a 4-12% gradient gel to resolve PAI-1/tPA 
complex, latent, and cleaved PAI-1 forms in non-reducing conditions for 75 minutes, at 150 volts. 
The equivalents of a new PAI-1 stock required to fully inhibit tc-tPA are 1-1.25 equivalents, or 
85% inhibition. Adequate wild-type PAI-1 inhibition is 85% active using this method. To produce 
latent PAI-1 for experiments, protein expression is performed at 25°C. The purified protein 
samples from the s100 column in this case are converted completely to the latent state by 
incubating at 37°C, with shaking at 75rpm for one week.  Latent protein stocks are confirmed to 
have no activity by the previously mentioned plate based activity assay, where no observable 
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2.3.b. Preparation of the N-terminal VN Protein Fragment, SMB Domain 
 The SMB domain and RGD sequence (amino acids 1-47 of VN) DNA sequence was cloned 
into the pET-32b expression plasmid vector with a preceding thioredoxin protein, N-terminal 6x 
histidine tag, and a region encoding for a thrombin cleavage site.  Recombinant expression of 
SMB domain was completed using Rosetta-gami 2(DE3) pLysS E. coli cell line equipped to fold 
disulfide-bonded proteins.  SMB domain plasmid DNA was transformed into the cells using a 
standard heat shock method of 42°C for 45 seconds, and colonies were grown LB agar plates that 
contained antibiotic selection of 50μg/mL ampicillin, 34 μg/mL chloramphenicol, and 12.5 μg/mL 
tetracycline. A single colony was isolated for liquid culture, which was grown in 12mLs of TB 
with the same antibiotics at 37°C, and 300 rpm shaking to an OD600 of 1.0 absorbance unit.  
Protein expression is induced by addition of 1mM IPTG for a total of 16 hours.  Cells were 
harvested by centrifugation at 10,000xg for 30 minutes at 4°C.  Cell lysis is performed using 
50mM sodium phosphate, 500mM NaCl, and 20mM imidazole which contains 20mg lysozyme 
and (1mg/100mg cell pellet) protease inhibitor cocktail, followed by sonication, and centrifugation 
at 10,000xg for 30 minutes.   
 The cell lysate containing overexpressed, his-tagged SMB domain is bound to an IMAC 
column, and isolated using an imidazole gradient of 20mM-1M. Eluted protein fractions are 
pooled, and dialyzed thoroughly in a thrombin cleavage buffer of 20mM Tris, 150mM NaCl, and 
2.5mM CaCl2, pH 8.3 at 25°C, removing the large concentration of imidazole.  Biotinylated 
thrombin (15U/400mg of SMB) is added for overnight cleavage of the thioredoxin-his-tag from 
SMB. The engineered histidine tag would add non-native metal ion binding site to the protein, and 
must be removed. Cleavage results in an N-terminal extension of four amino acids (GSAM), in 
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addition to the first 47 residues of VN. Complete cleavage was confirmed by running the mixture 
over the IMAC column again, collecting the flow through, and analyzed by electrophoresis on a 
10% polyacrylamide SDS-PAGE gel under reducing conditions. Next, the mixture is run over a 
streptavidin column for complete removal of thrombin, and passed over the S100 column (volume 
600mL) in 50mM sodium phosphate, 300mM NaCl, and 1mM EDTA pH 6.25 at 4°C.  In the final 
step, a column with active W175F PAI-1 bound is used as an affinity chromatography step for 
isolation of correctly folded SMB domain. SMB protein mixture is bound column which is 
equilibrated in 50mM sodium phosphate, 300mM NaCl, and 1mM EDTA at 4°C. SMB fractions 
are eluted using the same buffer, but lowering the pH to 4.0. Sample purity was confirmed by 
running 10% polyacrylamide SDS-PAGE in reducing conditions.  Protein concentration is 
measured by absorbance at 276 nm, using beer’s law, where SMB extinction coefficient ε276 = 
4500M-1cm-1, and with a molecular weight of 5678.26 g/mol. SMB binding is verified using an 
SPR assay in which a 1:1 PAI-1:SMB mixture is flown over a CM5 chip coated with VN.  A 
correctly folded SMB should bind PAI-1, competitively inhibiting PAI-1 binding to the VN chip in 
the SPR assay. 
 
2.3.c. Hydrogen-Deuterium Exchange Reactions 
 PAI-1 and SMB protein stocks were diluted into a pre-incubation buffer, consisting of 5 
mM MOPS, 100 mM (NH4)2SO4, 6.5 mM NaCl, 2 mM sodium acetate, and 0.1 mM EDTA pH 
7.4 at 25°C.  This resulted in PAI-1 at 5 µM, in which the buffer and salt components were 
identically balanced in composition among all experimental conditions. This permitted complex 
formation and/or rapid exposure to copper2+ ions preceding addition of deuterium (D2O) buffer. 
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For the copper2+ conditions, the buffer also included 215 µM total CuSO4, having a final 
calculated free copper2+ concentration of 2.3 µM. After copper2+ addition, the pH was adjusted to 
pH 7.4 at 25°C using NaOH.   The experimentally determined first sphere MOPS/copper2+ affinity 
value β1 is 4.00 [140].  The following quadratic formula was employed to calculate free copper2+ 
concentration 10^β1 = Ka; Ka = 1/Kd; Mf = Mt – [(Mt + Bt + Kd) – ((Mt + Bt + Kd)2 – 4Bt Mt)1/2]/2 
where Mf is the concentration of free copper2+, Mt is the concentration of total copper2+, and Bt is 
the buffer concentration (MOPS), and the Kd is the dissociation constant between copper2+ and 
MOPS.  It should be noted that EDTA is present to prevent trace metal ion effects and for protein 
stability; it was subtracted from the total metal ion concentration prior to free copper2+ 
calculation. For conditions including the SMB domain, there was a 2-fold molar excess (10 µM) 
relative to the PAI-1. A scheme of HDX reactions is illustrated in Figure 2.7. Pre-incubation 
solutions (8 µL) are diluted 20-fold (final volume of 160 uL) into deuterium buffer (5 mM 
MOPS, 100 mM (NH4)2SO4, 6.5 mM NaCl, 2 mM sodium acetate, and 0.1 mM EDTA pD 7.8 at 
25°C ) and incubated at 25°C, and time-point aliquots (10, 30, 180, 600 seconds) were taken by 
quenching with 1.38% (3.2 µL) formic acid and flash-freezing in liquid nitrogen. Quenched 
samples underwent proteolysis using 16 µL of pepsin (final concentration of 0.5 mg/mL) on ice 
for two minutes.  The peptides are then injected using an ice-cold Hamilton syringe into an 
Acquity HDX liquid chromatography system kept at 4°C (Waters, Milford, MA).  Samples flow 
through a Vanguard BEH C18, 2x5 mm pre-column (Waters) at a rate of 300 µL/min and then 
eluted using a Acquity BEH 1x100 mm C18 analytical column using a gradient of: 8-15% B over 
0.5 minutes, 15-35% B in 5.5 minutes, and 35-85% B over 0.5 minutes at a rate of 40 μL/min and 
into the mass spectrometer. A sample total ion chromatogram of LC elutions for undeuterated 
active wtPAI-1 is shown in Figure 2.8. Peptide ions were analyzed on a Waters Synapt G1 
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quadrupole-time-of-flight (Q-TOF) mass spectrometer. The instrument underwent daily 
calibrations to 3ppm accuracy. Deuterium uptake plots were constructed by plotting average mass 
shifts of each peptide as a function of the incubation time in logarithm form (Figure 2.10).  
Normalized exchange was calculated from experimental peptides with respect to fully deuterated 
controls (100%).  Fully deuterated control samples were generated through PAI-1 incubation in 4 
M deuterated guanidine in D2O for four hours, then identical reaction quenching, treatment, and 
analysis. calibrations to under 3ppm accuracy.  Undeuterated wild-type and variant PAI-1 peptic 
peptides were fragmented using tandem (MS2) CID to identify each peptide to be analyzed using 
MASCOT (Matrix science)  (Figure 2.9).  The following equation was used to calculate average 
mass of each peptide in all experiments: average mass = ∑i(miIi)/(∑i Ii) where i is each isotope 
peak and running from 1 to the total number of isotope peaks in the isotopic packet, the centroid 
mass of isotope peak i is shown by mi, and Ii represents the intensity of isotope peak i.  
2.4. Results 
2.4.a. Adapted HDX-MS Conditions are Required to Measure Metal Ion Effects 
 The previous HDX-MS studies using N-terminally histidine-tagged PAI-1, and phosphate 
buffered saline (PBS) [91] rendered incompatible conditions for these metal ion experiments on 
wild-type PAI-1.  Similar to our previous work on metal ion effects with PAI-1 [109], we 
employed a MOPS buffer system to preserve metal ion solubility. We also have expressed a PAI-1 
construct without a His-tag to diminish non-specific metal interactions.  Because of this, it was 
first important to test whether our wild-type PAI-1 in MOPS buffer yields reproducible HDX 
results compared with previous studies [91] [139]. Initial HDX reactions on wild-type PAI-1 and 
His-tagged PAI-1 in both PBS and MOPS determined that the presence or absence of a N-terminal  
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Figure 2.7 HDX Reaction Scheme. Hydrogen deuterium reactions are completed using a 
protiated protein that is diluted into 95% deuterium oxide to start exchange. The reactions are 
conducted at a specific temperature, pH, and time frame that allows for monitoring of dynamic 
changes within the protein. After specific time points, samples are removed and the HDX is 
quenched by addition of formic acid to drop the pH, and then are flash frozen in liquid nitrogen. 
This prevents the possibility of isotopic back exchange, and also protonates basic groups on the 
protein for detection in the mass spectrometer. Following, the samples are individually thawed on 
ice, and immediately subjected to proteolysis by pepsin on ice. The resulting peptides are injected 
into a cooled liquid chromatography system with a C18 hydrophobic column for separation prior 
to entry into the mass spectrometer. The peptides are ionized through electrospray ionization and 
are subsequently separated by quadrupole and time of flight mass analyzers before entering the 
detector to be viewed as spectra. The undeuterated versions of the peptide (blue) are identified by 
MASCOT, each peptide mass shift is monitored and analyzed by DynamX software. Finally, the 
mass shifts in daltons of a time course are plotted as a function the logarithm time to produce 
HDX uptake plots.	  	  	  





Figure 2.8 Liquid Separation of PAI-1 Peptides by RP-LC. Directly after proteolysis by 
pepsin, a sample is injected into the high pressure liquid chromatography system. The 
peptides bind to the C18 hydrophobic analytical column under aqueous conditions, and are 
then eluted by a gradient of increasing acetonitrile. Shown above is the total ion 
chromatogram of the peptides, with the relative abundance of peaks at each retention time 
as peptides elute from the column. This chromatogram is of active wild-type PAI-1 in the 
undeuterated form, it was used initially to identify peptic peptides spanning all regions of 
PAI-1, for later comparison with deuterated time course samples under a number of 
experimental conditions.	  	  	  	  







Figure 2.9 MASCOT Identified PAI-1 Peptic Peptides. After MS/MS fragmentation of PAI-1 
peptides, we were able to identify 42 PAI-1 peptic peptides using the program MASCOT. This 
program predicts the cleavage patterns of multiple proteases, and calculates the theoretical masses for 
the peptides. Our mass spectrometry results lead to 42 direct peptide matches to our MASCOT 
potential matches. Their relative locations along the primary sequence and secondary structure of PAI-
1 are listed above.      	  






Figure 2.10 Mass Shifts Due to Deuterium Incorporation. The mass shift due to isotopic 
exchange of heavier deuterium is shown over 3 experimental time points in comparison to an 
undeuterated active wtPAI-1 peptide. The peaks shown are the isotopic packets of naturally 
occurring isotopes of H, N, C, and O in the peptide, which changes to a bell shape when 
deuterium incorporates into functional groups of each atom. The average masses of each isotopic 
packet are plotted in duplicate for each deuterium uptake plot as a function of logarithm time.	  	  	  	  





	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  
Figure 2.11 Representative Deuterium Uptake Plots Comparing the Deuterium Uptake 
of PAI-1 +/- N-terminal His-tag, in PBS Buffer and MOPS Buffer.  A deuterium uptake 
bar graph for the same PAI-1 peptide spanning residues 64-92 (hD-s2A) after 10 minutes of 
exchange using active wild-type PAI-1 (red) or active PAI-1 with an N-terminal histidine tag 
(green) in 5 mM MOPS, 100 mM (NH4)2SO4, 6.5 mM NaCl, 2 mM NaOAc, and 0.1 mM 
EDTA. Deuterium uptake bar graph are also shown for this peptide in after 10 minutes of 
exchange on active wtPAI-1 (blue), and active wtPAI-1 with the histidine tag (purple) in 10 
mM phosphate buffer, 2.7 mM KCl, and 137 mM NaCl.  Pre-incubation samples (8uL) were 
diluted 20-fold (160uL) into deuterated buffer, exchange occurring at 25°C, and aliquots were 
taken after 10 minutes by quenching upon addition of 1.38% (3.2 uL) formic acid and flash-
freezing in liquid nitrogen.  The PAI-1 peptides, including 64-92, were generated using pepsin 
proteolysis. The peptides were injected into a cooled HPLC and analyzed using ESI-qTOF 
mass spectrometry as described in the Materials and Methods section.  	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His-tag has no effect on PAI-1 dynamics in each buffer; results for all peptides were compared 
and peptide 64-92 (hD-S2A) is shown as an example from the data set (Figure 2.11). While the 
HDX results were comparable in PBS buffer for both forms of PAI-1, a surprising 20% reduction 
in deuterium uptake was generally observed using the MOPS buffer system. We attribute this 
reduction in D-uptake to the presence of ammonium sulfate in the MOPS buffer, which is known 
to have a stabilizing effect on proteins. The only exception to this trend was observed with 
highly dynamic peptides that were fully deuterated within the experimental timeframe. Moreover, 
the reduction in deuterium uptake in MOPS vs. PBS buffer offers an advantage for observing 
differences in HDX that will arise from ligands that increase protein dynamics.  In PBS, many 
peptides reach fully exchanged levels very quickly, so the dynamic range in HDX experiments on 
PAI-1 is expanded using the MOPS buffer to slow the exchange.  
 
2.4.b. Addition of Increases Dynamics of PAI-1 in Functionally Relevant Regions 
 
 The effect of copper2+ ions on the amide backbone dynamics of active wtPAI-1 was 
investigated in the presence as well as the absence of the SMB domain of VN.  All of the 
deuterium uptake plots for these experiments conditions are displayed in (Figure 2.12). 
Representative deuterium uptake plots are presented in Figure 2.13 to illustrate copper2+ exchange 
effects on three PAI-1 peptic peptides (Figure 2.13). In the absence of ligands, active form of 
wtPAI-1 is highly dynamic.  Peptides comprising the lower backside underlying the shutter (hB, 
hC), flexible joint region (hD, hE, s1A), shutter region (s3A, s5A) and gate region (s3C, s4C, s3B) 
experience substantial deuterium uptake as a function of time in the experiment (Figure 2.12). The 
only regions structurally resistant from isotopic exchange are located in β-sheet B in the protein 
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core, which is in line with previous work [91].  Addition of the SMB domain of VN resulted in 
extensive protection to exchange to the binding interface in the flexible joint region, but also to the 
peptides spanning the backside underlying shutter, comprising the better part of the lower half of 
wtPAI-1 (Figure 2.12).  Addition of copper2+ results in an increase in isotopic exchange, meaning 
increased dynamics in regions covered by representative peptides 46-59 and 99-113, compared 
with active unligated wtPAI-1 (Figure 2.13).  As seen in previous work [91], SMB domain 
binding to PAI-1 resulted in lower isotopic exchange, consistent with reduced structural dynamics 
in the regions spanning these peptides.  When copper2+ and SMB domain are incubated with    
PAI-1, comparable exchange is observed relative to the addition of SMB for the peptides in Figure 
2.13. However, the effect was not for all peptides; an example of a peptide that is unaffected by 
copper2+ addition in the presence or absence of the SMB domain is 152-163 (Figure 2.13).   
Since several PAI-1 peptides likewise exhibited an increase in deuterium uptake as a result of 
copper2+ binding, it was first important to examine where this effect corresponded to on the 
primary sequence of PAI-1.  To facilitate this analysis the relative deuterium content, presented as 
percent of the full deuteration level, was calculated for each peptide, with and without copper2+ 
bound to PAI-1, and the difference in relative deuterium content was plotted as a heat map along 
the primary sequence (Figure 2.14). Peptide 46-59 (hB-hC loop) exhibited a significant increase 
of exchange in the presence of copper2+, indicative of an increase of dynamics in this region 
underlying the shutter.  Immediately following this peptide in the sequence, peptides representing 
the flexible joint region (64-94 (hC-hD), 99-113 (s2A-hE), 114-128 (hE-s1A), and 139-151 (hF)) 
also exhibit increased exchange consistent with elevated dynamics.  In addition, peptides spanning 
283-298 (s6A-hI) and 299-306 (loop between hI & s5A), immediately before strand 5A of the  





Figure 2.12 Deuterium Uptake Plots Active wtPAI-1 in the Presence and Absence of 
Copper2+ and SMB domain: HDX-MS experiments were performed on wtPAI-1 (red), 
wtPAI-1 + copper2+ (green), wtPAI-1 + SMB domain (blue), and wtPAI-1 + SMB + copper2+ 
(purple).  Deuterium uptake plots represent the increase in mass (Da) for each individual PAI-
1 peptide as a function of time.  The mass shift of each PAI-1 peptide having reached full 
experimental deuteration is denoted by the dashed black line.	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 Figure 2.12 Deuterium Uptake Plots Active wtPAI-1 in the Presence and Absence of 
Copper2+ and SMB domain (cont.): HDX-MS experiments were performed on wtPAI-1 (red), 
wtPAI-1 + copper2+ (green), wtPAI-1 + SMB domain (blue), and wtPAI-1 + SMB + copper2+ 
(purple).  Deuterium uptake plots represent the increase in mass (Da) for each individual PAI-1 
peptide as a function of time.  The mass shift of each PAI-1 peptide having reached full 
experimental deuteration is denoted by the dashed black line.	  






 Figure 2.12 Deuterium Uptake Plots Active wtPAI-1 in the Presence and Absence of 
Copper2+ and SMB domain (cont.): HDX-MS experiments were performed on wtPAI-1 (red), 
wtPAI-1 + copper2+ (green), wtPAI-1 + SMB domain (blue), and wtPAI-1 + SMB + copper2+ 
(purple).  Deuterium uptake plots represent the increase in mass (Da) for each individual PAI-1 
peptide as a function of time.  The mass shift of each PAI-1 peptide having reached full 
experimental deuteration is denoted by the dashed black line.	  






 Figure 2.12 Deuterium Uptake Plots Active wtPAI-1 in the Presence and Absence of 
Copper2+ and SMB domain (cont.): HDX-MS experiments were performed on wtPAI-1 
(red), wtPAI-1 + copper2+ (green), wtPAI-1 + SMB domain (blue), and wtPAI-1 + SMB + 
copper2+ (purple).  Deuterium uptake plots represent the increase in mass (Da) for each 
individual PAI-1 peptide as a function of time.  The mass shift of each PAI-1 peptide having 
reached full experimental deuteration is denoted by the dashed black line.	  







Figure 2.12 Deuterium Uptake Plots Active wtPAI-1 in the Presence and Absence of 
Copper2+ and SMB domain (cont.): HDX-MS experiments were performed on wtPAI-1 (red), 
wtPAI-1 + copper2+ (green), wtPAI-1 + SMB domain (blue), and wtPAI-1 + SMB + copper2+ 
(purple).  Deuterium uptake plots represent the increase in mass (Da) for each individual PAI-1 
peptide as a function of time.  The mass shift of each PAI-1 peptide having reached full 
experimental deuteration is denoted by the dashed black line.	  







Figure 2.13:  Representative Data from HDX-MS on Active wtPAI-1.   
Panel a: PAI-1 structure depicting the location of three representative HDX peptides. The 
HDX peptide spanning residues 46-59 of hB, hC and the loop connecting them is colored 
orange.  The HDX peptide spanning residues 99-113 of C-terminal end of s2A, hE and the 
loop connecting them is colored yellow.  The HDX peptide spanning residues 152-163 of the 
N-terminal portion of s3A and part of the preceding loop connecting to hF is colored pink.   
Panel b, c and d: HDX plots of representative peptides comparing the effects of copper2+ 
addition (+/- SMB).  Deuterium uptake plots are shown for three PAI-1 peptides: 46-59 
(LQLTTGGETQQQIQ) (panel b), 99-113 (FVQRDLKLVQGFMPHF) (panel c), and 152-
163 (LGKGAVDQLTRL) (panel d).  HDX-MS experiments were performed on wtPAI-1 
(red), wtPAI-1 + copper2+ (green), wtPAI-1 + SMB domain (blue), and wtPAI-1 + SMB + 
copper2+ (purple).  Deuterium uptake plots illustrate the increase in mass (Da) as a function of 
time for the individual peptic peptides.      	  




Figure 2.14 The Effects of Copper2+ on PAI-1 Dynamics: Examining the Primary 
Sequence. HDX-MS data were collected for various periods of exchange listed on the far left.  
For each of the 4 time points, deuterium exchange of wtPAI-1+copper2+ is given as a percentage 
difference relative to that observed for wtPAI-1 alone.  The data +/- copper2+ were normalized 
with respect to a fully deuterated control (100%) in which PAI-1 is denatured by guanidine in 
the presence of D2O for 4 hours to evaluate deuterium exchange in the unfolded form.  The 
primary sequence of PAI-1 is shown along the top of each row, with locations of secondary 
structure elements α-helices (green) and β-strands (blue) throughout the sequence. The identity 
of individual peptic peptides that were analyzed is depicted by the gray boxes along the 
sequence, and uptake results for each peptide at the four time points is shown in the columns 
below each peptide.  The proteolysis yielded peptides spanning the majority of the PAI-1 
sequence, giving essentially complete coverage in the HDX-MS experiments. The observed 
deuterium uptake values shown are the percentage difference between the two experimental 
conditions ([wtPAI-1 + Cu] – [wtPAI-1 alone]). The normalized percent difference was color 
coded using the following scheme: Percent difference of > -20% in dark blue, -20 to 10% in 
light blue, -10 to 10% in white, 10 to 20% in orange, and > 20% in red.	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shutter region, feature increased dynamics when copper2+ is bound.  It is important to note that 
copper2+ binding has no effect on exchange in peptides of several regions of PAI-1.  In our 
measurements, peptides covering the first two N-terminal peptides, which include hA and 
preceding N-terminal residues, beta sheets B and C, hG, hH, and the C-terminus are not affected 
by copper2+ binding. To interpret the spatial signature of copper2+ binding on PAI-1 dynamics we 
transferred the heat map shown in Figure 2.14 and onto the three-dimensional structure of PAI-1  
(Figure 2.15). Each of the peptic peptides affected by copper2+ addition is localized to the flexible 
joint region and areas underlying the shutter strands of beta sheet A. Taken together, our 
observations from the experimental conditions indicate that copper2+ binding causes localized 
rather than global changes in PAI-1 dynamics, at the time scale investigated.  Furthermore, it is 
apparent that copper2+ binding increases dynamics in regions of PAI-1 that are important for 
maintaining anti-protease active, metastable PAI-1 conformation; namely the flexible joints region 
and underlying helices in the shutter region. 
 
2.4.c. SMB Domain Binding Negates Copper2+ Effects on the Dynamics of PAI-1 
 
 As the SMB domain of VN binds PAI-1, containing the primary high-affinity binding site 
for PAI-1 [97], this results in significant resistance against isotopic exchange in several peptides. 
This includes peptides 46-59 (hB-hC), 99-113 (s2A-hE), 114-128 (hE-s1A), 299-306 (hI loop- 
s5A) (Figures 2.12, 2.16), This is consistent with previously published results [91], although the 
SMB effect is generally less pronounced in the present study due to the reduced dynamics of PAI-
1 in MOPS buffer compared to PBS.  The noted peptides are located in or proximal to the flexible 
joint region, including the SMB binding interface.  Likewise, binding of both copper2+ and the  
	   70  
 
Figure	  2.15  Copper2+ Increases Localized Dynamics in the Flexible Joints Region and 
Underlying Shutter Helices, SMB negates copper2+ effects.  
Panel a: Structural heat map of copper2+ effects on wtPAI-1. The normalized percent difference 
of deuterium uptake of wtPAI-1 + copper2+ versus wtPAI-1 alone for the peptic peptides in 
Figure 2.14 was represented on a crystal structure for active PAI-1 (pdb: 3Q02).  The percent 
difference in deuterium uptake is determined for the three minute HDX time point, represented 
by the following color scheme:  > -20% in dark blue, -20 to -10% in light blue, -10 to 10% in 
dark gray, 10 to 20% in orange, and > 20% in red.  Areas of light gray signify residues for 
which there was no sequence coverage.  
Panel b: Structural heat map of copper2+ + SMB effects on PAI-1. The normalized percent 
difference of deuterium uptake of wtPAI-1 + SMB + copper2+ versus wtPAI-1 alone for peptic 
peptides in Figure 2.16 was represented on a crystal structure for active PAI-1 (pdb: 3Q02).  
The percent difference in deuterium uptake is determined for the three minute HDX time point. 
The same colors representing percent differences apply for the heat map key. 
Panel c: Heat map of copper2+ effects (+/- SMB) on a PAI-1 structure. The normalized percent 
difference of deuterium uptake comparing wtPAI-1 + SMB + copper2+ versus wtPAI-1 + SMB 
for the same peptic peptides was represented on a crystal structure for active PAI-1 (pdb: 
3Q02).  The percent difference in deuterium uptake is determined for the three minute time 
point. The same colors representing percent differences apply for the heat map key. 
 
 	  





Figure 2.16 Determining the Effect of SMB and Copper2+ on PAI-1 Dynamics: Examining 
the Primary Sequence: HDX-MS data were collected for various periods of exchange listed on 
the far left.  For each of the 4 time points, deuterium uptake of wtPAI-1+SMB+copper2+ is given 
as a percentage relative to that observed for wtPAI-1 alone.  The data for the experimental 
conditions +/- copper2+ and the SMB domain were normalized with respect to a fully deuterated 
control (100%) in which PAI-1 is denatured by guanidine in the presence of D2O for 4 hours to 
determine the deuterium exchange in the unfolded form.  The primary sequence of PAI-1 is 
shown along the top of each row, with secondary structure elements α-helices (green) and β-
strands (blue) at their respective locations throughout the sequence. The identity of individual 
peptic peptides that were analyzed is represented in the gray boxes along the sequence, and 
uptake results for each peptide at the four time points are listed in the columns below each 
peptide. The deuterium uptake values listed are the percentage difference between the two 
experimental conditions ([wtPAI-1 + Cu +SMB] – [wtPAI-1 alone]). The normalized percent 
difference was color coded using the following scheme: Percent difference of > -20% in dark 
blue, -20 to 10% in light blue, -10 to 10% in white, 10 to 20% in orange, and > 20% in red.  	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SMB domain produced similar patterns of HDX protection observed upon the binding of the 
SMB alone, a general phenomenon illustrated by the example peptides in Figure 2.13. As 
observed with binding of just the SMB domain, peptides 47-59 (hB-hC), 99-113 (s2A-hE), 114-
128 (hE-s1A), and 299-306 (hI loop-s5A) (Figures 2.12, 2.16) are areas highly protected from 
exchange when both ligands are bound. Mapping of the results for binding of SMB and copper2+  
shows similar protection patterns observed with binding of the SMB alone [91], and shows 
reduced dynamics in the flexible joints region (Figure 2.15). Importantly, the high affinity of 
copper2+ for PAI-1, previously measured with a Kd < 100nM [109], appears unaffected upon the  
binding of the SMB domain. This is apparent from isothermal titration calorimetry experiments 
(See Chapter 3) in which the copper2+ binding isotherm is unchanged comparing PAI-1 and the 
PAI-1-SMB complex.  Furthermore, there is no binding of copper2+ to the isolated SMB domain 
by calorimetry. Thus, the changes in dynamics observed in these HDX experiments are due to 
binding and conformational effects of SMB and copper2+ and not to changes in affinity, which 
would alter saturation levels. 
 Only the N-terminal peptide (residues 1-15) was substantially protected with both ligands 
bound, compared to the binding of SMB (Figure 2.12, 2.15). Since peptide 1-7 is unaffected, and 
peptide 1-15 is protected (Figure 2.12, 2.15) the protection by the combined binding of SMB and 
copper2+ must be sub-localized to the second half of the peptide (8-15). The N-terminal histidine 
residues in positions 2 and 3 are part of a potential copper2+ binding site. However, these residues 
are located in an unprotected, dynamic region and it is not possible to predict whether complex 
formation with copper2+ would cause protection of their backbone amide hydrogens. Therefore, the 
absence of copper2+-SMB-induced protection in peptide 1-7 does not rule out possibility 
interaction between copper2+ and the N-terminal histidine residues. Nevertheless, our data show 
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that in the presence as well as the absence of copper2+, SMB domain binding protects against 
changes in dynamics that are correlated with the destabilization that is promoted as a result of 
copper2+ binding.  
 
 
2.4.d Copper2+ Affects Protein Dynamics in the Same Regions within H2AH3A-PAI-1 and 
Wild-Type PAI-1 
 As the recent crystal structure of W175F-PAI-1 revealed a zinc positioned proximal to the 
two N-terminal histidines of PAI-1 at positions 2 and 3 in the protein chain (pdb: 3Q02), 
experiments were designed to assess whether copper2+ asserts its effect on PAI-1 dynamics through 
binding to these same residues.  A form of PAI-1 was engineered with alanine substitutions for 
these two histidines, and HDX experiments were performed to test for copper2+ effects on 
dynamics.   The example uptake plot in Figure 2.17 compares exchange rates for active wtPAI-1 
with active H2AH3A-PAI-1 in the presence and absence of copper2+.  Data are shown for 
representative peptides 46-59 (hB-hC loop) and 99-113 (hE-s1A).  A complete set of uptake plots 
of H2AH3A-PAI-1 with and without addition of copper2+ are presented in Figure 2.18. Comparing 
wild-type PAI-1 to H2AH3A-PAI-1 revealed a decrease in HDX rates as a result of incorporating 
this double amino acid substitution into PAI-1 (Figure 2.17). Also, as with wild-type PAI-1, the 
variant shows an increase in deuterium exchange in the presence of copper2+ compared with 
H2AH3A-PAI-1 alone.  Across the primary sequence, changes in dynamics due to Copper2+ 
addition occur in similar regions seen with active wild-type PAI-1 upon copper2+ binding (Figure 
2.18).  The regions that experience changes are apparent when the copper2+ effects are mapped 
onto the structure of H2AH3A-PAI-1 (Figure 2.17).  The peptides spanning the hB-hC loop, hD,  
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Figure 2.17 Comparing the Effects of Copper2+ Addition on H2AH3A-PAI-1.   
Panels a and b: Deuterium uptake plots for two PAI-1 peptides in H2AH3A-PAI-1 and wtPAI-1: 
a- 46-59 (LQLTTGGETQQQIQ) and b-99-113 (FVQRDLKLVQGFMPHF).  HDX-MS 
experiments were performed on wtPAI-1 (red), wtPAI-1 + copper2+ (green), H2AH3A-PAI-1 
(purple), and H2AH3A-PAI-1 + copper2+ (orange).  Deuterium uptake plots illustrate the increase 
in mass (Da) as a function of time for each peptic peptide. 
Panel c: Structural heat map of copper2+ effects on H2AH3A-PAI-1.  The normalized percent 
difference of deuterium uptake of H2AH3A-PAI-1 + copper2+ versus H2AH3A-PAI-1 alone for 
the peptic peptides Figure 2.19 was represented on a crystal structure for active PAI-1 (pdb: 
3Q02).  The percent difference in deuterium uptake is determined for the three minute HDX time 
point, represented in the following color scheme:  > -20% in dark blue, -20 to -10% in light blue, 
-10 to 10% in dark gray, 10 to 20% in orange, and > 20% in red.  Areas of light gray signify 
residues for which there was no sequence coverage. 
Panel d: Structural heat map of H2AH3A-PAI-1 dynamics compared with wtPAI-1.  The 
normalized percent difference of deuterium uptake of H2AH3A-PAI-1 versus wtPAI-1 for the 
peptic peptides was represented on a crystal structure for active PAI-1 (pdb: 3Q02).  The same 
colors representing percent differences apply for the heat map key. 
Panel e: Structural heat map of copper2+ effects on H2AH3A-PAI-1 compared with wtPAI-1.  The 
normalized percent difference of deuterium uptake of H2AH3A-PAI-1 + copper2+ versus wtPAI-1 
+ copper2+ for the peptic peptides was represented on a crystal structure for active PAI-1 (pdb: 
3Q02).  The same colors representing percent differences apply for the heat map key. 	  






Figure 2.18 Deuterium Uptake Plots Active wtPAI-1 versus H2AH3A PAI-1 in the 
Presence and Absence of Copper2+: HDX-MS experiments were performed on wtPAI-1 
(red), wtPAI-1 + copper2+ (green), H2AH3A PAI-1 (magenta), and H2AH3A PAI-1 + 
copper2+ (orange).  Deuterium uptake plots represent the increase in mass (Da) for the each 
individual PAI-1 peptide as a function of time.  The mass shift of each peptide having reached 
full experimental deuteration is denoted by the dashed black line. 	  







Figure 2.18 Deuterium Uptake Plots Active wtPAI-1 versus H2AH3A PAI-1 in the Presence 
and Absence of Copper2+ (cont.): HDX-MS experiments were performed on wtPAI-1 (red), 
wtPAI-1 + copper2+ (green), H2AH3A PAI-1 (magenta), and H2AH3A PAI-1 + copper2+ (orange).  
Deuterium uptake plots represent the increase in mass (Da) for the each individual PAI-1 peptide 
as a function of time.  The mass shift of each peptide having reached full experimental 
deuteration is denoted by the dashed black line. 
 	  





 Figure 2.18 Deuterium Uptake Plots Active wtPAI-1 versus H2AH3A PAI-1 in the 
Presence and Absence of Copper2+ (cont.): HDX-MS experiments were performed on 
wtPAI-1 (red), wtPAI-1 + copper2+ (green), H2AH3A PAI-1 (magenta), and H2AH3A PAI-
1 + copper2+ (orange).  Deuterium uptake plots represent the increase in mass (Da) for the 
each individual PAI-1 peptide as a function of time.  The mass shift of each peptide having 
reached full experimental deuteration is denoted by the dashed black line.	  




 Figure 2.18 Deuterium Uptake Plots Active wtPAI-1 versus H2AH3A PAI-1 in the 
Presence and Absence of Copper2+ (cont.): HDX-MS experiments were performed on 
wtPAI-1 (red), wtPAI-1 + copper2+ (green), H2AH3A PAI-1 (magenta), and H2AH3A PAI-1 
+ copper2+ (orange).  Deuterium uptake plots represent the increase in mass (Da) for the each 
individual PAI-1 peptide as a function of time.  The mass shift of each peptide having reached 
full experimental deuteration is denoted by the dashed black line.	  







 Figure 2.18 Deuterium Uptake Plots Active wtPAI-1 versus H2AH3A PAI-1 in the 
Presence and Absence of Copper2+ (cont.): HDX-MS experiments were performed on 
wtPAI-1 (red), wtPAI-1 + copper2+ (green), H2AH3A PAI-1 (magenta), and H2AH3A 
PAI-1 + copper2+ (orange).  Deuterium uptake plots represent the increase in mass (Da) for 
the each individual PAI-1 peptide as a function of time.  The mass shift of each peptide 
having reached full experimental deuteration is denoted by the dashed black line.	  







Figure 2.19 Effect of Copper2+ on H2AH3A-PAI-1 Dynamics, Examining the Primary 
Sequence. HDX data of H2AH3A-PAI-1 alone and H2AH3A-PAI-1 + copper2+ were acquired 
for comparison with wild type. Exchange data were collected for various periods listed on the 
far left.  For each of the 4 time points, deuterium uptake of H2AH3A-PAI-1+copper2+ is given 
as a percentage relative to that observed for H2AH3A-PAI-1 alone.  The data in both 
experimental conditions were normalized with respect to a (100%) fully deuterated control in 
which PAI-1 is denatured by guanidine in the presence of D20 for 4 hours to determine the 
deuterium exchange in the unfolded form.  The primary sequence of PAI-1 is shown along the 
top of each row, with secondary structure α-helices (green) and β-strands (blue) in their 
locations throughout the sequence. The identity of individual peptic peptides that were analyzed 
is represented in gray boxes along the sequence, and uptake results for each peptide at the four 
time points are displayed in the columns below each peptide. The listed deuterium uptake 
values are the percentage difference between the two experimental conditions ([H2AH3A-PAI-
1 + Cu] – [H2AH3A-PAI-1 alone]). The normalized percent difference was color coded using 
the following scheme: Percent difference of > -20% in dark blue, -20 to 10% in light blue, -10 
to 10% in white, 10 to 20% in orange, and > 20% in red. 	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hE, hF, hI, and s5A all have elevated exchange as a result of copper2+ addition, like wild-type PAI-
1 (Figure 2.15). A structural comparison of the H2H3A and wild-type PAI-1 both in the presence 
of copper2+ exposes changes in the gate region. The dynamics of the gate region are lower in wild-
type, compared with the variant, indicating a possibility of a metal ion-binding site in the region. 
From a structural perspective, H2AH3A variant and wild-type PAI-1 are affected by copper2+ in 
largely similar regions, including the flexible joints region and helices that border the shutter 
region, although there are some differences. If we compare dynamics in the absence of ligands, we 
observe the regions of lower dynamics that appear to result directly from the mutation at the N-
terminus. Figure 2.17 shows the difference in dynamics comparing H2AH3A-PAI-1 and wild-type 
PAI without ligands, and Figure 2.17 shows the differences mapped onto the structure for the two 
forms of the protein with added copper2+. The decreased dynamics in H2AH3A-PAI-1 at multiple 
sites in the protein is apparent, either in the presence or absence of copper2+. One intriguing 
difference of note between the variant and wtPAI-1 is observed with peptides 1-15, 8-15 (hA) that 
include the substituted residues.  These peptides are protected from exchange in the presence of 
copper2+ and SMB in wtPAI-1, but show no differences when copper2+ alone is added to wtPAI-1 
(Figure 2.12).  Conversely, addition of copper2+ results in an increase in exchange for the same 
peptides in H2AH3A-PAI-1. Apart from this difference, the overall response in dynamics to 
copper2+ complexation is quite similar for wtPAI-1 and H2AH3A-PAI-1 suggesting that the 
copper2+-induced destabilization is not mediated through the binding of copper2+ to the two N-
terminal histidines of PAI-1.     
2.4.e Copper2+ has Modest Effects on the Dynamics of Latent wtPAI-1	    
Previous binding studies showed that metals ions bind to the active as well as the latent form of 
PAI-1, although the latter binds somewhat weaker [109]. It is therefore important to determine 
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whether copper2+ affects the dynamics of both the active and latent form of PAI-1. HDX studies 
were thus pursued with latent wild-type PAI-1 in the presence and absence of added copper2+. In 
the absence of copper2+, results from peptides throughout PAI-1 illustrate an almost global 
reduction in HDX rates that accompanies the conformational change to the latent form, consistent 
with previous work [91]. Furthermore, there are only minor changes in dynamics with the latent 
form in the presence of added. This is illustrated by deuterium uptake for all peptides (Figure 
2.20) and also by representative uptake plots of peptides 46-59 (hB-hC loop) and 99-113 (s2A-
hE) (Figure 2.21) and the map along the primary sequence (Figure 2.22). The representative 
uptake plots in Figure 2.21 compare latent wtPAI-1 in the presence and absence of copper2+ with 
active wtPAI-1 in the presence and absence of ligand. A view of the copper2+ effect on latent 
wtPAI-1 is represented on the three-dimensional structure in Figure 2.21. While there are modest 
changes in dynamics for a few peptides, the differences are not localized to one region on the 
structure; nor are they located in regions known to influence latency conversion, or protease 
inactivation. 
2.4.f. Copper2+ Accelerates Local Unfolding of an Underlying Shutter Peptide on a Time-
Scale Relevant for the Latency Transition 
 Recent work has identified local unfolding events in PAI-1 HDX peptides that transpire on 
timescales relevant to the latency process [85].  The signature of an unfolding event in the HDX-
MS data is the presence of bimodal isotope distributions (see methods for further explanation). In 
the case of a transient unfolding event, protein molecules which have not yet visited the unfolded 
state will yield a low mass population in the mass spectrum; whereas protein molecules that have 
visited the unfolded state will yield a high mass population. The mass difference between the two  
 






Figure 2.20 Deuterium Uptake Plots Active wtPAI-1 versus Latent wtPAI-1 in the 
Presence and Absence of Copper2+. HDX-MS experiments were performed on wtPAI-1 (red), 
wtPAI-1 + copper2+ (green), latent wtPAI-1 (brown), and latent wtPAI-1 + copper2+ (teal).  
Deuterium uptake plots represent the increase in mass (Da) for the individual PAI-1 peptides as 
a function of time.  The mass shift of each peptide having reached full experimental deuteration 
is denoted by the dashed black line.  	  







 Figure 2.20 Deuterium Uptake Plots Active wtPAI-1 versus Latent wtPAI-1 in the 
Presence and Absence of Copper2+ (cont.): HDX-MS experiments were performed on wtPAI-
1 (red), wtPAI-1 + copper2+ (green), latent wtPAI-1 (brown), and latent wtPAI-1 + copper2+ 
(teal).  Deuterium uptake plots represent the increase in mass (Da) for the individual PAI-1 
peptides as a function of time.  The mass shift of each peptide having reached full experimental 
deuteration is denoted by the dashed black line.	  







Figure 2.20 Deuterium Uptake Plots Active wtPAI-1 versus Latent wtPAI-1 in the 
Presence and Absence of Copper2+ (cont.): HDX-MS experiments were performed on wtPAI-
1 (red), wtPAI-1 + copper2+ (green), latent wtPAI-1 (brown), and latent wtPAI-1 + copper2+ 
(teal).  Deuterium uptake plots represent the increase in mass (Da) for the individual PAI-1 
peptides as a function of time.  The mass shift of each peptide having reached full experimental 
deuteration is denoted by the dashed black line.	  







Figure 2.20 Deuterium Uptake Plots Active wtPAI-1 versus Latent wtPAI-1 in the Presence 
and Absence of Copper2+ (cont.): HDX-MS experiments were performed on wtPAI-1 (red), 
wtPAI-1 + copper2+ (green), latent wtPAI-1 (brown), and latent wtPAI-1 + copper2+ (teal).  
Deuterium uptake plots represent the increase in mass (Da) for the individual PAI-1 peptides as a 
function of time.  The mass shift of each peptide having reached full experimental deuteration is 
denoted by the dashed black line.	  







 Figure 2.20 Deuterium Uptake Plots Active wtPAI-1 versus Latent wtPAI-1 in the 
Presence and Absence of Copper2+ (cont.): HDX-MS experiments were performed on 
wtPAI-1 (red), wtPAI-1 + copper2+ (green), latent wtPAI-1 (brown), and latent wtPAI-1 + 
copper2+ (teal).  Deuterium uptake plots represent the increase in mass (Da) for the 
individual PAI-1 peptides as a function of time.  The mass shift of each peptide having 
reached full experimental deuteration is denoted by the dashed black line.	  




Figure 2.21 Latent wtPAI-1 Features Minimal Changes in HDX in the Presence and 
Absence of Copper2+. 
Panels a and b: Representative deuterium uptake plots comparing the effects of copper2+ addition 
in latent wtPAI-1.  Deuterium uptake plots are shown for two PAI-1 peptides: 46-59 
(LQLTTGGETQQQIQ) and 99-113 (FVQRDLKLVQGFMPHF).  HDX-MS experiments were 
performed on active wtPAI-1 (red), active wtPAI-1 + copper2+ (green), latent wtPAI-1 (blue), and 
latent wtPAI-1 + copper2+ (brown).  Deuterium uptake plots illustrate the increase is mass (Da) as 
a function of time for each PAI-1 peptic peptide. 
Panel c: Heat map of copper2+ effects on a latent PAI-1 structure.  The normalized percent 
difference of deuterium uptake of latent wtPAI-1 + copper2+ versus latent wtPAI-1 alone for the 
peptic peptides Figure 2.22 was represented on a crystal structure for active PAI-1 (pdb: 3Q02).  
The percent difference in deuterium uptake is shown for the three minute HDX time point, 
represented in the following color scheme: > -20% in dark blue, -20 to -10% in light blue, -10 to 
10% in dark gray, 10 to 20% in orange, and > 20% in red.  Areas colored light gray signify 
residues for which there was no sequence coverage. 	  







Figure 2.22 Determining the Effect of Copper2+ Binding on Latent PAI-1 Dynamics: 
Examining the Primary Sequence:  Deuterium uptake of latent wtPAI-1 alone and latent 
wtPAI-1 + copper2+ were acquired for comparison with active wild type.  Exchange data were 
collected for various periods listed on the far left.  For each of the 4 time points, deuterium 
uptake of latent wtPAI-1+copper2+ is given as a percentage relative to that observed for wtPAI-
1 alone.  The data in both experimental conditions were normalized with respect to a fully 
deuterated control (100%) in which PAI-1 is denatured by guanidine in the presence of D20 for 
4 hours to determine the deuterium exchange in the unfolded form.  The primary sequence is of 
PAI-1 is shown along the top of each row, with secondary structure α-helices (green) and β-
strands (blue). The identity of individual peptic peptides that were analyzed is represented by 
the gray boxes along the sequence, and uptake results for each peptide at the four time points 
are displayed in the columns below each peptide. The listed deuterium uptake values are the 
percentage difference between the two experimental conditions ([latent wtPAI-1 + Cu] – [latent 
wtPAI-1 alone]). The normalized percent difference was color coded using the following 
scheme: Percent difference of > -20% in dark blue, -20 to 10% in light blue, -10 to 10% in 
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populations is proportional to the number of backbone amide hydrogens exposed to the solvent as 
a consequence of the unfolding event. The rate of unfolding can be measured as the rate at which 
the low mass and high mass populations interconvert.  Three peptides detected in the HDX-MS 
experiments on PAI-1 demonstrated these events: 46-63 (hB-hC) with a t1/2 ~ 80 seconds at 15°C 
(< 10s at 37°C), 16-40 (hA-s6B) with a t1/2 ~ 18 minutes at 37°C, and 307-340 (s5A) with a t1/2 ~ 
24 minutes at 37°C [85].  As the HDX experiments conducted here were done at 25°C in MOPS 
buffer and terminated after 10 minutes of exchange, we did not sample the appropriate time and 
temperature to observe the unfolding of regions covered by peptides 16-40 and 307-340.  The 
unfolding previously observed in the hB-hC peptide was much more frequent and is therefore 
sampled in the experiments conducted here (Figure 2.23). Interestingly, the change to MOPS 
buffer decreased the rate of unfolding significantly and only a negligible fraction of molecules 
have visited the unfolded state after 10 min incubation as judged by the limited peak broadening. 
Most importantly, addition of copper2+ not only accelerates the unfolding event substantially (t1/2 
~20 sec), but the spacing between the two mass populations resembles that previously observed 
when PAI-1 was analyzed in PBS buffer.  This means that copper2+ addition not only counteracts 
the effect of MOPS on the rate of unfolding, but copper2+ also reverts the geometric extent of 
unfolding in the region to that observed in PBS.  As expected, we also observed this bimodal peak 
distribution in the variant H2AH3A-PAI-1 (data not shown). Taken together, the correlation 
between accelerated local unfolding and accelerated latency transition upon addition of copper2+ 
to PAI-1 further supports the hypothesis that unfolding events contribute in significant ways to 
the mechanism by which active PAI-1 rearranges to the latent inactive conformation. 
 
  










Figure 2.23 Local Unfolding Kinetics of PAI-1 Peptide 46-63 Accelerated in Presence of 
Copper2+.  The raw mass spectra of peptide 46-63 for active wtPAI-1 alone (left) and active 
wtPAI-1 + copper2+ (right) are shown for HDX time points 10, 30, 180, and 600 seconds. The 
peptic peptide (residues 46-63), is located underlying the shutter strands s3A/s5A), which is 
hypothesized to undergo local unfolding on a timescale consistent with early in the latency 
transition process. 	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2.5 Discussion 
 
2.5.a. Copper2+ Increases Dynamics in Similar regions Protected by the SMB Domain 
 
 Copper2+ significantly destabilizes PAI-1 in the absence of VN, but substantially enhances the 
delay of latency conversion of the presence of VN.  Since the SMB domain of VN curtails PAI-1 
dynamics [91], we hypothesized that copper2+ addition would increase isotopic exchange if protein 
dynamics have a regulatory role in the rate of transition.  We observed that the same regions that 
are more dynamic in the presence of copper2+, become stabilized in the presence of SMB domain, 
supporting our hypothesis. The flexible joint region, gate region, and shutter region are known to 
be involved in steps in the mechanism for the structural transition of PAI-1 from the active to 
latent form [83, 96, 105, 141].  The observed changes in dynamics were in predominantly 
overlapping regions affected by binding of the SMB domain and copper2+, including the flexible 
joint region, and N-terminal part of hF [142].  Additionally, we observed changes due to copper2+ 
addition in the area underlying the shutter strands in hB-hC and the proximally located hI.  
Importantly, the altered dynamics were not a global effect, but were localized structurally.  In other 
words, some dynamic, as well as protected regions of PAI-1 were unaffected as a result of copper2+ 
binding in our data.  
 
 Prior biochemical and HDX work was conducted on PAI-1 in the presence of Mab-1 antibody 
[138] and RNA aptamers [103] to evaluate their stabilizing effects. These ligands bind to PAI-1 in 
the flexible joint region as well as to hC in the case of the antibody [103]. Mab-1 binding stabilizes 
PAI-1 by 1.4 fold [138], while the aptamers do so by 3-4 fold [103]. Strikingly, peptides spanning 
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this region also reported decreased exchange in the presence of the Mab-1 [91], aptamers [139], 
and the SMB domain [91], albeit with differing protection patterns for the various ligands.  The 
binding of copper2+ accelerates the latency transition [79] and strongly increased HDX exchange 
for peptides spanning helices hB, hC, and hI. Taken together, these findings add to the evidence 
that the dynamics of hB, hC, and hI have an important role in the latency transition process [139].    
 Our results feature more protection than in previous studies, caused by the buffer optimization 
from PBS to MOPS for metal ion studies.  This switch was vital for maintaining an appropriate 
dynamic window for PAI-1 in the presence of a ligand that increases exchange.  In the 
experiments using PBS buffer, many of the peptides reach full deuteration during the early time 
points [91]. The buffer change to MOPS helped maintain an adequate dynamic window for 
monitoring HDX with a ligand that increases PAI-1 dynamics. The tendency of phosphate to 
precipitate divalent metal ions precluded the use of PBS, but it allowed us to observe copper2+ 
effects that increased exchange rates of an already dynamic unligated form of active wtPAI-1. On 
the other hand, changing to MOPS buffer hindered our ability to measure changes in exchange of 
less dynamic species. For example, binding of the SMB domain to PAI-1 protected HDX in 
peptides of the flexible joint region in MOPS, but the effect was markedly less compared to the 
same HDX experiment in PBS [91]. Binding of SMB and copper2+ to PAI-1 results in a 2.5 fold 
stabilization compared with just binding of SMB [79]. One would expect to observe further 
protection from exchange with both ligands present compared to just SMB, but our experimental 
conditions showed no difference between them. The MOPS buffer system incurring a stabilizing 
structural effect on PAI-1 provides at least a partial explanation for this result.     
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2.5.b. Copper2+ Does Not Bind PAI-1 N-terminal Histidines to Mediate Changes in Dynamics  
 
 The most recent PAI-1 crystal structure provided amino acid residue targets from the N-
terminus and gate region (H2, H3, E212, D222, E350, E242) as potential metal ion ligands [95]. 
We hypothesized that copper2+ may bind to the N-terminal residues to increase dynamics. If this 
hypothesis was correct, we would expect this increases of dynamics in a variant lacking these 
residues to be eradicated. We first observed a global decrease in dynamics as a result of the 
mutations, the source of which remains unclear. Nonetheless, it was clear that H2AH3A-PAI-1 
follows a similar pattern as the wild-type protein regarding dynamic changes in the presence of 
copper2+. Altogether, these data indicate that the N-terminal histidines are not the residues that 
coordinate metal to produce elevated dynamics and accelerated latency transition kinetics. 
 
2.5.c. Latent wtPAI-1 is Insensitive to Copper2+ Effects on Dynamics     
 
 A global reduction in dynamics was observed when comparing active and latent PAI-1, due to the 
conformational change that yields a more compact, rigid structure.  The only region with increased 
exchange in the latent form of PAI-1 is in the gate region, due to the widening of β-sheet C strands 
that is necessary to allow for the RCL to pass through during loop insertion.  Addition of copper2+ 
to latent PAI-1 resulted in modest increases in exchange from a few isolated peptides, but had no 
effect on the flexible joint region.  Copper2+ addition had minimal influences on dynamics near the 
gate region, an area that opens up as a result of conformational shift to the latent state.  Although 
there could be several reasons for these observations, the most likely interpretation lies at the heart 
of the study. That is the metastable nature of PAI-1 that keeps it poised for protease inactivation 
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and drives it toward a timed inactivation as it converts to a latent form.  Clearly, active PAI-1 is 
highly dynamic and sensitive to ligands that promote changes in protein dynamics that influence 
the overall conformation.  Latent PAI-1 is inherently restricted in dynamics and thus not as prone 
to effects upon ligand binding.       
 
2.5.d. Copper2+ Accelerates an Early Unfolding Related to the Latency Transition   
 
 As mentioned above, the need to perform experiments on copper2+, a ligand that increases 
PAI-1 H-D exchange rates, required a modification of experimental conditions (temperature and 
buffer) to slow the exchange rates within a measurable window.  This adjustment offered an 
opportunity for us to observe a local unfolding event that occurs in the timeframe of the 
experiment.  This is local unfolding of peptide 46-63 (hB-hC) that occurs with a t1/2 of 80 seconds 
at 15°C, and t1/2 < 10 seconds at 37°C in PBS buffer [85].  The observation of local unfolding in 
this region provides some insight into the mechanism by which copper2+ exerts its effect and 
promotes the conformational change toward latency.  In the present study, the same peptide 
(peptide 46-63) experiences local unfolding, in MOPS buffer in 10 minutes at 25°C, but the 
experimental timescale would have to be extended to view the local unfolding kinetics 
completely.  The addition of copper2+ under these conditions decreased the t1/2 to ~ 30 seconds.  
Since PAI-1 has a half-life for conversion to the latent form (37°C) of approximately 1 hour, with 
a decrease to 10 minutes upon binding of copper2+, these rates of local peptide unfolding observed 
by HDX likely correspond to early events in the latency transition process.   The other peptides 
(16-40 and 299-306) have t1/2 for unfolding values on the order of the latency transition process 
itself [85].  It is important to note that we also observe local unfolding in peptide 46-63 of 
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H2AH3A-PAI-1 with copper2+ bound, indicating that copper2+ exerts it effects on PAI-1 by 
binding elsewhere than the two N-terminal histidines.  Taken together, these results show that 
copper2+ binding facilitates an early transition presumed to be on the pathway to latency.   
  
2.6. Conclusions 
 The major objective of this work was to investigate the effects of copper2+ on protein 
dynamics of PAI-1 in the active, latent, and SMB bound forms, as well as the active variant 
H2AH3A. PAI-1 functions in concert with VN at sites of injury in the vasculature to control 
hemostasis, and associates with the extracellular matrix of healthy and pathological states such as 
inflammatory response, tumor development, obesity. In circulation, tissue, and extracellular 
stores, copper2+ has involvement in these same pathophysiological conditions, although it is less 
well understood. Our recent finding of copper2+ effects on PAI-1 inhibitory activity and stability 
in the active form, which are dependent on the presence of VN [79], stimulated our interest in 
how protein dynamics could be correlated to function. In the presence of copper2+ concentrations 
that are physiologically relevant, PAI-1 converts to the latent form faster and exhibits increased 
dynamics. In the presence of SMB or both ligands, which stabilize PAI-1 in the active form, leads 
to decreases in dynamics of the very same regions within PAI-1. The binding of SMB domain 
negates copper2+ effects when both are present, resulting in similar protection to when SMB alone 
is bound to PAI-1. Since copper2+ accelerates the latency transition, but the SMB domain delays 
conversion to the latent state, these data on the dynamic behavior of PAI-1 agree well with the 
measurement of PAI-1 latency conversion in the presence of the ligands using kinetic approaches 
[79]. In addition to many of the known structural features of PAI-1 involved in the transition 
process, including the flexible joint region, shutter region, and gate region, the dynamics of 
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helices hB-hC-hI emerge as important factors that determine conformational stability.  Moreover, 
local unfolding observed in a peptide spanning hB-hC, this unfolding transpires with an 
accelerated half-life in the presence of copper2+.  The timescales indicate this local unfolding 
event takes place early in the latency conversion process.  Observation of the unfolding events 
upon copper2+ addition suggests that PAI-1 undergoes a similar path to the latent state in the 
presence and absence of copper2+.  The results of this study indicate that protein dynamics 
influence the PAI-1 latency transition process. Examination of ligands that stabilize and de-
stabilize PAI-1 show that they decrease and increase dynamics, respectively.  Therefore, 
physiologically important metal ion ligands that influence the latency transition in a VN-
dependent manner affect changes by shifting protein dynamics in important regions of PAI-1. Our 
findings that ligands have specific effects on protein dynamics is particularly intriguing since 
PAI-1 is a metastable protein that converts from active to inactive conformations under 
physiological conditions.  These  effects of copper2+ on PAI-1 offer a mechanistic understanding 
of the peculiar metal ion effects, dependent on vitronectin, which can affect stability in a variety 
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Chapter 3 Identification and Functional Characterization of PAI-1 Metal Ion Binding Site  
 
3.1. Introduction 
3.1.a. Metal Ion Effects on PAI-1 
 Our laboratory has recently uncovered unexpected effects of transition metals on the rate of 
PAI-1 latency transition, and these effects are dependent on the presence of VN. PAI-1 transition 
metal ion affinity was first discovered through binding to an immobilized metal ion affinity 
column (IMAC) without requiring a 6x histidine tag [79]. IMAC resin charged with divalent 
metal ions such as maganese2+, cobalt2+, nickel2+, copper2+, and zinc2+ bound to PAI-1, albeit with 
varying affinities [79]. Several of the aforementioned transition metal ions, along with 
physiologically relevant alkali earth metal ions calcium2+, and magnesium2+, were incubated with 
PAI-1 to determine effects on the half-life of active PAI-1 in the presence and absence of VN 
[79]. PAI-1 alone remains active with a half-life of 70 minutes, whereas PAI-1 with VN exhibits 
some stabilization with a longer half-life of 90 minutes. PAI-1 is slightly stabilized in the 
presence of Ca2+, Mg2+, and Mn2+, and the same modest stabilization is observed when these metal 
ions are incubated with PAI-1 and VN [79]. Cu2+, Ni2+, and Co2+ have a much more dramatic 
effect, significantly destabilizing PAI-1 (t1/2 ~ 10 minutes). Notably, the binding of VN and the 
transition metal ions provide significant stabilization (t1/2 ~ 3-4 hours) [79].  
  
 PAI-1 is stabilized primarily through the N-terminal SMB domain of VN interacting with the 
flexible joint region of PAI-1 [97]. However, the proteins have an extended binding interface that 
extends beyond the SMB domain of VN [98, 100]. Do the observed copper2+ effects on stability 
occur through binding to PAI-1, VN, or a combination of both proteins at their binding interface?  
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This was tested through stability measurements on PAI-1 in which the effects of SMB domain 
were compared with full length VN. In measurements including the SMB and copper2+, the half-
lives were comparable to those measured of full length VN with copper2+ [79], demonstrating that 
observed metal ion effects are mediated through PAI-1, the SMB domain, or a combination of both 
when they interact. Additionally, gel based activity assays were completed to monitor the relative 
amounts of tPA-bound, latent, and substrate-like PAI-1 in the presence of metal ions. Significantly 
more latent PAI-1 was observed for destabilizing metal ions Cu2+, Ni2+, and Co2+ compared to the 
stabilizing metal ions [79]. In addition, these metal ions (most notably copper2+) appear to promote 
PAI-1 substrate-like behavior [79]. This indicates that copper2+ affects the rate limiting step of 
inhibition (refer to Figure 1.4) in which the rate of RCL insertion (klim) determines if full 
inhibition or release of the protease occurs.  
 
 The binding of different forms of PAI-1 to metal ions was also characterized by surface 
plasmon resonance (SPR), competition assays, and stopped-flow kinetics [109]. Active as well as 
latent PAI-1 bind immobilized nickel2+ on the SPR chip in the low micromolar range, with the 
latter binding 3.5 fold weaker [109].  High concentrations of Mg2+ were able to competitively 
inhibit PAI-1 binding to immobilized nickel2+, which indicates that the metal ions bind in the same 
location, despite their difference in effects on PAI-1 stability [109]. Other methods were used to 
characterize ion binding to PAI-1 for each metal, since metal ions like Mg2+ and Mn2+ modestly 
stabilize PAI-1, whereas the transition metal ions display more dramatic effects. Stopped-flow 
experiments monitoring intrinsic tryptophan fluorescence determined binding differences in PAI-1 
comparing the effects of the metal ions tested. Binding of metal ions that stabilize PAI-1 (Mg2+, 
and Mn2+) fit best to a double exponential equation while the binding behavior of those that 
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destabilized PAI-1 (Cu2+, Ni2+, and Co2+) fit best to a triple exponential equation [109]. In other 
words, metal ions that featured the same effects in the stability assay exhibited the same binding 
via stopped-flow.    In the case of the destabilizing metal ions, the intrinsic fluorescence has an 
initial decrease that is concentration dependent, indicating that it is likely a binding phase [109]. 
Following this initial binding, the intrinsic fluorescence exhibits a biphasic increase that is not 
concentration dependent [109]. The first of the two phases represents the occurrence of an 
unknown conformational change, and the last phase is attributed to the latency conversion, as this 
occurs with a rate constant near that of latency conversion measured by the stability kinetics assay 
[109]. Copper2+ binds PAI-1 at low nanomolar concentrations, while nickel2+ and cobalt2+ bind at 
much higher micromolar concentrations, determined by the binding phases of the approach to 
equilibrium data [109]. Stability kinetics experiments involving two different metal ions provided 
further evidence that the metal ions bind in the same location [109]. When PAI-1 is incubated with 
saturating concentrations of Cu2+ and either Mg2+, or Ni2+, the kinetics of latency observed appear 
to represent an “average” of the effects exhibited by either individually [109], and support the 
notion that the metal ions were competing for binding to the same site on PAI-1.  
 The main aim of the work described in this chapter is to understand the molecular basis for 
metal ion effects on PAI-1. Several questions were raised- Where do metal ions, particularly 
copper2+, bind to PAI-1? How does copper2+ binding accelerate latency conversion of PAI-1? How 
do copper2+ and VN (or SMB domain) stabilize PAI-1 more so than VN can alone? To address 
these questions, we pursued a mutagenesis approach to test for specific residues involved in metal 
ion binding, based on predictions from the PAI-1 crystal structure. Stability kinetics assays in the 
presence and absence of metal ions were performed on the PAI-1 variants to assess if the rate of 
latency conversion was altered due to the mutations. Also, we used a gel based metal ion titration 
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assay to determine metal ion sensitivity changes due to incorporation of mutations. Finally, we 
characterize copper2+ binding to wild-type and variant PAI-1 using isothermal titration calorimetry 
(ITC). Taken altogether, the results support a model with multiple specific metal-binding sites on 
PAI-1 that are localized to particular regions that influence the active to latent transition in 
different ways.            
  
3.1.b. A Search for Potential Metal Ion Binding Sites on PAI-1 
 Interestingly, the active W175F PAI-1 crystal structure featured a zinc ion coordinated in the 
asymmetric dimer interface of the crystal (Figure 3.1) [95]. Carboxylate containing gate region 
residues E212, D222, E242, and E350 contribute to coordination from one PAI-1 molecule, and N-
terminal histidine residues H2, and H3 from another PAI-1 [95]. This structure presented potential 
metal ion coordination residues that could be responsible for metal ion effects imparted on PAI-1.    
To computationally predict metal ion binding clusters within PAI-1, we also used a modified 
version of the MUltiple Geometries (MUG) algorithm that predicts calcium2+ binding clusters 
within proteins. The algorithm identifies several oxygen containing amino acid residues in close 
spatial proximity on crystal structures. Metal ions such as calcium2+ or magnesium2+ are classified 
as harder, less polarizable acid ligands, which are coordinated by relatively harder oxygen 
containing bases. These metal ions are often found in octahedral coordination geometry. By 
contrast, transition metal ions such as copper2+ or nickel2+  are softer, more polarizable acid ligands 
that are typically coordinated by softer nitrogen or sulfur containing bases. These metals are most 
often found in tetrahedral coordination geometry.  
  
 










Figure 3.1: W175F PAI-1 Crystal Structure Residues Coordinating Zinc2+ Ion in 
Asymmetric Dimer Interface. The active PAI-1 crystal structure containing only one 
mutation (W175F) coordinated a zinc ion with N-terminal histidines (H2, H3) of one PAI-1 
molecule (green, left), and carboxylate groups (E212, D222, E242, E350) of the gate region 
contributing to coordination from the second PAI-1 molecule (purple, right). This interface is 
situated at the asymmetric dimer interface of the crystal lattice. From Jensen et al., JBC. 2011.     	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 Because of these differences, our collaborator, Dr. Jenny Yang, modified the MUG algorithm 
to include nitrogen and sulfur containing amino acids histidine and cysteine in the spatial cluster 
proximity prediction. It should be noted that there are 13 histidines and no cysteines within PAI-1. 
The modified metal ion binding cluster prediction was performed on the active 14-1b PAI-1 crystal 
structure (pdb code 1B3K). Five potential binding clusters were identified through the 
computational search (Figure 3.2). Of most interest were two binding clusters because of the 
functional relevance of their locations on PAI-1. A binding cluster featuring E212, D222, E242, 
and E350 residues of the gate region were the same residues observed to bind zinc in the crystal 
structure. There was also very interesting binding cluster that included E81 of hD, and H364 of 
s4B somewhat proximal to the N-terminal histidines in the crystal structure.  Importantly, Mangs 
et al. completed a study in which all of the histidines of PAI-1 were mutated and characterized to 
investigate their role in stabilization of the active form at lower than physiological pH [92]. This 
work identified one histidine that is primarily responsible for the pH sensitive activity of PAI-1, 
and also showed that mutation of other histidines can produce significant amounts of latent PAI-1 
in the purified fractions [92].  
 A sequence alignment was performed for the residues predicted in possible metal ion binding 
sites: H2, H3, E81, E212, D222, E242, E350, and H364, comparing different PAI-1 species, as 
well as other serpins (Figure 3.3). PAI-1 from different species retains strong sequence 
conservation of all the residues aligned except for H2, and H3. However, within serpins, these 
residues are far less conserved, with only E242 retaining conservation among different serpins. 
Based on this evidence, we chose to investigate the following sites in the study: Site A comprising 
the N-terminal histidines; Site B comprising E81 and H364; and Site C of the gate region  
 




Figure 3.2 MUG Algorithm Copper2+ Binding Clusters within PAI-1. In collaboration with 
Jenny Yang at Georgia State, copper2+ ion binding clusters were predicted. The following clusters 
were identified in the prediction: E212, D222, E242; E212, D222, E350; D89, E90, H229; E81, 
H364; E53, D297, D305. The clusters are represented on the active PAI-1 structure (pdb 3q02) 
with the side chains as green, red, and blue space filling spheres. The RCL is represented in 
yellow, the central beta sheet is represented in red. The remainder of PAI-1 is shown in gray.   







Figure 3.3: Sequence Alignment of Investigated Residues in PAI-1 Species and other 
Serpins. The human PAI-1 residues hypothesized to be involved in metal ion binding clusters 
were compared by sequence alignment with PAI-1 from with other species and other serpins 
using BLAST to assess the level of sequence identity of these residues within PAI-1 and the 
serpin family. Human PAI-1 was aligned with rat, pig, mouse, monkey, bull sequences, and 
also related serpins α1-anti-trypsin, anti-chymotrypsin, anti-thrombin, neuroserpin, and α2-anti-
plasmin. The residues that retain identity with human PAI-1 are identified in bold.	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containing E212, D222, E242, and E350. The three hypothesized metal ion clusters will be 
referenced in this way henceforth for clarity.    
3.1.c. Isothermal Titration Calorimetry  
 Isothermal titration calorimetry (ITC) is a technique that directly measures the enthalpy 
change of an interaction to obtain thermodynamic parameters such as Gibbs free energy change 
(ΔG), enthalpy change (ΔH), entropy change (TΔS), affinity (Ka), and stoichiometry (n) (Figure 
3.4). The instrument has a reference cell held at constant temperature, maintained by constant 
power from the reference heater. The instrument also has an experimental cell, where (in most 
experiments) the sample to be tested is loaded. Prior to the start of the experiment, the 
experimental cell temperature is equilibrated to the reference cell within tenths of a degree Celsius. 
The syringe typically contains the titrant, which is delivered into the experimental cell by 
sequential injections over set intervals. When ligand is injected and interacts with protein, the 
temperature changes depending on the type of reaction taking place. If an endothermic reaction 
takes place, the cell temperature decreases; it is then re-equilibrated to the reference cell by 
feedback power. If an exothermic reaction occurs, the temperature increases and the opposite 
occurs to re-equilibrate the temperature with the reference cell. This injection and re-equilibration 
process is repeated until the amount of ligand saturates the binding sites on the protein, manifested 
by injections with negligible heat change.  
 
 The raw data are displayed as the µcal/sec power used to re-equilibrate as a function of the 
experimental time over the course of the experiment with multiple injections. The reaction taking 
place as a result of each injection causes a release or absorption of heat (qi), which is directly  
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Figure 3.4: ITC Instrument and Data Output. A Schematic of the ITC instrument is displayed, 
showing the reference cell, experimental cells, and relative locations of the syringe, protein and 
ligand. Each injection brings a change in the heat of the experimental cell, and power is applied to 
bring the temperature back to the reference cell. That power is plotted in μcal/sec for each injection, 
as a function of time. From the preliminary data, each injection peak is integrated, and the values 
are plotted in kcal/mol of injectant as a function of the ligand to protein molar ratio. The enthalpy 
change of the reaction can be determined by the value of the difference between the lower and 
higher baselines of the data in the isotherm. A fitting the data to a mathematical model determines 
the thermodynamic parameters- stoichiometry, Kd, and ΔH, which can be used to calculate ΔG and 
ΔS using the Gibb’s free energy equation. The stoichiometry of the reaction is the ligand 
concentration at the midpoint of the isotherm curve. The affinity of the interaction can be described 
as the slope of the isotherm transition from all available binding sites to all occupied binding sites.	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proportional to the amount of ligand that binds to the protein (v x ΔLi), and the binding reaction 
enthalpy (ΔH). This relationship of heat to protein ligand binding can be described by the 
equation qi = v x ΔH x ΔLi, where v is the reaction cell volume, i is the injection number, and ΔLi 
is the change in ligand that is protein bound after each injection.  The amount of heat change is 
calculated by integration of the area of each injection curve. As more ligand binds to protein, the 
concentration of unligated protein decreases with more injections, and the peak signal decreases 
until full saturation occurs. In a transformed plot, the peaks for each injection are integrated and 
plotted as kcal/mol of ligand injection as a function of the molar ratio of ligand to protein. The 
quantity of ΔLi, or change in ligand bound to protein [P] over the course of the injections (i to i-1) 
is directly related to the affinity between the ligand and the protein (Ka). This relies on the Gibb’s 
free energy thermodynamic relationship, ΔG = ΔH-TΔS and ΔG = -RTlnKa to obtain a full 
thermodynamic analysis of a ligand-protein interaction as a result of direct heat detection.         	  	  
3.2. Materials and Methods 
 
3.2.a. PAI-1 Stability Assay 
 To measure the latency conversion half-life of PAI-1, 0.1uM PAI-1 was incubated in 50mM 
MOPS, 100mM (NH4)2SO4, 0.1 mM EDTA pH 7.4 at 37°C. At various time points,  0.1uM PAI-1 
is mixed with 0.1uM two chain tPA in 50mM MOPS, 100mM (NH4)2SO4, 2 mM EDTA, and 1% 
(w/v) BSA, pH 7.4 at 37°C. tPA substrate Spectrozyme  tPA at 1mM (in the same buffer as tPA) is 
added to the PAI-1/tPA mixtures and the reaction is monitored for 5 minutes at 405 nm. Time 
points were collected for approximately 10 half-lives, and each assay is performed in triplicate. A 
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schematic of how the assay monitors PAI-1 activity over the time points is presented in Figure 3.5 
The tPA activity (linear slopes) of each time point are plotted as a function of time.  The inverse of 
these values (PAI-1 activity) were normalized and fit to a single exponential decay function xt = 
x0e-kt, in which x0 is the starting PAI-1 activity, xt is amount of PAI-1 activity at a specific time, t, 
and k is the rate of decay. The half-life is then determined by the calculation ln(2)/k. The data are 
fit in Graphpad Prism to determine the rate of latency conversion (klat) and half-life of latency 
conversion. An example fit with calculated klat and t1/2 is shown in Figure 3.6. Assays containing 
metals were completed by incubation of 1.1 mM, or 300uM total CuSO4 in the PAI-1 buffer. All 
proteins used in assays containing copper2+ are buffer exchanged into 50mM MOPS, 100mM 
(NH4)2SO4 pH 7.4 at 37°C prior to dilution into assay buffer. Copper2+ addition resulted in a 
decrease of pH, so NaOH was used to correct the pH to 7.4.  
3.2.b. Metal Ion Titration Gel Assay  
  A gel based assay was employed to measure the PAI-1/tPA complex formation in the 
presence of a wide range of metal ion concentrations. Buffer exchange of PAI-1 is performed 
using a PD25 column into 50mM MOPS, 100mM (NH4)2SO4 pH 7.4 at 37°C. A copper stock 
solution is made in the same buffer, correcting the pH after copper addition to pH 7.4 at 37°C. 
PAI-1 at 4uM was incubated with copper2+ concentrations ranging from 5uM to 1331 uM (total 
Copper2+, same buffer) for 30 minutes at 37°C, followed by addition of an equimolar amount of 
single chain tPA. For each assay, three control samples of PAI-1, tPA, and PAI-1/tPA are included 
that were not incubated with metal ion. SDS-PAGE loading dye is added, each sample is boiled for  
 







Figure 3.5 Stability Assay Protocol:  In this assay, aliquots of PAI-1 are mixed with a slight 
access of tPA.  Over time PAI-1 converts to the latent state, which equates to an increase in 
tPA activity, which is measured directly.  This is illustrated by comparing time 0 representing 
completely active, then half active, then no active PAI-1 at the end of the assay.  The graph on 
the right shows tPA activity over time, and the negative slope of tPA activity, which is how 
determining PAI-1 activity over time can calculate klat or t1/2. 







Figure 3.6 Wild-Type Stability Assay Sample Data Fit. The relative PAI-1 activity at each 
time point is normalized where 1.0 is at time 0 and 0.0 is at the lower baseline of the data fit. 
The data is plotted as a function of PAI-1 incubation time in minutes. The data are fit to a first 
order exponential decay equation to calculate klat and t1/2. The blue, purple, and red curves 
represent independent experiments that are averaged, followed by calculation of standard error 
for the t1/2 measurements. 	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10 minutes, and then electrophoresed on a 4-12% gradient gel. Gels are stained using Coommassie 
blue overnight, followed by three 90 minute destaining steps in deoionized water with 30% 
methanol, 7.5% glacial acetic acid. Imagelab (Biorad) software was used to create a photographic 
image of the gel and measure the densitometry for the PAI-1/tPA complex bands in each gel lane. 
The data are normalized to a 0% gel background and a 100% PAI-1/ tPA complex formation band 
in the absence of metal ions. An example gel using wild-type PAI-1 in the assay is shown in 
Figure 3.7. Each assay is completed in duplicate and the average percent complex formation is 
plotted as a function of the logarithm of the total copper2+ ion concentration in GraphPad Prism. 
The standard deviation was calculated for inclusion of error bars for wild-type PAI-1 and each 
variant. Samples containing SMB domain were incubated at 2:1 SMB:PAI-1 ratio and for 2 hours 
to account for intrinsic difference in rate of latency conversion (klat). 
3.2.c. Isothermal Titration Calorimetry  
 ITC was used to determine the enthalpy change, stoichiometry, and Kd of copper2+ to wild-
type and variant PAI-1. Active or inactive PAI-1 is exchanged into a buffer containing 50mM 
MOPS, 250mM (NH4)2SO4, pH  7.4 at 10°C using a PD10 column. Following the column, buffer 
matching is ensured by dialysis for two hours at 4°C. Using dialysate, a copper2+ sulfate stock 
solution was prepared and the pH was corrected after copper2+ addition to yield a pH of 7.4 at 
10°C. Protein samples were quantified by absorbance at 280nm. For each experiment, 2.2mL of 
20uM PAI-1 was made, along with 4 mL of (300uM-2000uM depending on experiment) copper2+ 
solution.  Both the protein solution and copper2+ solution undergo a degassing step for 10 minutes 
at 5°C prior to the experiment. The PAI-1 solution was loaded into the 1.394 mL ITC cell, the 
copper solution was loaded into the syringe. The instrument was set to 10°C, and set to dispense a  







Figure 3.7 Gel Assay Densitometry for Wild-Type PAI-1. Each metal ion titration gel assay 
sample is a mixture of 1:1 PAI-1:tpA with a particular concentration of copper2+. The samples 
electrophoresed by non-reducing SDS-PAGE to separate complex, free tPA, and latent/cleaved 
PAI-1. The first three lanes contain PAI-1, tPA and untreated complex, respectively. The 
following lanes contain increasing amounts of copper2+. The amount of complex corresponding to 
the appropriate band in the gel is quantified by Imagelab software, and the data are normalized to 
the untreated complex sample (100%) and a gel background sample (0%). Assays are performed 
in duplicate and plotted as a function of copper2+ concentration.	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2uL preliminary injection. This was followed by 5uL injections, each over 10 second duration, 
which occur at 120 second intervals so that the system to re-equilibrate to baseline temperature of 
in between injections. Each experiment uses a total of 54 injections, and each experiment was 
performed in at least duplicate. Control experiments measuring the heat of exchange between the 
copper solution and a matching buffer solution containing no protein were subtracted from all 
experimental data. Initial baseline correction was completed in NITPIC (University of Texas, 
Southwestern), followed by data fitting in SEDPHAT (National Institute of Health) using either a 
one site binding model, or a two site non-symmetric binding model, as appropriate. The data fits 
are represented using the software GUSSI (University of Texas, Southwestern).  
3.3. Results 
3.3.a. Mutations Modestly Affect the Stability of PAI-1 
  To determine the location of metal binding site(s) on PAI-1, we utilized site-directed 
mutagenesis to modify residues hypothesized to bind copper2+. The rationale for the mutations 
comes from the W175F crystal structure [95], in which N-terminal histidines H2, H3 (site A), and 
gate region residues E212, D222, E242, and E350 (Site C) take part in copper2+ coordination. 
Additionally, the computationally predicted site involving E81A of hD and H364A of s4B (Site 
B), is proximal to the N-terminal histidines. Alanine replacements were generated at each of the 
individual positions to test for metal binding deficiency (Figure 3.8). We hypothesized that a PAI-
1 variant deficient in metal ion binding would have a half-life of latency transition that is similar in 
the presence and absence of copper2+.  
 






Figure 3.8: Location of Proposed Metal Binding Residues on PAI-1. The following residues 
are highlighted in the W175F crystal structure (pdb: 3Q02): H2A (orange), H3A (orange), E81 
(purple) E212 (blue), D222 (red), E242 (green), E350 (magenta), and H364 (teal). These 
residues coordinated a zinc2+ ion from the crystallization media in the asymmetric dimer 
interface of the crystal in which the carboxylate containing residues (E212, D222, E242, E350) 
contributed from one PAI-1 molecule and histidine containing (H2A and H3A) residues 
contributed from another. The MUG algorithm (Jenny Yang, Georgia State) also 
computationally predicted this cluster of E212, D222, E242, and E350 as a metal binding 
cluster. A second cluster from the MUG algorithm containing E81, and H364 is also 
investigated.     	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We tested the stability of the PAI-1 variants with and without copper2+ to determine half-
lives that reflect the rates of latency conversion. Copper2+ destabilizes wild-type PAI-1; in the 
absence of copper2+, PAI-1 remains in the active form for a half-life of 70 minutes (Figure 3.9). 
While in the presence of a saturating concentration of copper2+, it is significantly destabilized to 
an average half-life of 11 minutes. The three PAI-1 variants with N-terminal histidine 
replacements (Site A, ie. H2A, H3A, and H2AH3A) compare very closely to wild-type in the 
absence of metal ions, with average half-lives of 72, 69, and 70 minutes, respectively. As 
expected, addition of alanine at either H2, H3, or at both sites results loss of binding to the 
charged nickel IMAC column during purification. This indicates that a metal ion binding site was 
abolished as a result of the mutations. In the presence of saturating amounts of copper2+, these 
variants exhibited rates of latency transition that were faster than wild-type PAI-1, with average 
half-lives for H2A, H3A, and H2AH3A of 4.1, 4.1, and 3.6 minutes in each, respectively, 
compared to 11 minutes for wild-type. This observation indicates that copper2+ does not promote 
latency conversion through interaction with the N-terminal histidines of PAI-1.  
Next, we determined half-lives that reflect the latency conversion of the gate region 
predicted cluster (Site C). Introduction of alanine mutations into the gate region residues results in 
modest changes in stability in the absence of copper2+ (Figure 3.10). D222A and E212A PAI-1 
have slightly shorter average half-lives of 56 and 60 minutes, respectively, and E242A and E350A 
PAI-1 have slightly longer average half-lives of 72 and 83 minutes, respectively, in comparison to 
a t1/2 of 70 minutes with wild-type PAI-1. This region of the protein is known to play a key role in 
latency conversion, so it is not altogether surprising to see minor differences due to alanine 
mutations in this region.  




 Figure 3.9: Stability Assays on N-Terminal Histidine Variants Site A(+/- Saturating Cu2+).  
Stability assays were performed to measure the latency conversion half-life of wild-type PAI-1 
for comparison to N-terminal region variants. PAI-1 at 0.1uM was incubated in 50mM MOPS, 
100mM (NH4)2SO4  0.1mM EDTA pH 7.4 at 37°C, the total metal concentration of 1100uM 
copper2+ in the metal ion containing conditions. PAI-1 inhibition was indirectly measured 
through tPA activity at A405 over the course of the experiment. Each of the bars represent a 
stability assay completed in triplicate in which the PAI-1 half-life was calculated from a one 
phase exponential decay function. The data analysis and fit are performed in Graphpad Prism. 
The green bars represent PAI-1 half-lives in the absence of metal ion ligand, and the blue bars 
represent PAI-1 half-lives in the presence of metal ion ligand.    	  	  	  	  	  




Figure 3.10: Stability Assays on Gate Region Variants Site C (+/- Saturating Cu2+).  
Stability assays were performed to measure the latency conversion half-life of wild-type PAI-1 
for comparison to gate region variants involved in coordination of zinc in the W175F structure. 
PAI-1 at 0.1uM was incubated in 50mM MOPS, 100mM (NH4)2SO4  0.1mM EDTA pH 7.4 at 
37°C, the total metal concentration of 1100uM copper2+ in the metal ion containing conditions. 
PAI-1 inhibition was indirectly measured through tPA activity at A405 over the course of the 
experiment. Each of the bars represent a stability assay completed in triplicate in which the 
PAI-1 half-life was calculated from a one phase exponential decay function. The data analysis 
and fit are performed in Graphpad Prism. The green bars represent PAI-1 half-lives in the 
absence of metal ion ligand, and the blue bars represent PAI-1 half-lives in the presence of 
metal ion ligand. 	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The E212A, D222A, E242A, and E350A variant form of PAI-1 exhibit average half-lives 
of approximately 10-15 minutes in all variants at saturating copper2+ concentrations. None of the 
four individual amino acid replacements yielded a PAI-1 variant that was observed to be 
significantly different from wild-type PAI-1 at the same copper2+ concentration  (t1/2 = 11 minutes). 
On the surface, this result suggests that we did not succeed in making a metal-binding deficient 
form of PAI-1 with the single mutations in Site C. On the other hand, copper2+ binds almost always 
in tetrahedral binding geometry, using four ligands [129]. Removal of two or more of these ligands 
may be required to observe if significant changes to copper2+ binding are conferred.  
With the hypothesis that one mutation might not be sufficient to alter PAI-1 metal ion 
binding, we introduced combinations of mutations to the proposed gate region-binding site, 
including E212AD222A PAI-1, D222AE242A PAI-1, and E212AD222AE242A PAI-1 (Figure 
3.10). These variants were tested in the presence and absence of saturating amounts of copper2+ in 
the stability kinetics assay to determine if they exhibit deficiencies in metal ion binding. In the 
absence of copper2+, there is significant stabilization as a result of combined mutations, where 
E212AD222A PAI-1 and D222AE242A PAI-1 have average half-lives of 131 minutes, and 126 
minutes, respectively. Even more stabilized was the triple variant E212AD222AE242A PAI-1, 
with an average half-life of 264 minutes. Clearly, this is further indication that substitutions in this 
region have an impact on PAI-1 latency kinetics, presumably because the uncleaved RCL must 
pass through the two gate region loops during the latency conversion process. Nonetheless, these 
mutations had little effect on the PAI-1 latency transition in the presence of saturating amounts of 
copper2+, with average half-lives that are not statistically different from that of wild-type PAI-1.  
Finally, we measured the stability kinetics with and without copper2+ for variant forms of 
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PAI-1 with substitutions in site B (E81A, H364A, and H2AH3AE81A) that were computationally 
predicted from the MUG algorithm. E81A PAI-1 converts to the latent form in absence of metal 
ions with a measured average half-life of 70 minutes, while the H364A PAI-1 had an average half-
life of latency conversion without copper2+ of 81 minutes (Figure 3.11). These compared well with 
the measured 70 minute t1/2 of wild-type without metal ions present, albeit a modest stabilization of 
H364A PAI-1. By contrast, the triple variant H2AH3AE81A PAI-1 was stabilized to an average 
half-life of 102 minutes.  When these variants were tested in the presence saturating amounts of 
copper2+, they were even more destabilized than wild-type PAI-1, with half-lives of approximately 
3 minutes for each, compared to 11 minutes for wild-type. This result also indicates that copper2+ 
does not promote latency conversion through interaction with these residues.  
Stability kinetics assays were also performed at less than saturating concentrations of 
copper2+ with wild-type and variant forms of PAI-1. Assays were performed at 300uM copper2+, 
with the aim to achieve measureable differences between wild-type and variant stabilities in the 
presence of copper2+ (Figure 3.12). With this sub-saturating level of copper2+, wild-type PAI-1 
average half-life of 16.8 minutes, thus the lower concentration of copper2+ still significantly 
accelerates the latency transition, although not as much as with the saturating 1.1mM copper2+ 
conditions. Measuring H2AH3A (Site A) PAI-1 latency conversion kinetics at lower copper2+ 
resulted in an average half-life of 5.4 minutes, which is significantly less when compared with 
wild-type PAI-1 at the same copper2+ concentration. This is an interesting, yet unexpected result 
since the mutations were designed to delay latency transition in the presence of copper2+.        
Similarly, E81A (Site B) PAI-1 tested at this lower copper2+ concentration resulted in an average 
half-life of 3.9 minutes, which is also significantly less than wild-type. The absence of  





Figure 3.11: Stability Assays on Site B E81A, H364, and H2AH3AE81A PAI-1 Variants 
(+/- Saturating Cu2+).  
Stability assays were performed to measure the latency conversion half-life of wild-type PAI-
1 for comparison to E81A, H364A, H2AH3AE81A PAI-1. PAI-1 at 0.1uM was incubated in 
50mM MOPS, 100mM (NH4)2SO4  0.1mM EDTA pH 7.4 at 37°C, the total metal 
concentration of 1100uM copper2+ in the metal ion containing conditions. PAI-1 inhibition 
was indirectly measured through tPA activity at A405 over the course of the experiment. Each 
of the bars represent a stability assay completed in triplicate in which the PAI-1 half-life was 
calculated from a one phase exponential decay function. The data analysis and fit are 
performed in Graphpad Prism. The green bars represent PAI-1 half-lives in the absence of 
metal ion ligand, and the blue bars represent PAI-1 half-lives in the presence of metal ion 
ligand.     





Figure 3.12: Stability Assays on Wild-Type, H2AH3A, E81A, D222A, and E242A 
PAI-1 Variants (+/- 300uM Cu2+).  
 Stability assays were performed to measure the latency conversion half-life of wild-
type PAI-1 for comparison to gate region variants involved in coordination of zinc in 
the W175F structure and E81 from the MUG algorithm. PAI-1 at 0.1uM was 
incubated in 50mM MOPS, 100mM (NH4)2SO4  0.1mM EDTA pH 7.4 at 37°C, the 
total metal concentration of 300uM copper2+ in the metal ion containing conditions. 
PAI-1 inhibition was indirectly measured through tPA activity at A405 over the course 
of the experiment. Each of the bars represent a stability assay completed in triplicate in 
which the PAI-1 half-life was calculated from a one phase exponential decay function. 
The data analysis and fit are performed in Graphpad Prism. The green bars represent 
PAI-1 half-lives in the absence of metal ion ligand, and the blue bars represent PAI-1 
half-lives in the presence of metal ion ligand. 	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hypothesized copper2+ binding residues from sites A and B appear to impart the opposite of the 
intended effect, which is further accelerating latency transition in the presence of copper2+. By 
contrast, D222A and E242A (Site C) PAI-1 exhibit different effects on PAI-1 stability in the 
presence of this lower copper2+ concentration. D222A PAI-1 tested at the lower copper2+ 
concentration resulted in an average half-life of 23.9 minutes, which is significantly longer than 
wild-type. Likewise, E242A PAI-1 tested at the lower copper2+ concentration resulted in an 
average half-life of 20.6 minutes, which is also statistically different than wild-type. Figure 3.13 
and Figure 3.14 feature a compilation of the stability kinetics of latency transition data for PAI-1 
variants with and without copper2+. We decided next to test these variants at a wide range of 
copper2+ concentrations for comparison of copper2+ concentrations that induce latency conversion. 
3.3.b. PAI-1 Variants Exhibit Differing Sensitivities to Copper2+ in Titration Assay 
 In a complementary approach to address our need to assess copper2+ effects on PAI-1, and on 
latency conversion in particular, we derived a means to measure the susceptibility of PAI-1 to 
undergo latency conversion at varying copper2+ concentrations.  Rather than using a fixed copper2+ 
concentration and varying time, we used a fixed time and varied copper2+ concentration. We 
titrated copper2+ into a fixed concentration of PAI-1, and monitored tPA complex formation in a 
gel based assay, testing a concentration range of 5-1331 uM metal ions and incubating the PAI-1-
metal ion complex for 30 minutes. Quantification by densitometry of the gel PAI-1/tPA complex 
bands at increasing copper2+ concentrations results in a sigmoidal semi-log plot, with an upper  
 
 






Figure 3.13 Compiled Stability Kinetics Data.	  The activity of each variant in 
equivalents required to inhibit tPA, klat and average half-life in the presence and absence 
of 1.1mM Cu2+, klat and average half-life in the presence and absence of 300 uM Cu2+ are 
presented for comparison.   	  	  	  











Figure 3.14 Compiled Stability Kinetics Data.	  The activity of each combination gate 
variant in equivalents required to inhibit tPA, klat and average half-life in the presence 
and absence of 1.1mM Cu2+ are presented for comparison.   	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baseline representing concentrations of metal ion to which PAI-1 is insensitive and mostly active, 
a transition region of metal ion sensitivity, and a lower baseline that represents metal 
concentrations that render PAI-1 latent. To compare wild-type PAI-1 with the variants, we used 
the midpoint in metal sensitivity, defined as the concentration of copper2+ in which 50% complex 
formation with tPA was achieved.  
 When we measured wild-type PAI-1 in this gel based metal ion titration assay, the midpoint 
of the sigmoidal transition was at approximately 150uM copper2+. We tested the N-terminal 
histidine variants Site A (H2A, H3A, H2AH3A) to determine what concentrations of metal ion 
induce latency conversion. In the stability assay, these variants converted to the latent form at 
comparable rates with wild-type PAI-1 in the absence of metal ions, but conversion of these 
variant forms occurs even faster than wild-type in the presence of copper2+. Interestingly, we 
observed dramatically lower midpoints in the N-terminal histidine variants compared with wild-
type regarding the concentration of copper2+ that defines the range of sensitivity for the latency 
conversion. The double variant H2AH3A PAI-1, as well as the single variants H2A and H3A  PAI-
1 have approximate midpoints of 20uM copper2 (Figure 3.15). These data compare well with 
stability kinetics data in the presence of copper2+, in which copper2+ accelerates latency of these 
variants faster than in wild-type PAI-1. The result indicates that copper2+ binding to the Site A 
histidines produces a neutral or stabilizing effect on PAI-1 latency transition.   
 Next, we performed the gel based metal ion titration assay on the four individual gate region 
variants for comparison with wild-type. The stability assay data of the single variants from this 
predicted site C compare fairly well in the presence and absence of copper2+, although at the lower 
copper2+ concentration D222A and E242A PAI-1 have modestly delayed half-lives in the presence  





 Figure 3.15: Metal Titration Gel Assays Comparing N-Terminal Region Variants and SMB 
Addition 
PAI-1 at 4uM was incubated in 50mM MOPS,100mM (NH4)2SO4 pH 7.4 at 37°C with total metal 
ion concentrations ranging from 5uM to 1331uM for 30 minutes at 37°C, followed by addition of 
an equimolar amount of tPA to form complex with remaining PAI-1  in the active form. This was 
monitored using a non-reducing SDS-PAGE. The PAI-1/tPA complex bands were quantified 
using densitometry on the program image lab, and normalized using an untreated PAI-1/tPA 
complex as 100% and a background gel sample as 0%. Each data point is a duplicate average of 
two assays. The wild-type PAI-1 data is represented in light blue triangles, H2A data is 
represented in orange triangles, H3A in red diamonds, and H2AH3A in teal triangles. 
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of copper2+. The variants E212A and E350A PAI-1 have a midpoint value that occurs at a similar 
copper2+ concentration of approximately 150uM (Figure 3.16). The overlapping error bars 
comparing variants with wild-type PAI-1 suggest that these variants are not statistically different 
from wild-type in their metal ion sensitivity. These data agree well with the stability assay data 
with copper2+ present. However, the variants E242A and D222A PAI-1 have midpoint copper2+ 
concentrations of approximately 250uM total copper2+, which are different compared with wild-
type (Figure 3.17). These data also agree well with the stability assay results with lower copper2+ 
present. The results indicate that one or both of these Site C residues could be involved in a metal 
coordination event that accelerates the latency transition.    
 The variants from the MUG predicted site B residues (E81A, H364A, and E81AH364A) were 
tested in the gel metal ion titration assay next. Introducing these mutations caused modest 
stabilizations to PAI-1 in the absence of copper2+, and yet when tested with copper2+, the latency 
transition accelerated to rate faster than that of wild-type. Strikingly, E81A PAI-1 looks the most 
sensitive to copper2+, with an approximate midpoint of 15uM (Figure 3.18). A triple variant 
containing H2AH3AE81A PAI-1 is also more sensitive than WT, but at an approximate sensitivity 
midpoint of 20uM, it is similar to the histidine variants. These results agree well with the stability 
kinetics in the presence of copper2+. Finally, H364A PAI-1 had a similar copper2+ sensitivity 
midpoint as wild-type PAI-1, but the curve transition was markedly different (data not shown). 
From these data alone, it is difficult to determine if H364 PAI-1 plays a role in copper2+ binding 
that influences PAI-1 function. Overall, the results of Site B argue that a copper interaction with 
this region would provide a neutral or stabilizing effect on PAI-1 latency transition.     






Figure 3.16: Metal Titration Gel Assays comparing Wild-Type and Gate Region PAI-1 
Variants 
PAI-1 at 4uM was incubated in 50mM MOPS, 100mM (NH4)2SO4 pH 7.4 at 37°C with total 
metal ion concentrations ranging from 5uM to 1331uM for 30 minutes at 37°C, followed by 
addition of an equimolar amount of tPA to form complex with remaining PAI-1  in the active 
form. This was monitored using a non-reducing SDS-PAGE. The PAI-1/tPA complex bands 
were quantified using densitometry on the program image lab, and normalized using an 
untreated PAI-1/tPA complex as 100% and a background gel sample as 0%. Each data point is a 
duplicate average of two assays. The wild-type PAI-1 is represented in light blue triangles, 
E212A represented in purple triangles, and E350A in green squares. 
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Figure 3.17: Metal Titration Gel Assays comparing Wild-Type and Gate Region PAI-1 
Variants. 
PAI-1 at 4uM was incubated in 50mM MOPS, 100mM (NH4)2SO4 pH 7.4 at 37°C with total 
metal ion concentrations ranging from 5uM to 1331uM for 30 minutes at 37°C, followed by 
addition of an equimolar amount of tPA to form complex with remaining PAI-1  in the 
active form. This was monitored using a non-reducing SDS-PAGE. The PAI-1/tPA complex 
bands were quantified using densitometry on the program image lab, and normalized using 
an untreated PAI-1/tPA complex as 100% and a background gel sample as 0%. Each data 
point is a duplicate average of two assays. The wild-type PAI-1 is represented in light blue 
triangles, D222A represented in pink circles, and E242A in magenta circles.       
       






Figure 3.18: Metal Titration Gel Assays comparing E81A Variants to Wild-Type PAI-
1. 
PAI-1 at 4uM was incubated in 50mM MOPS,100mM (NH4)2SO4 pH 7.4 at 37°C with total 
metal ion concentrations ranging from 5uM to 1331uM for 30 minutes at 37°C, followed by 
addition of an equimolar amount of tPA to form complex with remaining PAI-1  in the 
active form. This was monitored using a non-reducing SDS-PAGE. The PAI-1/tPA complex 
bands were quantified using densitometry on the program image lab, and normalized using 
an untreated PAI-1/tPA complex as 100% and a background gel sample as 0%. Each data 
point is a duplicate average of two assays. The wild-type PAI-1 data is represented in light 
blue triangles E81A in dark blue circles, and H2AH3AE81A in black circles. 
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 We then investigated the influence of SMB domain on the midpoint concentrations of 
copper2+ sensitivity in the latency conversion.  PAI-1 bound to SMB domain remains in the active 
form 1.5 longer than PAI-1 alone. Gel titration assays were performed on wild-type PAI-1 and 
H2AH3A PAI-1 in the presence of a 2 fold molar excess of SMB domain of VN. We observed 
similar midpoints in copper sensitivity (~200 uM copper2+) for both the wild-type PAI-1 and 
H2AH3A PAI-1 with SMB bound (Figure 3.19). Since SMB changes the half live of PAI-1 
without addition of metal ions, we were careful not to directly compare these two data sets with 
wild-type and H2AH3A alone. Nonetheless, with SMB present, the difference in metal ion 
sensitivity comparing wtPAI-1 and the H2AH3A variant is abolished, in stark contrast to the 
sensitivity of these two forms of PAI-1 without SMB bound. The compiled results from the metal 
ion titration gel assay are given in Figure 3.20. These results are consistent with our observation 
from HDX studies that binding of the SMB domain negates metal ion effects on protein dynamics 
(Refer to Chapter 2).   
3.3.c. Differences in Latent/Variant PAI-1 Copper2+ Binding Identified by ITC 
 We performed ITC on various forms of PAI-1 to measure the enthalpy change of interaction 
(ΔH), and dissociation constant (Kd) for the interaction of the various forms of PAI-1 with 
copper2+. First, we compared latent forms of wild-type PAI-1 with the H2AH3A variant, titrating 
in a buffer matched solution containing copper2+ sulfate in the injection syringe. Both proteins 
were confirmed to be latent by an activity assay, much like what is performed on active protein 
stocks. Previously, we determined by SPR that wild-type PAI-1 binds a nickel2+ charged NTA chip 
in both the active and latent forms, albeit tighter in the active form [109]. Since the H2AH3A does  
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Figure 3.19: Metal Titration Gel Assays comparing Wild-Type and H2AH3A ( +/- 
SMB).  
 PAI-1 at 4uM was incubated in 50mM MOPS,100mM (NH4)2SO4 pH 7.4 at 37°C with total 
metal ion concentrations ranging from 5uM to 1331uM for 30 minutes at 37°C, followed by 
addition of an equimolar amount of tPA to form complex with remaining PAI-1 in the 
active form. The SMB containing samples were incubated for 2 hours at 37°C for adequate 
comparison. This was monitored using a non-reducing SDS-PAGE. The PAI-1/tPA 
complex bands were quantified using densitometry on the program image lab, and 
normalized using an untreated PAI-1/tPA complex as 100% and a background gel sample as 
0%. Each data point is a duplicate average of two assays. The wild-type plus SMB data is 
represented in light green diamonds, and H2AH3A plus SMB in dark blue circles. 
  
 








                                          
    
Figure 3.20 Compiled Metal Titration Gel Assay Data.  
The compilation of metal titration gel assay data is shown, each midpoint copper2+ 
concentration is represented in micromolar concentration.   
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not bind an IMAC column, we hypothesized that these mutations would result in loss of a 
copper2+ binding transition in the ITC binding isotherm. Also, we chose to start with a comparison 
of the PAI-1 latent forms because the active form converts to the latent state quickly in the 
presence of metal ions. Fortunately though, the conformational changes during latency transition 
feature no detected enthalpy changes in the ITC [86]. This result was replicated in our lab by 
equilibrating the ITC control and experimental cells at 37°C, and titrating buffer into active PAI-1 
for 16 hours (data not shown).  
 After optimizing the experimental conditions, we achieved binding isotherms with latent wild-
type PAI-1. We first tested latent wild-type PAI-1 in the ITC with the cells set to 10°C, and higher 
salt (250mM) to prevent non-specific binding. Copper2+ titration into latent wild-type PAI-1 
resulted in two clear transitions. Fitting to a two-site binding isotherm model resulted in Kd’s of 
50nM, and 2.1uM for the respective binding sites, with respective enthalpy changes of  -12.2, and -
4.6 kcal/mol (Figure 3.21). The data fit with a lower global chi squared to a two-site model, when 
compared with a one-site model, as illustrated in Figure 3.21. This makes sense given the prior 
knowledge that latent wild-type PAI-1 was able to bind to immobilized nickel2+ by SPR. We 
hypothesized that one of these transitions was due to binding at Site A N-terminal histidines. 
Copper2+ titration into latent H2AH3A PAI-1 was clearly weaker, as evidenced by the lack of an 
initial baseline using similar copper2+ concentrations to those used in the active protein titrations. 
As suspected, these data featured one binding transition. Fitting to a one-site binding isotherm 
model yielded a Kd of 1.96 uM, and an enthalpy change of -8.5 kcal/mol (Figure 3.22). Due to the 
close similarity in affinity of the one transition in latent H2AH3A PAI-1 and the second transition 
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Figure 3.21: ITC on Latent Wild-type  PAI-1, fit to a one and two site model.  
Panel a) Latent 20uM wild-type PAI-1 was dialyzed into 50mM MOPS, 250mM (NH4)2SO4 pH 
7.4 at 10°C (two site model). Copper at 300, 400, and 500uM was added to the buffer matched 
dialysate from a concentrated stock, and pH corrected to pH 7.4 at 10°C. Syringe copper was 
injected into the cell containing PAI-1 in injections of 5uL over 10 second duration, over 120 
second intervals, 54 injections total. The data are subtracted from runs in which CuSO4 in the 
same buffer was titrated without protein to remove background metal ion-buffer heat of 
interaction. The data are converted into kcal/mol of injectant as a function of the molar ratio of 
copper to latent PAI-1. Global data fitting was performed in Sedphat Software to a two site 
binding model, and the fit is represented using Gussi software.  
Panel b) Global data fitting of the same data was performed in Sedphat Software to a one site 
binding model, and the fit is represented using Gussi software.  
 	  




Figure 3.22: ITC on Latent H2AH3A PAI-1.  
Latent 20uM H2AH3A PAI-1 was dialyzed into 50mM MOPS, 250mM (NH4)2SO4 pH 7.4 at 
10°C. Copper at 400uM was added to the buffer matched dialysate from a concentrated stock, and 
pH corrected to pH 7.4 at 10°C. Syringe copper was injected into the cell containing PAI-1 in 
injections of 5uL over 10 second duration, over 120 second intervals, 54 injections total. The data 
are subtracted from runs in which 400uM CuSO4 in the same buffer was titrated without protein 
to remove background metal ion-buffer heat of interaction. The data are converted into kcal/mol 
of injectant as a function of the molar ratio of copper to latent PAI-1. Data fitting was performed 
in Sedphat Software to a one site binding model, and the fit is represented using Gussi software. 
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of latent wild-type, we concluded that the tighter first transition of wild-type PAI-1 was 
contributed through binding of the N-terminal histidines. Also, it should be noted that even in the 
case of latent H2AH3A PAI-1 we observed copper2+ binding, which suggests the copper2+ binding 
site accelerating the rate of latency transition exists in one of the other hypothesized (Site B or C), 
or that this site only exists in the active form.    
  Our chief concern for testing active forms of PAI-1 in the ITC was ensuring that it does not 
convert to the latent form during the experiment. As mentioned, the temperature for all ITC 
experiments were 10°C, which prolongs the time PAI-1 remains active in the presence of metal 
ions. We also increased the salt concentration from 100mM as in the stability and titration assays, 
to 250mM for all ITC experiments. This change in particular resulted in two fortuitous effects. 
This eliminated detectable MOPS-copper2+ heats of interaction in control ITC experiments 
involving no PAI-1, and also lead to significantly decreased copper2+ sensitivity in wild-type, and 
H2AH3A in the gel based metal ion titration assay at this higher salt concentration (Figure 3.23).   
 As a further cautionary measure, we tested the active stabilized variant W175F as a standard 
for comparison with titrations of wild-type PAI-1. The single W175F PAI-1 variant is located on 
the PAI-1 structure in the hinge region of shutter strand s3A and is not located on the PAI-1 
structure near the proposed metal ion binding clusters. Titration of copper2+ into wild-type PAI-1 
revealed tight binding. Fitting of the data to a two-site binding isotherm model resulted in Kd’s of 
20 nM, and 60nM, with respective enthalpy changes of -12.2, and -9.2 kcal/mol (Figure 3.24). 
Additionally, the stabilized W175F PAI-1 had similar thermodynamics to wild- type, fitting to the 




Figure 3.23: Metal Titration Gel Assays comparing Wild-Type and H2AH3A with Higher 
Salt. 
PAI-1 at 4uM was incubated in 50mM MOPS,250mM (NH4)2SO4 pH 7.4 at 37°C with total metal 
ion concentrations ranging from 5uM to 1331uM for 30 minutes at 37°C, followed by addition of 
an equimolar amount of tPA to form complex with remaining PAI-1  in the active form. This was 
monitored using a non-reducing SDS-PAGE. The PAI-1/tPA complex bands were quantified 
using densitometry on the program image lab, and normalized using an untreated PAI-1/tPA 
complex as 100% and a background gel sample as 0%. Each data point is a duplicate average of 
two assays. The wild-type PAI-1 data at normal conditions is represented in pink triangles, wild-
type with higher salt in brown triangles, and H2AH3A with higher salt in green squares. 
 
  
	   140 
 
  
Figure 3.24: ITC Fit on the Tighter Transitions of Active Wild-Type PAI-1 
Active 20uM wild-type PAI-1 was dialyzed into 50mM MOPS, 250mM (NH4)2SO4 pH 7.4 
at 10°C. Copper2+ at 350, and 400uM was added to the buffer matched dialysate from a 
concentrated stock, and pH corrected to pH 7.4 at 10°C. Syringe copper was injected into 
the cell containing PAI-1 in injections of 5uL over 10 second duration, over 120 second 
intervals, 54 injections total. The data are subtracted from runs in which CuSO4 in the same 
buffer was titrated without protein to remove background metal ion-buffer heat of 
interaction. The data are converted into kcal/mol of injectant as a function of the molar ratio 
of copper to active PAI-1. Global data fitting was performed in Sedphat Software to a two 
non-symmetric site binding isotherm, and the fit is represented using Gussi software. 
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 two-site model with Kd’s of 10 nM and 20nM, and enthalpy changes of -14.9, and -15.1 kcal/mol, 
respectively (Figure 3.25). Due to the overlap in affinity of the transitions, it is difficult to 
determine the individual enthalpy of each transition in these titration data. There is a slope 
associated with the baseline at high metal ion concentrations, which opens the possibility of a 
weaker binding site. Testing ITC of active wild-type PAI-1 with higher copper concentrations did 
indeed reveal that a weaker binding site exists, as suggested from the baseline abnormalities 
existing at higher copper2+ concentrations in the active wild-type and W175F PAI-1 ITC 
experiments (Figure 3.24, 3.25). These experiments using higher copper2+ concentrations with 
active wild-type PAI-1 yielded a Kd of 2.1 uM and enthalpy change of -8.2 kcal/mol for this third 
transition (Figure 3.26). This affinity compares well with the second transition of latent wild-type, 
or the latent H2AH3A transition.  
  Copper titration into active forms of D222A, and E242A gate region PAI-1 variants of the 
MUG predicted Site C that exhibited lower copper2+ sensitivity in the metal ion gel assays. 
Interestingly, these variants resulted in tight transitions that fit to two site models. Fitting of the 
D222A PAI-1 data to a two-site binding isotherm model resulted in Kd’s of 10 nM, and 10nM, and 
enthalpy changes of -20.2, and -20.2 kcal/mol, respectively. (Figure 3.27). Similarly, Fitting of the 
E242A PAI-1 isotherms to a two-site model resulted in Kd’s of 9.2 nM and 20nM, with enthalpy 
changes of -17.2, and -17.0 kcal/mol, respectively (Figure 3.28). In this respect, these variants 
exhibited similar binding behavior as active wild-type or W175F PAI-1. However, close 
examination of the baseline at higher copper2+ in these experiments reveals interesting differences. 
The baseline at higher copper2+ concentrations for the D222A PAI-1 isotherm data suggests the 
presence of a weaker binding site, in which isotherms with increased amounts of copper2+ would be 






Figure 3.25: ITC of Active W175F PAI-1. 
 Active 20uM W175F PAI-1 was dialyzed into 50mM MOPS, 250mM (NH4)2SO4 pH 7.4 
at 10°C. Copper at 300uM was added to the buffer matched dialysate from a concentrated 
stock, and pH corrected to pH 7.4 at 10°C. Syringe copper was injected into the cell 
containing PAI-1 in injections of 5uL over 10 second duration, over 120 second intervals, 
54 injections total. The data are subtracted from runs in which 300uM CuSO4 in the same 
buffer was titrated without protein to remove background metal ion-buffer heat of 
interaction. The data are converted into kcal/mol of injectant as a function of the molar 
ratio of copper to active PAI-1. Data fitting was performed in Sedphat software to a two 
site non-symmetric binding isotherm, and the fit is represented using Gussi software. 
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Figure 3.26 ITC Fit of the Weak Transition in Active Wild-Type PAI-1. 
Active 20uM wild-type PAI-1 was dialyzed into 50mM MOPS, 250mM (NH4)2SO4 pH 7.4 
at 10°C. Copper2+ at 2mM was added to the buffer matched dialysate from a concentrated 
stock, and pH corrected to pH 7.4 at 10°C. Syringe copper was injected into the cell 
containing PAI-1 in injections of 5uL over 10 second duration, over 120 second intervals, 
54 injections total. The data are subtracted from runs in which 2mM CuSO4 in the same 
buffer was titrated without protein to remove background metal ion-buffer heat of 
interaction. The data are converted into kcal/mol of injectant as a function of the molar ratio 
of copper to active PAI-1. Data fitting was performed in Sedphat Software to a one site 
binding model, and the fit is represented using Gussi software. 
 





Figure 3.27: ITC Data Fit of Active D222A PAI-1 
Active 20uM D222A PAI-1 was dialyzed into 50mM MOPS, 250mM (NH4)2SO4 pH 7.4 at 
10°C. Copper2+ at 350uM was added to the buffer matched dialysate from a concentrated 
stock, and pH corrected to pH 7.4 at 10°C. Syringe copper was injected into the cell 
containing PAI-1 in injections of 5uL over 10 second duration, over 120 second intervals, 
54 injections total. The data are subtracted from runs in which 350uM CuSO4 in the same 
buffer was titrated without protein to remove background metal ion-buffer heat of 
interaction.  The data are converted into kcal/mol of injectant as a function of the molar 
ratio of copper to active PAI-1. Data fitting was performed in Sedphat Software to a two 
non-symmetric site binding model, and the fit is represented using Gussi software. 	  	  	  	  	  



















Figure 3.28: ITC Data Fit of Active E242A PAI-1 
Active 20uM E242A PAI-1 was dialyzed into 50mM MOPS, 250mM (NH4)2SO4 pH 7.4 at 
10°C. Copper2+ at 350uM was added to the buffer matched dialysate from a concentrated 
stock, and pH corrected to pH 7.4 at 10°C. Syringe copper was injected into the cell 
containing PAI-1 in injections of 5uL over 10 second duration, over 120 second intervals, 
54 injections total. The data are subtracted from runs in which 350uM CuSO4 in the same 
buffer was titrated without protein to remove background metal ion-buffer heat of 
interaction. The data are converted into kcal/mol of injectant as a function of the molar ratio 
of copper to active PAI-1. Data fitting was performed in Sedphat Software to a two non-
symmetric site binding model, and the fit is represented using Gussi software. 	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required to obtain a fit (data not shown). In the case of E242A PAI-1 however, there does not 
appear to be a weaker micromolar binding transition. The presence of a weaker transition will be 
determined in an E242A PAI-1 binding isotherm with higher concentrations of copper2+. These 
data indicate that the gate region Site C may contain the site that accelerates PAI-1 latency, albeit 
at micromolar affinities. Additionally, the data argue for the involvement of E242 within this site, 
rather than D222.   
  Finally, we tested the effect of SMB domain on the thermodynamics of PAI-1 copper2+ 
binding. We used W175F PAI-1 with a 1.2 molar equivalent of SMB domain, otherwise keeping 
conditions constant. We observed a titration isotherm that was similar to W175F in the absence of 
SMB, fitting to a two-site model with Kd’s of 20 nM and 30nM, and enthalpy changes of -14.3 and 
-13.8 kcal/mol, respectively (Figure 3.29). This result compares well with active W175F and wild-
type PAI-1, further supporting that PAI-1 remains predominantly active during our ITC 
experiments.  We next asked whether or not SMB domain directly interacts with copper2+. 
Significantly, titration of the SMB domain with copper2+ did not result in a titrating heat signal 
(Figure 3.30). This is an important result as it indicates that copper2+ does not interact with SMB 
and exerts direct effects on PAI that are measured in the ITC experiments on the PAI-1-SMB 
complexes.  
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Figure 3.29: Copper2+ Binding to SMB Bound PAI-1  
Active 20uM W175F PAI-1 with 24uM SMB domain was dialyzed into 50mM MOPS, 
250mM (NH4)2SO4 pH 7.4 at 10°C. Copper at 300uM was added to the buffer matched 
dialysate from a concentrated stock, and pH corrected to pH 7.4 at 10°C. Syringe copper 
was injected into the cell containing PAI-1 in injections of 5uL over 10 second duration, 
over 120 second intervals, 54 injections total. The data are subtracted from runs in which 
300uM CuSO4 in the same buffer was titrated without protein to remove background 
metal ion-buffer heat of interaction. The data are converted into kcal/mol of injectant as a 
function of the molar ratio of copper to active PAI-1. Data fitting was performed in 
Sedphat Software to a two non-symmetric site binding model, and the fit is represented 
using Gussi Software. 	  

















 	  	  
	  
Figure 3.30 ITC of Copper2+ Titration into SMB Domain. 
 SMB domain at 20uM was dialyzed into 50mM MOPS, 250mM (NH4)2SO4 pH 7.4 at 
10°C. Copper at 400uM was added to the buffer matched dialysate from a concentrated 
stock, and pH corrected to pH 7.4 at 10°C. Syringe copper was injected into the cell 
containing PAI-1 in injections of 5uL over 10 second duration, over 120 second intervals, 
54 injections total. No attempt was made to fit the data as there was no observable titrating 
signal. 	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3.4 Discussion/Conclusions 
3.4.a. What Role do the N-terminal Histidines Play in Modulating PAI-1 Function? 
The stability kinetics data for the N-terminal histidine variants (Site A) H2A, H3A, and H2AH3A 
showed that these variants retained the peculiar effect of metals ion to promote the latency 
transition. Indeed, half-lives in the presence of copper2+ were reduced to 4 minutes, compared with 
11 in wild-type PAI-1. In the metal titration gel assays, we observed that these variants were even 
more sensitive to metal ions than wild-type PAI-1. These results clearly demonstrate that copper2+ 
binding to the N-terminal histidines is not responsible for promoting a more rapid latency 
transition. Strikingly however, H2AH3A PAI-1 appears even more sensitive to copper2+ effects 
than wild-type PAI-1. As observed on the structure, the N-terminal histidines are located on the 
opposite side of the protein from the central β-sheet A, proximal to but not overlapping with the 
flexible joints region. The H2AH3A amino acid substitutions remove the tightest first binding 
transition, and this supports a working model of the N-terminal histidines involvement in a tight 
binding site. Thus copper2+ binding to those residues must have a neutral or stabilizing effect on 
PAI-1 stability if their removal results in significantly faster conversion in the presence of 
copper2+. 
These results are consistent with HDX experiments comparing wild-type PAI-1 and 
H2AH3A PAI-1 in the presence of bound copper2+ (See Chapter 2). In wild-type PAI-1, copper2+ 
binding results in an increase to protein dynamics in specific regions of the protein, e.g. the 
flexible joints region underlying shutter region of hB-hC, and hI. Indeed, the same increases in 
protein dynamics are observed with H2AH3A PAI-1 in the presence of copper2+, underscoring the 
conclusion that the N-terminal histidines do not comprise a site that accelerates the rate of latency 
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conversion. There is little evidence of metal ion effects on stability through binding at the N-
terminus of PAI-1 via HDX, although local unfolding of proximal hA determined by HDX appears 
to occur on a timescale consistent with latency transition [85]. Interestingly, another circulatory 
protein, serum albumin contains an N-terminal histidine copper binding motif that has been 
characterized [143]. Prion protein PrC also binds to copper2+ via N-terminal histidines, which may 
initiate misfolding and aggregation in neurological disorders [144].  
3.4.b. Evidence for Copper2+ Coordination Site in the Gate Region that Affects Stability 
 We observed in the metal titration gel assays that D222A and E242A PAI-1 had transition 
midpoints for copper sensitivity at higher copper2+ concentrations than wild-type PAI-1. In 
contrast, alanine mutations at residues E212 and E350 PAI-1 did not significantly influence the 
copper2+ concentrations that induce PAI-1 latency. D222 is located on the N-terminal portion of 
s2B, and E242 is located on the loop that connects s3B-hG. From the PAI-1 structure, it is 
observed that D222 is partially buried, whereas E242 is solvent exposed (Figure 3.8). This is of 
functional relevance because the gate region loops (s3C-s4C and s4B-hG) are the loops that open 
up to allow the RCL to pass through and eventually insert into the central β-sheet as s4A. E212 is 
located on s1B; although it is located proximally to D222 and E242 in the gate region, the data 
from the alanine switch do not suggest its involvement in metal binding. E350 is located on S1C, 
just C-terminal of the RCL loop. Strand s1C is of functional importance because it becomes 
unstructured and extends to allow the RCL passage through the gate region loops. However, in the 
active form, E350 is distal from D222 and E242. While the conformational change in s1C could 
affect a closer proximity for E350, evidence from the metal titration gel assays does not indicate a 
role for E350 in copper binding to the region.  
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 Stability kinetics assays testing D222A and E242A PAI-1 in the presence and absence of 
copper2+ suggest that E242A PAI-1 has similar kinetics in the absence of metal ions, while D222A 
PAI-1 may be stabilized by the mutation itself. Additionally, ITC of both variants indicates that 
D222A PAI-1 binds copper2+ similar to wild-type, and E242A PAI-1 isotherms do not feature the 
weaker transition of micromolar affinity, which is proposed to be the copper2+ coordination site 
that accelerates PAI-1 latency. We have also identified that this binding transition is present in the 
latent forms of PAI-1 as well. A copper2+ binding site that favors conversion to the latent state 
should still exist in the latent form, and may even bind tighter than in the active state. Future ITC 
experiments with higher copper2+ concentrations in the latent and active forms of E242 could shed 
light on this hypothesis.  
 An interesting corroborating observation comes from comparing HDX for wild-type PAI-1 
and H2AH3A PAI-1 in the presence of copper2+ (See Figure 2.17 HDX chapter). Comparison of 
the wild-type PAI-1:copper2+ complex with H2AH3A PAI-1 bound to copper2+ reveals protection 
from exchange for several peptides that span the binding site that contains E242. Copper2+ binding 
is preferred in Site A, which is an order of magnitude tighter than the proposed gate region site. 
Thus, changes in protection events in the HDX are more easily observed in copper2+ binding to 
gate region site in the variant lacking the Site A histidines, compared with wild-type PAI-1. A 
hypothesis from the current data is that copper2+ is coordinated by a site involving E242.  This 
glutamate residue has proximal, but currently untested, metal ion binding residues such as E244 
also of the s3B-hG loop, and H219 of s2B. This differs from the original predicted Site C, as the 
other three residues show no evidence of deficiencies in copper2+ binding, apart from the inclusion 
of E242.  This proposed metal ion coordination involving E242 moving closer to H219 would 
	   152 
move the s3B-hG loop away from the other gate region loop, s3C-s4C, facilitating their opening 
and thus the path to the latent state. 
3.4.c E81 and H364 Residues in Site B May Represent a Secondary Tight Binding Site within 
Active PAI-1   
 Amino acid substitution of the MUG algorithm predicted site B residues (E81, H364) resulted 
in comparable effects to H2AH3A PAI-1 in the stability assays with copper2+ and in the metal ion 
titration assay.  In the presence of copper2+, E81A PAI-1 converted to the latent state significantly 
faster than wild-type. E81A PAI-1 was also most sensitive to copper2+ in the titration assay. E81 is 
located on hD of the flexible joint region, and H364 is located proximally in s4B of the inner core 
of the protein. We suspect that E81 is part of a secondary binding site, in which copper2+ binding 
provides a neutral or stabilizing influence on rate of latency transition. This is because removal of 
E81 results in a faster conversion to the latent state in the presence of copper2+ compared with 
wild-type. However, robust copper2+ binding analysis of E81A PAI-1 in the active and latent forms 
by ITC is required to confirm this proposed site B. We hypothesize that as PAI-1 converts to the 
latent form, the shutter region strands spread out, moving helix D away (E81) from the protein 
core (H364) and the N-terminus (H2, H3), eliminating contribution to a binding site. This may be 
an explanation for the reduction in binding when comparing wild-type PAI-1 in the active form to 
the latent. Future testing with combination variants in the active and latent forms will be required 
to confirm this mechanism of the tight secondary site. Future testing with combination variants in 
the active and latent forms will be required to confirm this mechanism of the tight secondary site.  
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3.4.d. ITC Identifies Key Differences in Copper2+ Binding of Active and Latent Variants   
 A compilation of the Kd, and ΔH values from ITC are listed in Figure 3.31. Importantly, an 
enthalpy change associated with the active, latent, and variant PAI-1 binding to copper2+ is 
reasonably consistent with a copper2+ -protein interaction. The isotherms H2AH3A PAI-1 in the 
latent form, and to a lesser extent latent wild-type, lack lower baselines compared with the active 
forms. The latent H2AH3A PAI-1 fits to a one site model with weaker, micromolar binding. The 
latent form of wild-type fits to a two site model, the first of which is attributed to copper2+ binding 
to H2 and H3, and the second transition is of weaker affinity, comparable to the latent H2AH3A 
PAI-1 data. Fortunately, PAI-1 conversion to the latent form is not accompanied by an enthalpy 
change, making it possible to do experiments on the active form. The active form of wild-type 
supports a three binding site model, the first site involves the Site A N-terminal histidines, a 
second that may involve Site B (E81). The third site is of weaker micromolar affinity involving 
E242, and is proposed to cause the accelerated transition to the latent state. The first two sites have 
low nanomolar affinity, although the secondary site can only be observed in active PAI-1. 
3.4.e. PAI-1 Bound to SMB negates Copper2+ Sensitivity (Wild-type and H2AH3A) 
 We separately tested wild-type and H2AH3A PAI-1 in the presence of the SMB domain to 
assess effects of ligand binding on metal ion sensitivity. Since H2AH3A PAI-1 has a similar half-
life to wild-type, we were able to directly compare the two forms of PAI-1 bound to SMB. While 
there are significant differences in the copper sensitivity of wild-type and H2AH3A PAI-1 in the 
absence of SMB, the metal sensitivities of both forms of PAI-1 bound to SMB are virtually  
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  Dissociation constant (uM) Enthalpy change (kcal/mol) Model Inc A 
          
Active WT (global) 0.02 (+/- 0.04),   0.06 (+/-0.2),   2.1(+/- 0.05)  -12.2(+/- 1.1),   -9.2(+/- 2.0),   -8.2(+/- 0.11) 
two,  
one 0.26 
Active W175F 0.01(+/- 0.009),   0.02(+/- 0.014) -14.9 (+/- 0.4),   -15.1( +/- 0.8) two site 0.3 
Latent WT (global) 0.05 (+/- 0.04),   2.1 (+/- 0.2) -12.2 (+/- 0.35), -4.6 (+/- 1.7)	  	   two site  0.6 
Latent H2AH3A 1.96 (+/- 0.1) -8.5 (+/- 0.8) one site 0.7 
Active W175F + SMB 0.03(+/- 0.01),   0.02(+/- 0.015) -14.3 (+/- 0.6),   -13.8(+/- 0.8) two site 0.29 
Active D222A 0.01(+/- 0.002),   0.01(+/-0.005) -20.2(+/- 0.7),  20.2(+/- 0.6) two site 0.28 
Active E242A 0.009(+/- 0.004),  0.02(+/- 0.006) -17.2(+/- 0.3),  -17.0(+/- 0.006) two site 0.3 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
 
Figure 3.31: Compilation of Data Comparing Thermodynamics of Copper2+ Binding in 
Active versus Latent, Variant PAI-1. The compiled ITC results are contained in the table of 
wild-type and variant PAI-1 in the active and latent forms. The thermodynamic data (ie. Kd 
values in uM, and enthalpy changes in kcal/mol)was acquired by fitting in Sedphat software to 
either one site or two site non-symmetric binding models as appropriate for each experimental 
condition.  	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identical. How can SMB binding to PAI-1 produce this result? As observed on the structure, the 
SMB domain binds in the flexible joint region. The N-terminal histidines do not overlap with the 
PAI-1/SMB binding interface, and the gate region containing E242 is on the opposite pole of the 
molecule relative to this region. Since the N-terminus, SMB binding interface, and E242 are not 
close to one another, it is not reasonable to propose SMB domain sterically blocking copper2+ 
binding to PAI-1. Furthermore, ITC studies titrating copper2+ into SMB domain gave no evidence 
of metal binding to the SMB domain. It is possible that SMB binding could lower the affinity for 
copper binding at the either of the two binding sites. However, our ITC results that yield a similar 
Kd of active PAI-1 to copper2+ in the presence or absence of SMB suggest otherwise. SMB 
binding most likely stabilizes PAI-1 in the same way in the presence or absence of metal ions, 
negating copper2+ effects that induce latency.   
3.5. Conclusions/Working Model     
 Figure 3.32 illustrates our working model of the molecular mechanisms by which copper2+ 
affects PAI-1 activity. PAI-1 undergoes a number of structural rearrangements on the path to the 
latent form, including opening of the gate region loops (teal), and opening of the shutter strands 
(green) for the RCL (orange) to insert as a new strand in the central β-sheet. SMB domain binding 
to the flexible joint region confers conformational stabilization to the active form by disfavoring 
conversion to the latent form. Conversely, metal ions appear to induce conformational conversion 
that facilitates latency. Through the metal titration gel assays and ITC we were able to identify 
E242 as the metal binding ligand that results in accelerated latency conversion. We propose that 
copper2+ binding to this region favors the opening of the gate region loops, facilitating the RCL 
loop to pass through and insert in the central β-sheet A. Since the loops remain open in the latent  




Figure 3.32: Working Model of the Molecular Effects of Copper2+ on PAI-1 
Activity. PAI-1 structural changes are highlighted in the RCL (orange), gate region 
loops (teal), shutter region strands (green), and the flexible joints region (red). The SMB 
domain binds to s1A (red), and the proposed copper2+ binding sites are shown on the 
structure. In the absence of copper2+, PAI-1 undergoes latency by the opening of the gate 
region loops, followed by RCL passage and insertion into the central beta-sheet. In the 
presence of copper2+, copper2+ binds to wild-type PAI-1 at the N-terminal histidines, and 
in proposed binding sites involving E81 and E242 of the gate region. The gate region 
binding site is the proposed as the metal binding site that induces latency. This results in 
facilitation of opening the gate region loops, and induced latency conversion. H2AH3A 
binds copper2+ in the proposed sites but not at the N-terminus that contains alanines. A 
secondary site involving E81 binds copper2+ in the active form. Mutation of these 
residues results in a neutral or stabilizing effect, since when mutated these residues 
convert to latent faster than wild-type in the presence of copper2+.  The SMB domain 
binds to favor PAI-1 in the active form, and also does so in a similar way when copper2+ 
is present. This stabilization of PAI-1 by SMB negates copper2+ induced latency.	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state, this site is still functional in the latent form, and it would explain why we still observe this 
binding even in the latent form of H2AH3A PAI-1. Our experimental evidence suggests that SMB 
stabilizes PAI-1 in the same way in the presence of copper2+, disfavoring conversion to the latent 
state. In other words, by this mechanism, SMB negates copper2+ effects that induce latency 
conversion. Mutation of the N-terminal histidines eliminates copper2+ binding to these residues. In 
the presence of copper2+, H2AH3A PAI-1 converts to the latent state faster than wild-type. This 
indicates that copper2+ binding that occurs involving these residues must have a neutral or 
stabilizing effect on PAI-1 latency. The E81A PAI-1 variant also results in an even higher 
propensity of copper2+ induce latency conversion compared with wild-type. We suspect that E81 
is part of a secondary binding site, in which copper2+ binding provides a neutral or stabilizing 
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Chapter 4 Characterization of Halide Binding Site on PAI-1 
This chapter is an adapted version of the published work: 
Crystal Structure of Plasminogen Activator Inhibitor-1 in an Active Conformation with Normal 
Thermodynamic Stability. Jan K. Jensen, Lawrence C. Thompson, Joel C. Bucci, Poul Nissen, 
Peter G. W. Gettins, Cynthia B. Peterson, Peter A. Andreasen and J. Preben Morth, J. Biol. Chem. 
2011. Volume 286, p.29709-29717. 
4.1. Introduction 
 
4.1.a. Evidence of PAI-1 Stabilization by Mutations and Halides 
 
 A high-resolution structural characterization (ie. crystal structure) of PAI-1 in the active form 
had remained elusive for many years due to the propensity of PAI-1 to convert to the latent from at 
an appreciable rate that corresponded to the timescale for the crystallization process. In order to 
stabilize active PAI-1, directed evolution studies identified residues that differ from the consensus 
serpin sequence [87, 90, 93]. Many of the resulting variants produced only modest stabilizing 
effects on PAI-1. The most dramatic stabilizing mutations came from a quadruple variant termed 
14-1b PAI-1 (containing N150H, K154T, Q319L, and M354I mutations), with a half-life for the 
latency transition of approximately 145 hours [87]. The mutations were synergistic, with the 
effects of the four being greater than the sum of the effects of the single variants [87]. A caveat, 
however, is that the four amino acid replacements significantly altered the thermodynamics of 
PAI-1 folding, with 14-1b PAI-1 having a melting temperature 10°C higher than wild-type PAI-1 
[87]. Halides such as chloride ions were also observed to stabilize PAI-1, so that varying NaCl 
concentrations from 50 mM to 1M resulted in dramatic stabilization to the active form [145]. This 
observation was part of a study that investigated the thermodynamic stability of PAI-1 active, 
	   160 
latent, and substrate-like forms under heat and chemical denaturation [145]. Thus, the stabilizing 
mutations and halide binding have interesting structural and functional implications on PAI-1 that 
prompted further study. 
 
4.1.b. A Chloride Binding Model from the Active 14-1b PAI-1 Structure 
 
 The structure of active and latent forms of 14-1b PAI-1 was determined by x-ray 
crystallography. Three of the four mutations were located close to one another where the base of β-
sheet A lies proximally to the loop connecting hF and s3A. The N150H and K154T substitutions 
are located on the hF-s3A loop, providing the potential for more hydrogen binding interactions 
with the central β-sheet A [1]. Nearby, the location of the Q319L amino acid switch can reinforce 
hydrophobic interactions in the hinge-like region at the base of s5A of the shutter [1]. Remote 
from these substitutions is M354I, which appears to stabilize hydrophobic interactions in s1C, just 
C-terminal of the RCL in the gate region [1]. The structures determined were consistent with 
previous work [82, 142], but of particular interest comparing 14-1b to wild-type PAI-1 was the 
identification of a chloride ion binding site in the central β-sheet A in the 14-1b variant. The 
structure depicted residues H150, S149 of the hF-s3A loop and K323, K325 of s5A participating in 
coordination of the chloride ion (Figure 4.1) [1]. Additionally, stability kinetics in the presence of 
halides determined the functional relevance of a halide-binding site within wild-type PAI-1. It was 
hypothesized that halide binding stabilized interactions between the hF-s3A loop and s5A that 
prevented translocation of hF, as well as opening of the shutter for RCL peptide insertion at the 
base of β-sheet A [1]. However, one of the stabilizing mutations of 14-1b PAI-1 was also one of 
the residues involved (H150) in the proposed chloride ion-binding site. Furthermore, two of the  





Figure 4.1 Shutter Region Chloride Ion Binding Model. The first hypothesis to explain salt 
stabilization of PAI-1 was through a chloride ion binding site in the shutter region of PAI-1 [1]. 
Residues S149 and H150 are shown in blue from the loop between helix hF and strand s3A, and 
residues K323 and K325 are shown in black from strand s5A. These four residues are shown to 
coordinate a chloride ion in the shutter. Since the RCL peptide insertion (orange) requires 
transient displacement of hF, chloride ion binding was presumed to stabilize interactions 
between hF-s3A loop and s5A. This would prevent full RCL peptide insertion and delay the 
latency transition time. However, further testing of the functional relevance of this hypothesis 
was required because H150 was one of the four mutations of 14-1b and is involved in the 
coordination. Also, two of the other three mutations of 14-1b are proximal to this area. 
Structural determination of the chloride ion binding in wild-type PAI-1 would determine the 
functional relevance of this model.	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other three amino acid substitutions introduced in the 14-1b variant were located near to the 
proposed chloride ion binding site, which likely caused structural changes. Because of these 
reasons, further structural characterization of a potential halide-binding site was needed to 
determine whether wild-type PAI-1, without the relevant mutations in this region, also exhibit this 
binding site. 
 
4.1.c. Functional Implication of W175F Crystal Structure and Alternative Chloride Binding 
Site 
  
 More recently, a crystal structure of PAI-1 with only one mutation (W175F) that produces a 
stable active form was determined by several collaborators, including our group (Figure 4.2). This 
amino acid substitution is located in the breach region on a structural hinge at the apex of shutter 
strand s3A (Figure 4.3). Functionally, this is the location where the first residues of the RCL loop 
are inserted into the space between shutter strands s3A, and s5A in the latency process. Although 
this mutation only results in a relatively modest stabilization of PAI-1 (t1/2 ~ 7 hours), of 
significance is that this variant retains similar thermodynamic characteristics in comparison to 
wild-type PAI-1. Circular dichroism (CD) and differential scanning calorimetry (DSC) 
experiments demonstrated that W175F PAI-1 has an indistinguishable melting point temperature 
compared with wild-type PAI-1. Conversely, 14-1b active PAI-1, and latent PAI-1 melting 
temperatures were significantly higher using the same techniques, indicating clear thermodynamic 
difference from wild-type PAI-1. The structural effect of the mutations was manifested upon 
successful crystallization of active W175F PAI-1.  








Figure 4.2 The Active W175F PAI-1 Structure. The structure of the active form of PAI-1 was 
determined with only one mutation W175F at the apex of s3A (pdb: 3q02). The RCL is shown in 
dotted black lines, with PAI-1 structure represented in ribbon style. The coloring scheme shows 
differences of this structure compared with the active 14-1b PAI-1 structure, in which blue is 
most similar, and then yellow, orange, or red are areas of increasing difference between the 
structures. The proposed shutter region chloride ion binding site is shown in gray, and the gate 
region chloride ion binding site is shown in green.   	  










Figure 4.3 Breach Region of W175F PAI-1 Crystal Structure. The breach region at the 
apex of the shutter strand s3A is illustrated from the active W175F PAI-1 crystal 
structure. Residues within 5Å of residue 175 are colored and their respective side chains 
are represented in stick form. For structural comparison, the W175F variant structure is 
superimposed on the active 14-1b PAI-1 crystal structure (pdb: 1DVM, shown in gray). 	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 The W175F PAI-1 structure featured several interesting differences from the original 
structural model of active PAI-1, 14-1b. The differences were most apparent in the locations of the 
mutations, but there were also changes remote from these areas. All but one of the previous PAI_1 
structures [97] contained a 310-like helix in the region that connects hF to s3A. The W175F 
structure has an extended loop in this region, indicating that the 310-like helix likely was an artifact 
of the introduced amino acid substitutions (Figure 4.4). The interesting other exception is the 14-
1b structure in which PAI-1 is bound to VN, which also does not produce the 310-like helix [97]. 
Another interested difference comparing the W175F and 4-1b structures is that hF has a slight 
clockwise rotation the W175F PAI-1 that propagates a structural change into the flexible joint 
region. Also, the loop connecting hD and s2A contains W86, which protrudes into the solvent in 
this structure compared to a buried inward orientation in previous work. There also is loss of a 
stabilizing salt bridge between D90 of this region and K145 that was previously observed in 14-1b 
PAI-1 structures. Overall, this results in a slightly different orientation of hD, and slightly shorter 
strands s2A, and s3A in the W175F PAI-1 structure. Importantly, the 14-1b PAI-1 chloride ion 
binding site in the center of β-sheet A was not observed in the W175F structure with the natural 
occurring amino acid residues present in the central β-sheet.  
 
 The W175F crystal structure did, however, contain a chloride binding site in the gate region of 
PAI-1, which has halide-binding contributions from a number of residues within the s3C-s4C loop, 
s3B-hG loop, and s1C, most notably R356 and S192 (Figure 4.5). The “back side” of PAI-1 shows 
the helices hG, hH shifted toward the chloride ion binding site, due to their contribution to 
coordination. It is hypothesized that intramolecular communication between the flexible joint  








Figure 4.4 Central β-sheet A and Helix F of Active W175F PAI-1. The central β-sheet A and 
helix F of Active W175F PAI-1 are highlighted in cartoon style in red. The loop between hF 
and s3A (T144-R162) is shown in yellow to highlight differences in this part of the structure 
from the active 14-1b PAI-1 structure. On the left, the Fourier difference of electron density is 
shown for the hF-s3A loop, the residues therein represented in stick form. In the middle, this 
region is superimposed with the same region in the active 14-1b structure ((pdb: 1dvm, gray), 
where the loss of the 310 helix is shown. On the right, this region is superimposed with the 
same region in the latent PAI-1 structure (1LJ5, gray).   	  









Figure 4.5 Gate Region Chloride Ion Binding Site.  The chloride ion binding site in the gate 
region of the active W175F PAI-1 structure is illustrated in detail. The chloride ion is represented in 
yellow, immediately surrounded by the Fourier difference electron density map in red. All of the 
residues within 5Å of the chloride ion are highlighted in color and their respective side chains are 
represented in stick form. This structure is superimposed on the structure of active 14-1b (pdb: 
1DVM, represented in gray) for structural comparison.   	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region and the gate region could be achieved through motion of these helices. These results 
suggest a new model for halide stabilization of PAI-1, in which the halide binds to the gate 
region, stabilizing interactions between the gate region loops s3C-s4C and s3B-hG. This mode of 
binding would disfavor opening of the gate region loops, and subsequent passage of the uncleaved 
RCL loop for peptide insertion.  
 
 To test the functional relevance of a gate region halide-binding site, we asked several 
questions. Does wild-type and W175F PAI-1 exhibit a stabilizing effect in the presence of halides? 
This would indicate whether or not the structural modifications due to the W175F mutation impact 
the halide binding. What halide concentrations are required to produce stabilizing effects? Finally, 
is there a preference for different halides binding in the site identified? To answer these questions, 
we tested wild-type and W175F PAI-1 in the presence of low and high concentrations of sodium 
halides, including NaF, NaCl, and NaBr. Out aim was to determine the physiological relevance 
and specificity of the newly proposed PAI-1 halide-binding site.  
 
4.2. Materials and Methods 
 
4.2.a. PAI-1 Stability Assay 
 To measure the latency conversion half-life of PAI-1, 100nM PAI-1 was incubated in 20mM 
HEPES, pH 7.4 at 37°C. The assays were performed using either low concentration (150 mM) of 
or a higher concentration (1.0M) of sodium halide (NaF, NaCl, NaBr).  At various time points 
during the incubation with halides, 0.1uM PAI-1 is mixed with 0.1uM two chain tPA in 20mM 
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HEPES, 1% BSA, pH 7.4 at 37°C. Spectrozyme tPA substrate (1mM) is added to the PAI-1/tPA 
mixtures and the reaction is monitored for 5 minutes at 405 nm. Data were collected at various 
time points anticipated for the duration of ~10 expected half-lives, and each assay is done in 
triplicate. The tPA activities (linear slopes) at each time point are plotted as a function of time.  
The inverse of these values (PAI-1 activity) were normalized and fit to a single exponential decay 
function in Graphpad Prism to determine the rate of latency conversion (klat) and half-life of 
latency conversion. 
4.3. Results 
4.3.a. NaCl Stabilizes Wild-type and W175F PAI-1 
 We tested the kinetics of wild-type and W175F in the presence of low (150mM) and (1.0M) 
high concentrations of NaCl to determine the relative rates of conversation to latency and to probe 
the role of the chloride ion binding site in the gate region (Figure 4.6-4.7). At the lower 
concentration of NaCl (150mM), PAI-1 remained in the active form in the assay for a half-life of 
49 minutes for wild-type PAI-1, and 199 minutes for W175F PAI-1. These values fall consistently 
within literature values for PAI-1, which can vary somewhat depending on buffer and 
experimental conditions [75, 79]. Furthermore, when PAI-1 is incubated with a high concentration 
of NaCl (1.0M), there is a marked reduction in latency transition rate in both wild-type and W175F 
PAI-1. Over the course of a 7-hour assay, less than 10% of PAI-1 was converted to the latent form. 
Thus, it is clear that high amounts of chloride significantly stabilize both wild-type and W175F 
PAI-1, with estimated half-lives that exceed 30 hours in the presence of 1.0M NaCl. This 
observation supports the existence of a halide-binding site in the gate region of PAI-1 in both wild-
type protein and the W175F variant.  
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4.3.b. PAI-1 Stabilization Chloride Ion Specific 
 We next asked if the observed stabilization of PAI-1 was specific to chloride ions or if other 
halides, namely fluoride or bromide ions, could produce the same effect (Figures 4.6-4.7). We 
tested wild-type and W175F PAI-1 at the same concentrations of NaF and NaBr as used above 
with NaCl (either 150mM or 1.0M). When measured at the lower concentrations, wild-type PAI-1 
incubated with NaF and NaBr converts to the latent form at comparable rates to the results 
observed with NaCl. The calculated half-lives at 150 mM NaF and NaBr are t1/2 = 57 minutes, and 
56 minutes, respectively, compared with 49 minutes with NaCl. This trend is also observed when 
we examine the same conditions for W175F PAI-1. The calculated half-lives for W175F PAI-1 
with low NaF, and NaBr are t1/2 = 246 minutes, 211 minutes, respectively compared with 199 
minutes in NaCl. However, when wild-type PAI-1 is incubated at the higher concentration (1.0M) 
of NaF, and NaBr, moderate stabilization occurs but not nearly to the extent of stabilization when 
PAI-1 is incubated with 1.0M NaCl. The calculated half-lives are t1/2 = 226 minutes, and 81 
minutes, respectively for NaF and NaBr compared with a t1/2  estimated to be over 1800 minutes 
with 1M NaCl. This result is recapitulated with W175F PAI-1 incubated with 1.0M sodium 
halides. The calculated half-lives are t1/2 = 546 minutes, and 239 minutes for NaF and NaBr, 
respectively compared to an estimated half-life of over 1800 minutes at the same concentration in 
NaCl. Altogether, our observations suggest that PAI-1 high concentrations of sodium halide are 
capable of stabilizing PAI-1, and this effect is specific and varies according to the identify of the 
various halide ions.  





Figure 4.6 Wild-type PAI-1 Significantly Stabilized by High Concentrations of NaCl. The 
stability kinetics of PAI-1 in the presence of several sodium halides (NaF, NaCl, NaBr) was 
measured using the stability kinetics assay. The normalized PAI-1 inhibitory activity is plotted as 
a function of PAI-1 incubation time. The experimental conditions are represented as follows: NaF 
are squares, NaCl are circles, NaBr are triangles. The open shapes represent the 150mM 
concentration of each sodium halide, and the dark filled shapes represent 1.0 M concentration of 
each sodium halide. Data are fit to an exponential decay equation to calculate rate and half-lives 
of PAI-1 latency transition.  	  




	  Figure 4.7 W175F PAI-1 Significantly Stabilized by High Concentrations of NaCl. The 
stability kinetics of PAI-1 in the presence of several sodium halides (NaF, NaCl, NaBr) was 
measured using the stability kinetics assay. The normalized PAI-1 inhibitory activity is plotted as 
a function of PAI-1 incubation time. The experimental conditions are represented as follows: NaF 
are squares, NaCl are circles, NaBr are triangles. The open shapes represent the 150mM 
concentration of each sodium halide, and the dark filled shapes represent 1.0 M concentration of 
each sodium halide. Data are fit to an exponential decay equation to calculate rate and half-lives 
of PAI-1 latency transition.	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4.4 Discussion/Conclusions 
4.4.a. A Chloride Specific Binding Site in Gate Region Stabilizes PAI-1 
 The original discovery of salt-dependent stabilization of PAI-1 through a possible chloride 
binding site that came from Stout et al. [1] with the 14-1b PAI-1 structure. The data presented here 
largely supports their hypothesis, with a specific site that appears to be chloride specific and which 
significantly stabilizes PAI-1 at high NaCl (1.0M) concentrations. However, the identity of the 
proposed chloride-ion binding site differs in the W175F structure. The retention of three wild-type 
amino acid residues near the hF-s3A loop and the base of the central β-sheet A in W175F relative 
to 14-1b gives different results for halide binding in the crystal structures. Notably, these three 
residues are in the vicinity of the proposed chloride ion binding site first proposed, in particular 
with regard to H150, which was implicated in original site for coordinating the chloride ion [1]. 
The absence of chloride ion binding to this region in W175F indicates that the binding event was 
presumably induced by the mutations of 14-1b, rather than naturally occurring in wild-type PAI-1. 
The kinetic results comparing wild-type and W175 PAI-1 show comparable half-lives in the 
presence of sodium halides, and then a similar and significant stabilization at high concentrations 
of NaCl. Other sodium halides tested stabilize both forms of PAI-1 somewhat, but more modestly 
than observed with NaCl (Figure 4.8).  
 The evidence with W175F and wild-type PAI-1 supports the presence of a physiologically 
relevant chloride ion binding site in the gate region of PAI-1. The location within the gate region 
positions chloride ion binding at a site that is remote from that of lone amino acid substitution in  
 










Figure 4.8: Compiled stability kinetics data of wtPAI-1 and W175F in the 
presence of sodium halides. The table in Figure 4.8 displays the average half-lives 
(t1/2) of wtPAI-1 and W175F PAI-1 in the presence of either 150mM or 1M of sodium 
halides. Each assay was performed in triplicate of three independent measurements, 
and the resulting values were used to calculate standard error.  	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the W175F protein. Our data suggest that the binding site has highest affinity for chloride ions 
because it is optimally sized for this physiologically relevant ion. The observed coordination site 
for halides in this area of PAI-1 suggests a model by which chloride ion binding can stabilize the 
active form. During the process of latency conversion, the gate loops widen, and s1C stretches out 
as the RCL passes through. The significant reorganization of the gate region during latency distorts 
the positioning of the coordinating residues to such an extent that chloride ion binding to the latent 
form would be very weak or likely absent. With the gate region so intimately linked to the stability 
of PAI-1, it is logical that chloride ion binding could cause the drastic changes we observe in our 
data. Our data does not follow traditional halide binding size patterns. We have characterized a 
functionally relevant chloride ion binding site on PAI-1 that may have a physiological and/or 
pathophysiological roles in healthy and disease states. 
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Chapter 5 Overall Conclusions/Future Directions 
 This work has helped explain the molecular basis for ligand effects on PAI-1 stability and 
dynamics, namely copper2+, SMB domain, and chloride ions. We have completed a full 
thermodynamic characterization of PAI-1 copper2+ binding in the active, latent, and SMB bound 
PAI-1 forms. Active PAI-1 binds copper2+ tightly, the affinity of which is the same with SMB 
bound, but with reduced binding in the latent form. Through site directed mutagenesis, we have 
identified three metal ion binding clusters that show functional and thermodynamic differences 
from wild-type PAI-1. We have fully characterized the dynamics of active and latent PAI-1 in the 
presence of copper2+, and SMB domain. PAI-1 stability is tied to protein dynamics, as ligands that 
decrease dynamics result in stabilization of active PAI-1, and those that enhance dynamics 
accelerate conversion the latent form. Copper2+ increases PAI-1 dynamics of peptides structurally 
localized to the flexible joints region, underlying shutter region and proximal helices. Interestingly, 
these same regions are the regions of PAI-1 where dynamics is decreased by the stabilizing SMB 
ligand. Finally, the recent crystal structure of W175F represents the most accurate structural model 
for active wild-type PAI-1 to date. A halide ion binding site in the gate region is identified that 
significantly stabilizes PAI-1 at high concentrations. The halide ion binding site is specific to 
chloride ions, as fluoride and bromide can not produce the same stabilizing effects on PAI-1.  
             Several future experiments are required to completely understand how copper2+ can 
destabilize PAI-1 but stabilize it in the presence of VN or SMB. We aim to further investigate the 
gate region proposed site involving E242, E244, and H219 that may accelerate latency transition. 
Single and combination PAI-1 variants will be generated and tested for comparison to Wild-type 
for stability, sensitivity, and binding in the presence of copper2+. Additionally, measurement of 
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H2AH3A, E81A, and H364A PAI-1 variants of latency conversion kinetics should be assayed in 
the presence of SMB domain and copper2+, to determine if copper2+ binding to these residues is 
indeed involved in the observed further stabilization of PAI-1/SMB. These variants will also 
undergo full thermodynamic characterization to copper2+ in the ITC with SMB bound to observe 
copper2+ binding differences.  
           Additionally, early observations of PAI-1 tPA interaction suggest that copper2+ produces 
an increase in “substrate-like” PAI-1. The PAI-1 klim of inhibition for PAI-1 to tPA and uPA 
should be performed by stopped-flow kinetics in the presence of copper2+ for comparison with the 
PAI-1 alone or with SMB bound stopped-flow data. After these studies are complete, a cell 
culture and animal model could be designed with wild-type and metal ion binding deficient 
variants to assess physiological relevance of PAI-1 copper2+ regulation through their interaction.       
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